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ABSTRACT 
 
Cancer care in many countries is delivered by healthcare professionals working together as 
multidisciplinary teams (MDTs). In the UK the delivery of care by MDTs is mandatory. The 
aims of the research reported here were to investigate the factors that affect the quality of 
clinical decision-making in MDT meetings, to develop and evaluate tools to measure this 
process, and to use these tools to evaluate interventions designed to improve the quality of 
such decisions. 
 
The introduction presents an overview of the evidence for clinical decision-making in MDT 
meetings, before Chapter 2 provides a critical appraisal of existing evidence, focussing on 
specific factors that affect decision-making by MDTs. 
 
My first empirical Chapters have explored the attitudes and experiences of MDT members 
and patients. Chapters 3 and 4 present analyses of national survey data that explore the views 
of MDT members from different professional groups across a range of tumour types.  
Chapters 5 and 6 present data from in-depth exploration of the views of urology MDT 
members and cancer patients respectively. 
 
Chapters 8 and 9 present data from studies that develop and cross-validate an observational 
tool for the assessment of decision-making in MDT meetings (MDT-MODe). I have used this 
4 
 
tool in Chapter 10 to assess the relationship between organisational factors, information use, 
teamworking and decision-making in urology MDT meetings.  
 
Having built up a picture of the factors that are important for good decision-making, Chapter 
11 reports a study that uses MDT-MODe to evaluate a multistage intervention to improve the 
quality of decision-making in urological MDT meetings. 
 
Finally, my general discussion reflects on the findings and the wider evidence base, explores 
the limitations and presents implications of my work for clinical practice, patient care, future 
research and policy. 
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1  INTRODUCTION 
1.1 Quality in cancer multidisciplinary teams (MDTs) 
Multidisciplinary teams (MDTs) provide a means of improving communication, coordination 
and decision making between healthcare professionals when weighing up treatment options 
with patients.(1)
 
However, the performance of MDTs is variable - the average overall 
compliance with established criteria in the UK (‗Peer Review‘ measures – these will be 
explained in detail later) across 1314 teams in 2008 was 73%, ranging from 7% to 100%.(2) 
Furthermore, the task of improving the quality and performance of the MDT meeting, which 
is the focus of clinical decision-making, has not previously been approached in a systematic 
manner.  
 
My programme of research will build on existing research in team performance in healthcare 
and apply qualitative and quantitative methodologies to scientifically assess the quality of, 
and devise methods of improving the quality of team decision-making in Urology MDT 
meetings.  
 
In this introductory Chapter I will review the current organisation of cancer services into 
MDTs, review literature on improving the quality of healthcare, and review the literature on 
clinical decision-making by MDTs. 
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1.2 Multidisciplinary teams in cancer care 
1.2.1 What is a MDT? 
Multidisciplinary teams (MDTs) are increasingly becoming the model of care for patients 
with cancer across the world. In the UK a MDT is made up of surgeons, physicians, clinical 
and medical oncologists, radiologists, pathologists, specialist nurses, palliative care 
specialists and may also include researchers, dieticians, radiographers, social workers and 
other allied healthcare professionals. A MDT has been defined as a ―group of people of 
different healthcare disciplines, which meets together at a given time (whether physically in 
one place, or by video or teleconferencing) to discuss a given patient and who are each able 
to contribute independently to the diagnostic and treatment decisions about the patient‖.(3)  
 
1.2.2 Cancer care before MDT working 
The arrangement of cancer services into MDTs and specialist centres was introduced 
following evidence of variation in the quality of cancer services across the UK.(4) In 
particular there was evidence of non-uniform access to specialist care, frequent reporting of 
inadequacies in cancer services, a disjointed system of referral to and between specialists, as 
well as variation in the frequency of individual treatments, the caseload for particular doctors, 
and crucially variation in patient survival. Up until the mid 1990‘s patients were referred to 
individual clinicians, and local services were arranged according to local expertise and the 
available facilities. Healthcare professionals worked in teams, but there was little 
standardisation of service organisation or operating procedures, and referrals were made on 
an ad hoc basis. Moreover, there were no mandatory standards to which services had to 
adhere, and no process of standardised assessment of services.(3) 
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1.2.3 Implementation of MDT working 
In the 1990‘s some evidence started to emerge regarding the benefits of treating patients with 
a multidisciplinary team approach, rather than treatment by individual clinicians.(5) In 
addition, studies had found that patients‘ surgical outcomes improved when they were treated 
by surgeons with higher numbers of cases, and in centres that carried out higher volumes of 
cases.(6) It was this evidence that the Chief Medical Officers for England and Wales drew on 
in the Calman-Hine report in 1995 to recommended that cancer care should be delivered by 
MDTs at specialist cancer centres arranged into site-specific cancer networks.(4) Following 
the publication of this report, which marked a change in the arrangement of cancer services, 
the UK Department of Health began to produce a series of evidence-based documents aimed 
to establish national standards for cancer care. The first was for breast cancer; similar 
documents for lung, colorectal, upper gastrointestinal and gynaecological cancers 
followed.(7-11) The guidance in these documents, called Improving Outcomes Guidance, 
included recommendation that patients were treated in cancer units and cancer centres by 
MDTs involving surgeons, physicians, oncologists, nurses and other MDT members. The 
delivery of cancer care by MDTs has increased from 20% in 1996 to over 80% by 2006, 
which is reflected in the guidance of The National Institute for Health and Clinical 
Excellence (NICE) which has continued to endorse this arrangement.(12;13) 
 
1.2.4 The setting of the MDT 
In practice, members of the MDT work to investigate, and treat patients with suspected or 
diagnosed cancer. MDTs are based in cancer units, which are speciality specific departments 
with the facilities and personnel capable of serving a local population of approximately 
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300,000 people. This involves the day to day running of hospital departments to provide 
cancer services to the local population across the whole care pathway, including clinics, 
diagnostic tests, therapeutic interventions and personal care and information. Once 
diagnosed, certain cases of high risk cancer, or those requiring specialist interventions can 
then be referred onto a specialist MDT, which operates from a cancer centre that heads a 
network of cancer units covering a population of one million. A cancer centre is usually a 
hospital department that is able to provide specific services, in particular complex surgery 
and radiotherapy. Patients from surrounding cancer units can be referred to the specialist 
MDT and treated at the cancer centre as required. 
 
1.2.5 The MDT meeting 
A focal aspect of the MDTs is the MDT meeting, which in the UK occurs typically once a 
week. In the UK all patients with suspected or diagnosed cancer must be referred to and 
discussed by the MDT in the MDT meeting. Referral is usually made by members of the 
MDT and patients can be discussed at any point along the treatment pathway, although 
typically this occurs at diagnosis, following treatment, and sometimes if there is a recurrence 
or progression of disease. The key task of the team during a MDT meeting is to collate and 
review information about the patient and their disease, discuss it, and make a decision for 
further investigation and treatment, Recommendations made by the MDT meeting are then 
discussed with patients and actioned by members of the team.  
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1.2.6 Regulation of MDTs 
The treatment of patients with cancer by MDTs has been mandatory since 2004, which is just 
one of the domains against which cancer services are assessed. The Manual for Cancer 
Services sets out measurable standards relating to the planning, commissioning, organising, 
and providing of cancer services that is likely to have a significant impact on health outcomes 
with the aim of identifying gaps in provision and checking the appropriateness and quality of 
existing services.(3) Compliance with the Manual for Cancer Services is assessed through the 
National Cancer ‗Peer Review‘ Programme. This programme involves the collection of 
information about individual teams through engagement of front line clinicians in reviews 
with the aim of being a catalyst for change. However, one criticism of the Manual for Cancer 
Services and the Peer Review process is that they focus largely on the structures and 
processes of cancer services, rather than on the MDT meeting, which is the focus of clinical 
decision-making. Indeed, there is little focus on requirements for clinical information or the 
process of clinical decision-making itself. One argument for the current assessment process is 
that it can only include standards that can be measured, and therefore improved.(3) To date, 
the process of decision-making, the use of clinical information, and team behaviours have not 
been measured, and therefore cannot be easily assessed or improved. 
 
1.3 Quality and performance in healthcare teams 
Outside cancer MDTs, in the past 10 years there has been significant interest and an ever 
expanding evidence base on the description, assessment and improvement of teamworking 
and team performance across a range of healthcare specialties.(14;15) Much of the research 
on team performance in healthcare was originally translated from work in other industries 
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that share the need for high reliability, high reliance on human interaction, and the potential 
for disastrous consequences when communications fail or team leadership is inadequate, such 
as commercial aviation and the military.(16;17) This work suggests that factors including the 
environment, team factors, and an individual‘s non-technical skills affect clinical 
outcomes.(18-22) Non-technical skills have been grouped into cognitive and behavioural 
skills. Behavioural skills refer to skills such as teamwork and leadership. Cognitive skills 
include situational awareness (the awareness of the surgeon to what is happening in the 
operating room) and decision making. Decision making includes the choices the surgeon 
makes e.g. when to operate, as well as judgements e.g. of risk.(15) Consideration of these 
factors alongside traditional indicators of performance such as the surgeons technical skills 
and patient factors has given rise to a new ‗systems approach‘ to performance in healthcare 
(Figure 1). Within healthcare, research on team skills was pioneered in surgery and 
anaesthesia and has since been adapted to other specialities including intensive care and 
emergency medicine. Work to improve team performance has been achieved using a variety 
of qualitative and quantitative methodologies which has led to the development of robust 
tools for team assessment and feedback through to simulation-based training.(18;23-25) 
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1.4 Clinical decision-making in surgery 
Decision making has recently gained prominence in the healthcare literature and in the 
literature on surgical skills in particular.(26;27) Most decisions in surgery involve a series of 
often rapid and unconscious interrelated steps and several different modes of decision making 
have been described including intuitive, recognition-primed, rule-based decision making and 
analytical decision making.(27-29) These strategies cover a spectrum of decisions which 
surgeons apply to particular situations, e.g. using an analytical strategy when deciding 
whether a patient needs surgery or not, or a rule based decision when deciding post 
Figure 1: The systems approach to surgical performance  
(Taken from Undre S, Arora S, Sevdalis N. Surgical performance, human error and patient safety in urological 
surgery. British Journal of Medical and Surgical Urology 2009 Jan;2(1):2-10.) 
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operatively whether to remove a drain. (30) Although some decisions in surgery appear to be 
isolated choices, they are in fact part of a complex care pathway. Fox and colleagues 
analysed the care pathway for patients with breast cancer and described approximately 65 
decision points along the care pathway, at which choices regarding diagnosis, work up, 
treatment and follow up have to be made.(31) The authors concluded that even a small 
margin of error at each decision point can accumulate across the whole care pathway to 
dramatically increase the chance of an error or lapse in service quality. Jacklin and colleagues 
have mapped the decision making process in general surgery and identified 18 key decisions 
across different phases of care (pre-, intra- and postoperative). The authors demonstrated that 
the process of deconstructing and assessing surgical decision making could be carried out 
reliably, both by another surgeon and a psychologist with good inter-rater reliability (30). 
These studies highlight that decision making in surgical oncology is a complex process that 
occurs over the whole care pathway. However, in reality decision making is performed by a 
variety of healthcare professionals, including surgeons, who work together to care for the 
patient. 
 
1.5 MDTs and clinical decision making 
Several authors have found that the establishment of MDTs in cancer care has had an impact 
on clinical decision making. Researchers have investigated the impact of MDTs on decision 
making and have shown that a decision by an MDT is different to that of an individual 
clinician (32-37). Forrest and colleagues found that after the introduction of MDT the number 
of patients with non-small cell lung cancer receiving chemotherapy rather than palliative care 
rose significantly (38). A review by Fleissig and colleagues postulates that MDT‘s provide a 
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means of improving decision making between healthcare professionals by bringing together 
key professionals with all the necessary knowledge, skills, and experience (1). The 
combination of a long care pathway with multiple decision points and the number of different 
healthcare professionals involved make decision-making in cancer care complex. Using a 
‗systems approach‘ provides some structure to the discussion of MDT decision making. 
Decision-making by MDTs can be understood in terms of the input-process-output model of 
team performance (Figure 2). The input-process-output model has been used extensively in 
team work literature, is established in the aviation industry and the NHS, and provides a 
useful framework for studying surgical teams (39). The model permits the relationship 
between team factors and team performance- in this case factors that affect decision making 
by MDTs- to be defined and manipulated.  
 
1.5.1 Inputs 
Using information to make decisions 
Several studies have assessed the different factors that are taken into account by members of 
the MDT when making decisions. Clarke and colleagues used judgement analysis to look at 
the cues used by consultant urologists when making treatment decisions about localised 
prostate cancer. They found that the cues used most frequently in these decisions were PSA, 
10 year predicted survival, MRI/Laparoscopic stage and Gleason score. Patient choice was 
used to make decisions much less frequently (40). A similar study by Wilson and colleagues 
found that patient choice was not used significantly by any of the 30 consultants, and that the 
cues most used were digital rectal examination result, stage of disease, PSA, age of patient 
and Gleason grade (41). Langenhoff and colleagues used conjoint analysis to develop a 
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decision model to help select patients suitable for surgery of liver metastases. They found that 
surgeons made their decisions based on the age of the patient, whether metastases were 
uni/bilateral and the proximity of the lesions to major blood vessels (42). Penel et al found 
that factors significantly associated with palliative intent when MDTs were deciding on 
treatment for patients with sarcoma were contraindication for GA, head and neck location, 
visceral sarcoma, tumour size  over 8cm, and presence of metastases (43). The results show 
that doctors favour biomedical cues when making treatment decisions. This is in contrast to 
an in-depth study by Junnola and colleagues that found that nurses acquire information on 
pain, family situation, pain medication, spread of cancer, psychosocial situation and use 
information from the patient, their own nursing knowledge and experience, the medical 
diagnosis, their nursing education, and personal values when making decisions (44). These 
studies suggest that by considering different types of information, the different members of 
the MDT come together to make decisions differently to any single individual, which may 
help to improve the quality of the decision. 
 
Team attendance and decision-making 
 Previous work into healthcare teams has shown that increased team diversity is correlated 
with increased effectiveness (45). This has been replicated by Haward and colleagues who 
studied a national sample of breast cancer care teams. They found that self-reported 
effectiveness increased with team size and team diversity (46).  Ruhstaller and colleagues 
argue that the core attendees must be surgeons, radiotherapists and medical oncologists and 
that it is beneficial to also include radiologists and pathologists, but that specialist nurses 
should be invited as an extended member of the MDT (47). Haward et al found that clinical 
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effectiveness was correlated with the proportion of breast care nurses (46) which suggests 
that specialist nurses should also be core members of the team. Indeed in the UK specialist 
nurses are core members of any cancer MDT and are seen to have a key role in the decision 
making process (3). Barriers to attending MDT meetings have been found by an Australian 
study to be due to time commitments, schedule clashes, too few cases to make attendance 
worthwhile (48). It is imperative that the key healthcare workers who are involved in the 
decision making of the MDT are given time to attend in their job plans. Surprisingly 
Macaskill et al found in 2006 that only 28% of surgeons surveyed had protected session for 
MDT meetings. Those whose meetings were unprotected occurred in mealtimes, and in the 
evening (49). These issues must be addressed in order to ensure maximal attendance and 
therefore optimum performance of decision making. 
 
Using technology to improve MDT decision-making 
The use of information and communication technology to enhance health care has recently 
been encouraged by policy makers (50). Modern telemedicine permits the sharing of real time 
images between sites over great distances. Kunkler and colleagues conducted a cluster 
randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision 
making. They found that there was no difference in compliance with clinical practice 
guidelines between telemedicine and face-to-face meetings. There was also no significant 
difference in the appropriateness of the decision or in the satisfaction that the decision was in 
the best interests of the patient. The only difference was in opinion over reaching a consensus 
which only just reached significance (51). This study shows that decision making with 
telemedicine can be high quality and acceptable to team members. Stalfors and colleagues 
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found that the ability to reach a decision at the first presentation of a case to the tumour board 
with telemedicine was similar to that with face-to-face meetings, and that there was no 
significant difference in the time to treatment between the two methods of meeting (52). The 
latter was also found by Davison et al who found that for patients with lung cancer there was 
no significant difference in the time to treatment when telemedicine was used compared to 
face to face meetings. In addition they found that the frequency of resections increased after 
the introduction of telemedicine (53). These studies suggest that by allowing discussion by 
expert clinicians who may otherwise not be included in the MDT decision making may be 
enhanced, and certainly is not impaired. 
 
1.5.2 Processes 
Modifying decisions 
The benefits of MDT decision making often come from the expert review of information 
presented to the team. Chang and colleagues compared the decisions made by tumour board 
review to the decision of the referring clinician for breast cancer patients. They found that 32 
of 77 decisions were modified by the tumour board and suggested that these changes come as 
a result of differences in interpretation of pathological specimens by specialist pathologists 
attached to the MDT as well as of clinical guidelines (36). This finding was supported by 
Ganesan and colleagues who looked at cases of ovarian cancer referred to their MDT. They 
found that 48 of 91 received a change of diagnosis leading to a change in treatment decision 
in 20 out of 91 cases (34). Newman et al found the MDT changed the treatment decision in 
48 of 149 cases that they reviewed and suggest that expert review of radiological and 
pathological information is responsible for some of the change, but also that the MDT offers 
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a forum to ‗disseminate new research findings and treatment strategies‘ which impact on 
clinical decision making (37). Kee and colleagues, when looking at treatment decisions made 
by members of MDT for lung cancer patients, used an expected utility model of analysis and 
suggested that the effect of the MDT is to increase internal consistency of decision making 
(54). This evidence suggests that the MDT changes the clinical decision, perhaps by 
implementing a quality control mechanism for radiological and pathological information, or 
by increasing the consistency of decision making.  
 
Leadership for decision-making 
Previous work on team working and effectiveness in the health service has shown that clear 
leadership is necessary for team performance (45). These findings were confirmed by 
Haward et al in breast cancer teams who also found that good leadership was associated with 
a number of leaders and significantly negatively correlated with having just one leader, lack 
of leadership clarity and leadership conflict (46). Good leadership is a prerequisite for 
effective teamwork and decision making, and likewise, visible and participative decision 
making facilitates successful teamwork. 
 
Teamworking and decision-making 
Improvements in clinical processes including decision making brought about by MDTs may 
not just result from consensus opinion, or expert review, but also because of improved team 
working (55). Qualitative studies by Lanceley and Kidger suggest that in MDT meetings 
traditional professional hierarchies are often followed which may lead to the exclusion of 
nurses and a bias towards biomedical information (56;57). This results in missing information 
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and poorer quality decisions which may lead to non-implementation (58;59). Effective 
teamwork relies on full collaboration of all team members and an atmosphere of trust and 
respect (1;47). 
 
Reaching a decision 
A Swedish study by Stalfors and colleagues into the ability of a Head and Neck tumour board 
to reach treatment decisions found reasons for failure to reach a diagnosis or treatment 
decision included lack of proper imaging, need for investigations regarding tumour extension, 
histological re-evaluation, and uncertainty regarding general cardiovascular status. The 
authors conclude that the ability to reach a decision at the first presentation to the tumour 
board is a good measure of team performance- they suggest that any delay in diagnosis or 
treatment decisions can negatively affect outcome, probably have a negative psychosocial 
impact on patients and their next-of-kin, as well as being costly to the healthcare system and 
to the patients.  Their results suggest that having the necessary information available to the 
MDT is a prerequisite for high quality surgical decision making (52).
 
 
Disagreement in decision-making 
One of the often stated benefits of MDTs is reaching a consensus of opinion when making 
decisions. However, disagreements do arise and how one deals with these is the subject of 
debate (1;47;60;61). Disagreement within MDTs does not seem to be common but when it 
does happen members appear reluctant to officially dissent. Sidhom et al surveyed clinicians 
involved in MDTs in Australia about whether they ever fundamentally disagreed with the 
final MDT decision and found that 15% said never, 58% rarely, 25% occasionally and 2% 
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often disagreed.  Less than a third of respondents had ever formally dissented, over two thirds 
having never done so, even when they had important disagreements (61). In another essay 
Sidhom and Poulsen state that each doctor who is present at a MDT is individually 
responsible and potentially liable for all decisions within their area of expertise, and that 
formal dissent would help to minimise this liability where they disagree (60). Ideally, all 
available options would be put to a patient and a process of shared decision making 
undertaken (47). Sidhom and Poulsen suggest that MDTs are a medico legally safe decision 
making process and that increased awareness of individual responsibility should promote 
better patient outcomes and the best decisions (60). 
 
1.5.3 Outputs 
Implementing decisions 
Several authors have looked recently at implementation of MDT decisions into clinical 
practice and found that between 98.6 and 84.9% of decisions made by MDTs are put into 
clinical practice (33;58;59;62;63). This research suggests that the decisions made by the 
MDT are acceptable to the physician caring for the patient, and to patients themselves. Where 
decisions were not implemented it was found to be for a number of reasons including co-
morbid health problems preventing the implementation of the management as suggested by 
the MDT, patients rejecting the suggested treatment, or other additional clinical information 
coming to light and rendering the decision inappropriate. Blazeby and colleagues suggest that 
improving the presentation at meetings of information about the comorbidities and treatment 
preference of patients- factors that are often not fully considered- will optimize treatment 
decisions and improve implementation (58), a view consistent with previous research into 
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clinical decision making (64). In their analysis of treatment decisions at a colorectal cancer 
MDT Wood and colleagues suggests that monitoring the implementation of MDT treatment 
decisions may be a good means of evaluating MDT decisions and informing areas of team 
performance that need improvement (59). 
 
Documenting decisions 
MDT decisions should be documented to provide a record of decisions for future reference. A 
survey of surgeons involved in MDTs in the UK found that at some meetings there was no 
formal mechanism for recording decisions, (49) and in a national survey of MDT 
coordinators one centre kept no record of MDT decisions (65). Good medical record keeping 
is part of good clinical care. Ideally records would be kept on an electronic record, accessible 
to all MDT members at any location. Recording reasons for the choice of particular 
treatments including consideration of performance status, age, comorbidities etc will help to 
improve transparency (47).
 
 
Communication of decisions 
Once decisions have been made it is important that they are quickly and accurately 
communicated to patients and other healthcare professionals involved in caring for the 
patient. Communication with patients depends on the type of information being conveyed. 
Catt and colleagues found that surgeons and oncologists had primary responsibility for 
conveying information to patients about their investigations, results and treatment options and 
prognosis, and clinical nurse specialists for covering the psychosocial well being of patients. 
These roles were generally well recognised by the different healthcare professionals (66). It 
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follows that it is important for patients to see medical as well as nursing members of the 
MDT for a full picture of the care pathway. Feldman-Stewart and colleagues found that 
different professional groups involved in caring for patients with prostate cancer agreed on 
what information was important for patients to know, although there was variability of 
opinion within groups (67). This suggests that patients will receive consistent information 
when meeting various members of the healthcare team, but the information experience of 
different patients may vary from one another.  The responsibility for communicating with 
primary care is variable, falling to MDT coordinators, nurses and administrators in different 
centres. Often the decision is communicated by means of a letter, fax or telephone call to the 
GP, or a combination (65). Penel and colleagues in France surveyed GPs regarding the 
structured report that their MDT sent to GPs following patient discussion. They found that 
GP‘s were generally happy with structured report but just over a third wanted more 
information regarding side effects of treatment, prognosis and follow up plans (68).
 
 
1.6 Discussion 
The systems approach provides a structured way of thinking about decision making in 
surgical oncology and identifies many of the factors that affect the quality of the process. 
Understanding decision-making in MDT meetings in a systematic manner reflects the 
thoughts of previous researchers who looked at the effect of the technical skills of the 
surgeon, as well as the environment, teamwork and other non-technical skills on surgical 
performance. The application of a systems approach to multidisciplinary cancer teams 
provides a framework that I can use to approach my research into the quality of decision-
making in MDT meetings. Although this Chapter begins to add some evidence to that 
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framework, the next step must be to establish the current evidence base with a systematic 
review of the literature on MDT decision making. Chapter 2 reports a systematic review, 
carried out in order to explore the strengths and limitations of current evidence and provide 
avenues for my future research. 
 
Figure 2: A systems approach to decision-making in MDT meetings. „Technical‟ refers to 
organisational factors and clinical skills. „Non-technical‟ refers to team skills. 
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THESIS AIMS 
My thesis reports a series of studies that will attempt to explore, measure and improve 
teamwork and team decision-making in urology multidisciplinary cancer team meetings. I 
start in the Introduction with a narrative review of the literature on team decision-making in 
cancer care, with a focus on surgical oncology and MDTs. In Chapter 2 I conduct a 
systematic review of the evidence for clinical decision-making in cancer MDT meetings, to 
review the existing evidence on factors that affect decision-making by MDTs. In Chapters 3 
and 4 I use data from a national survey, which explores the views of MDT members from 
different professional groups across a range of tumour types, to analyse consensus and 
difference between tumour types for a range of statements (Chapter 3), and attitudes towards 
teamworking and patient-centeredness in MDT decision-making (Chapter 4). In Chapters 5 
and 6 I use the findings from Chapters 1 to 4 as a framework to explore in depth the personal 
experiences and views of patients and of members of urology MDTs. Evidence from existing 
literature, and the experiences of healthcare professionals and patients are used in Chapter 7 
to inform the development of a tool for the observational assessment of team decision-
making in MDT meetings- MDT-MODe. In Chapter 8 the validity of MDT-MODe is tested 
through cross-validation against the self-assessment of MDT members, before the tool is used 
to prospectively assess the relationship between decision-making efficacy, organisational 
factors, information availability and team members‘ contribution in Chapter 9. Having built 
up a picture of the factors that are important for decision-making in MDT meetings, and 
equipped with a tool to measure this process, Chapter 10 will describe the development and 
evaluation of MDT-QuIC, an intervention to improve decision-making in MDT meetings. 
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Finally, in Chapter 11 I will report a prospective study that uses MDT-MODe to evaluate a 
multistage intervention to improve the quality of clinical decision-making in MDT meetings. 
 
The aims of this thesis are: 
1. To review and evaluate the evidence-base for team decision-making by 
multidisciplinary cancer teams (Introduction and Chapter 2) 
2. To assess the views and experiences of health care professionals regarding decision-
making in MDT meetings (Chapters 3, 4 and 6) 
3. To evaluate the views of cancer patients in order to inform subsequent studies and 
ensure this research is patient-centred (Chapter 5) 
4. To scientifically develop and evaluate objective assessment tools for use in urology 
MDT meetings (Chapters 7 to 9) 
5. To develop and evaluate an intervention to improve decision-making in urology MDT 
meetings (Chapters 10 and 11) 
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2 TEAM DECISION MAKING BY CANCER 
MULTIDISCIPLINARY TEAMS: A SYSTEMATIC REVIEW 
 
2.1 Chapter overview  
In Chapter 2 I present a systematic review of the evidence for clinical decision-making in 
cancer MDT meetings, to review the existing evidence on factors that affect decision-making 
by MDTs. 
 
2.2 Introduction 
A narrative review of MDT effectiveness by Fleissig et al highlights that there is little 
evidence that MDTs improve the quality of clinical decision making and very little is known 
about the decision-making process itself (1).
 
As I mentioned in the Introduction, the majority 
of research has looked at the effect of MDTs on various measures of process, whether it is the 
ability to reach a decision, the quality of the decision, a change in decision or whether a 
decision is implemented. The body of research into MDT working in cancer care appears to 
be extremely diverse, covering multiple cancer specialties, many different methodologies, 
assessing a variety of outcomes.  
 
2.3 Aims 
The aim of this Chapter is to systematically review the literature on decision-making in 
cancer MDTs to assess the factors that affect decision-making and their value for patients. 
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My analysis assesses the information preferences, interpretation of information, changes to 
decisions, and implementation of decisions by MDT members. It also analyses membership, 
leadership, and workload of the MDT as well as the effect of telemedicine and the 
involvement of patients on decision-making by the MDT. 
Table 1: Search strategy 
1 (decision$2 or conclusion$1 or judgement$1 or opinion$1 or choice$1 or choose or chose$1 or 
select$3 or option$1 or (decision adj making) or attitude$1).mp. or decision-making.ti,ab. [mp=title, 
original title, abstract, name of substance word, subject heading word] 
2 (malignan$2 or tumour$1 or tumor$1 or carcinoma).mp. or neoplas$2.ti,ab. [mp=title, original title, 
abstract, name of substance word, subject heading word] 
3 decisions/ or (decision/ adj making/) or decide/ or choice/ or option/ or opinion/ or attitude/ 
4 malignancy/ or tumour/ or tumor/ or cancer/ or neoplasm/ 
5 multidisciplinary/ or multi-disciplinary/ or (multi/ adj disciplinary/) 
6 (multidisciplin$3 or multi-disciplin$3 or (multi adj disciplin$3) or multiprofession$2 or multi-
profession$2).mp. or (multi adj profession$2).ti,ab. [mp=title, original title, abstract, name of 
substance word, subject heading word] 
7 1 or 3 
8 4 or 2 
9 6 or 5 
10 8 and 7 and 9 
11 10 
12 limit 11 to (abstracts and English language and humans) 
13 limit 12 to yr="2004-2009" 
14 remove duplicates from 13 
 
2.4 Methods 
2.4.1 Search strategy and selection criteria 
I undertook systematic literature searches of Embase, Medline, PsycINFO (using OvidSP), 
and the Cochrane database. The free text and MeSH search terms used were variations of 
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―decision-making‖, ―neoplasm‖, ―multi-disciplinary‖ and ―team‖. Results were limited to 
human beings, English language, and dates 1999 to 15
th
 May 2009 (Table 1). I also hand-
searched studies through consultation with experts in the field, scrutiny of reference lists of 
retrieved papers, existing reviews, guidelines and Department of Health documents. 
Retrieved titles and abstracts had to relate to decision-making by healthcare professionals, 
who attend multi-disciplinary cancer teams. Articles had to present empirical data for 
decisions relating to diagnosis or treatment of patients that occurred as part of the MDT 
meeting. These criteria were applied to a sample of 100 titles and abstracts by another 
researcher with a background in psychology (Brown) to check the validity of the selection 
criteria. Cohen‘s Kappa coefficient was 0·790. 
  
2.4.2 Quality assessment and data abstraction 
Quality of the included papers was assessed formally with an assessment tool designed for 
use in systematic reviews of heterogeneous articles (69). I scored the papers in different 
domains from zero to two giving a minimum of zero and a maximum for quantitative papers 
of 18 and for qualitative papers of 24 (the quality scoring data are included in Appendices 1 
and 2). Internal validity was checked against a random sample of ten quantitative papers 
(32;34-36;44;51;55;68;70;71) and all three qualitative studies (56;57;72) scored by another 
researcher (Nagpal). Quantitative papers were assigned a number from one to 34 and a 
random sample was selected using an online random number generator (73). Cohen‘s Kappa 
coefficient was 0·765.  
Data were abstracted by myself for: country in which the study was undertaken; clinical 
specialty; setting of the MDT; number of participants; patient characteristics; healthcare 
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professional characteristics; study design; objectives; and study findings. Given the 
heterogeneous nature of the outcomes being assessed summary measures were not possible. 
 
2.5 Results 
2.5.1 Study Characteristics 
2484 articles were retrieved by the search criteria above (Figure 3). 2432 articles were 
excluded by review of title or abstract, and a further 26 by reviewing the full text. Nine 
studies were identified from hand-searching and were included in the review. The 37 
included studies were articles published in peer-reviewed journals between 2000 and 2008 
inclusive. Papers were from ten countries: UK (n=20),(32;38;40;41;46;49;51;53-
59;65;71;72;74-76) France (n=4),(43;62;68;77) USA (n=3),(35-37) Australia 
(n=3),(48;61;70) and Germany (n=2).(33;63) Hong Kong,(78) Finland,(44) Holland,(42) 
Sweden,(52) and India.(34) Ten specialities were represented: breast 
(n=12),(36;37;46;48;49;51;70;72;74;75;77;78) lung (n=5),(38;53;54;62;71) gynaecology 
(n=4),(34;35;56;57) urology (n=3),(32;40;41) upper gastrointestinal (n=3),(33;55;58) 
colorectal (n=3),(42;59;76) sarcoma (n=2),(43;68) brain (n=1),(63) and head and neck 
(n=1).(52)  One study looked at nurses,(44) one investigated MDT coordinators,(65) and one 
surveyed Consultant/Attending-level surgeons involved in MDT meetings.(49) One study 
was set at a local MDT.(32) Eight studies were undertaken at teaching hospitals (33-
38;44;78) and 16 at specialist or regional MDTs.(43;48;51-56;58;59;62;63;68;71;74;75) 
There was one regional survey from Australia,(61) and a further eight studies were national 
surveys – one from Australia,(70) and seven from the UK.(40;41;46;49;65;72;76) (Table 2) 
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Figure 3: Study selection flow diagram 
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Table 2: Study characteristics 
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Effect of MDT on 
decision 
Women with breast 
lesions referred to 
tumour board. Median 
age 49 (26-82) 
Surgical oncologist, radiation 
oncologist, medical oncologist, 
radiologist, pathologist, plastic 
surgeon. 
Prospective Intervention (MDT 
meeting), pre-post intervention 
assessment. 
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Use of telemedicine 
MDT structure and 
process 
N/S Surgeons, radiologist, medical 
oncologists, radiation oncologists, 
nurses, pathologist. 
12 consecutive weeks of face-to-face 
MDT followed by 12 weeks of 
video-conferences. Video connected 
3 sites. 
3x face-to-face and 3x telemedicine 
MDTs recorded and analysed by 
anthropologist and linguist. 
Pre-trial and post trial questionnaires 
about attitudes towards MDT and 
telemedicine. 
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Use of decision 
tools 
Breast cancer patients MDT made up of 15-20 cancer 
specialists. 
Intervention study assessing the 
effect of computer decision tool on 
decision making. Pre-post control. 
Survey of clinician attitudes to 
computer decision tool. 
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Effect of MDT on 
decision 
Patients with 
inoperable NSCLC 
Control: 18% <60, 
66% male. 
Intervention: 18% <60, 
60% male. 
Respiratory physicians, surgeons, 
medical oncologists, clinical 
oncologists, palliative care physician, 
radiologist, nurse specialist. 
Retrospective case note analysis of 
control group. Intervention group 
prospectively analysed. 
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Effect of MDT on 
decision 
Cases of ovarian 
cancer referred to the 
MDT. 
Consultants and residents at 
department of pathology and medical 
oncology. 
Prospective Intervention (MDT 
meeting), pre-post intervention 
assessment. 
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 Effect of MDT on 
decision 
Patients with 
gynaecological 
cancers. 116 new, 121 
post operative review. 
Attending physicians, residents, 
oncology nurses and research staff, 
social workers. 
Prospective Intervention (MDT 
meeting), pre-post intervention 
assessment. 
H
aw
ar
d
 
et
 a
l 
2
0
0
3
 
1
2
 
U
K
 
B
re
as
t 
N
at
io
n
al
 
su
rv
ey
 
5
4
8
†
 
Leadership in MDT 
MDT structure and 
process 
N/A Surgeons, breast nurses, pathologists, 
radiologists, clinical oncologists, 
medical oncologists. Mean age 45.5 
(SD 8.1); female 46.5%. 
Random sample of English Breast 
teams. Postal questionnaire. 
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Information used 
for decision 
N/A Registered nurses 
 
Simulated case descriptions with 
survey to ascertain information used 
by nurses. 
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MDT structure and 
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 Use of telemedicine N/S Oncologist, surgeons, radiologist, 
oncologist, breast care nurses. 
MDTs randomised into 4 weekly 
blocks (telemedicine 48/ face-to-face 
28). Survey into attitudes towards 
MDT before and at 28 weeks. 
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 Use of telemedicine Patients with breast 
cancer 
Consultant surgeons, oncologists, 
pathologists, radiologists and breast 
care nurses. 
Cluster randomisation of 12x 4-week 
blocks of telemedicine or face-to-
face with 2:1 ratio. 2 consecutive 6-
month periods; Cost-minimisation 
analysis; Survey. 
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Use of decision 
tools 
Information used 
for decision 
Decision model 
trialled on 48 cases of 
metastatic colorectal 
cancer. 
Colorectal surgeons Computer based decision model 
designed from cues used by surgeons 
when making treatment decisions. 
Decision model compared with Real 
treatment for 48 patients. 
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Implementation of 
MDT 
Decision failure 
72.9% male, 43% 
<65yrs, 39.8% 65-75, 
17.1% >75. 
24: Thoracic surgery, thoracic 
oncology, pulmonology, 
radiotherapy, radiology, pathology, 
nuclear medicine. 
Prospective cohort of 344 patients 
discussed at 51 meetings over 1 year. 
F/U for 9 months. 
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Implementation of 
MDT 
Median age 55 (3-90). 
57% male. 
Neuropathology, neuroradiology, 
neurology, neurosurgery, radiation 
oncology. 
Retrospective analysis of random 
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Leadership in MDT 
MDT structure and 
process 
N/A 136 surgeons involved in breast 
cancer. 
 
127 consultant surgeons. 
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with British Association of Surgical 
Oncology. 
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Effect of MDT on 
decision 
149 consecutive 
patients referred to 
tumour board for 2nd 
opinion. 
Surgeons, oncologists, radiologists, 
pathologists, radiation oncologists, 
nurses. 
Retrospective case notes review 
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Sarcoma, melanoma, 
carcinoma of unknown 
primary. Curative 
intent 42, palliative 68. 
GP's who had referred a patient in the 
18 months preceding the study. 
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Information used 
for decision 
Effect of MDT on 
diagnosis/treatment 
Patients with Soft 
tissue sarcoma. 
Median age 53 (18-
99), 50% male 
Surgeon, radiation oncologist, 
medical oncologist, radiologist, 
pathologist. 
Retrospective notes review cohort 
study 
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Use of decision 
tools 
Female breast cancer 
patients. 
Surgeons, radiologist, oncologist, 
radiotherapist, pathologist, 
oncogenetecist 
6 months of control MDT meetings 
analysed retrospectively, followed by 
6 months of MDT meetings using 
decision tool analysed prospectively. 
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Effect of MDT on 
diagnosis/treatment 
MDT structure and 
process 
Legal aspects of 
MDT decision 
Discussion 
environment 
Patient involvement 
in MDT 
N/A Male 63%. 
Surgeons, Medical oncologists, radiation 
oncologists, radiologists, pathologists, 
haematologists, physicians. 
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 Use of telemedicine 
MDT structure and 
process 
N/A Colorectal cancer teams Postal survey 
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Implementation of 
MDT 
Use of telemedicine 
ENT patients Oncology, radiology, pathology, dental 
surgery, general surgery, thoracic 
surgery, dietetics, 
Prospective cohort of referred patients to 
weekly MDT 1 year. 
Retrospective nested case-control with 
telemedicine as exposure. 
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Information used for 
decision 
Reliability of 
decision making 
N/A Consultant urologists 57 simulated cases using 9 cues (13 
duplicated). Preference for 3 treatments 
for prostate cancer. 
60 
 
A
u
th
o
r
 
D
a
te
 
Q
u
a
li
ty
 s
co
re
 
(1
8
) 
C
o
u
n
tr
y
 
S
p
ec
ia
li
ty
 
M
D
T
 S
et
ti
n
g
 
N
u
m
b
er
 
Themes Cases Healthcare professionals Study design 
W
o
o
d
 e
t 
al
 
2
0
0
8
 
1
0
 
U
K
 
C
o
lo
re
ct
al
 
S
p
ec
ia
li
st
 
2
0
1
‡
 
Implementation of 
MDT 
Colorectal cancer new 
and old presentation. 
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2.5.2 Study Quality  
The median quality score for quantitative papers was nine of 18 (range 3-15) and for 
qualitative papers was 13 of 24 (range 9-14). Study methodology included non-randomised 
control trials (n=10), surveys (n=9), cohort studies (n=7), observation studies (n=5), 
qualitative studies (n=3), simulations (n=3), and one randomised control trial (n=1). Due to 
the heterogeneity of the included studies results could not be combined. (Appendices 1 and 2) 
Every endpoint presented in the studies has been included in the results tables. Some studies 
have multiple endpoints and these were split across different tables to enable cross-study 
comparison (Table 2). 
 
2.5.3 Decision-making efficacy: failures to make decisions and decision 
implementation (Table 3)  
One study found that a decision on management could be reached at the first MDT meeting in 
only 73% of cases. Reasons for failure were often attributable to gaps in the information 
needed to make decisions, including proper imaging, investigations of tumour stage, review 
of pathology and comorbidities.(52) In another study, the proportion of MDTs reaching a 
firm decision at the first MDT presentation was only 47.6%, but underlying reasons were not 
investigated.(62) Time pressure is one factor that has been linked with failure or difficulty to 
reach a decision.(56) 
Disagreements within MDT are uncommon, and even when they occur team-members are 
reluctant to officially dissent.(61)
 
Interestingly, only 48% of respondents in this study were 
aware of their individual liability for MDT decisions – which is important, not least because 
those dissenters are still legally responsible.
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Table 3: Decision-making efficacy: failures to make decisions and decision implementation 
Lead author Themes Results 
Blazeby  et al  2005 
Compliance with MDT 
decision 
41/271 not implemented (15·1%, 95% CI 11·1-20·0%): 18 (43·9%) patient co morbidity, 14 (34·2%) patient choice, 8 (19·5%) 
when more clinical info available. 
Bumm  et al  2007 
Compliance with MDT 
decision 
32/807 (4%)  MDT decisions were not implemented. No further information given. 
Lanceley et al 2008 
To explore the process of 
decision-making in MDT. 
The team: 30+members. Meetings highly pressurised, crowded, swift and technical. Little time. Some members resented 
technicality. Meetings favoured traditional professional hierarchies. 
 
Leo et al  2007 
Compliance with MDT 
decision 
15/344 (4·4%) MDT decisions not implemented. (7 refused treatment. 5 co-morbidities prevented treatment. 1 doctor gained 
second opinion. 2 lost to follow up). 
Establishment of diagnosis 
and treatment plan at MDT 
meeting 
164/344 (47.6%) decisions possible at first meeting, 112 (32.6%) at second, 51 (14.8%) at third and 17 (5%) at later meetings. 
Lutterbach et al  
2004 
Compliance with MDT 
decision 
45/500 (9%) of MDT decisions were not implemented. (26  due to lack of progression, 5 due to decline in condition. 14 due to 
local physician choice). 
Sidhom   et al 2008 
Awareness of individual legal 
liability if MDT negligent 
Awareness of individual liability 48%  
Significant disagreement with 
final decision: 
15% never, 58% rarely, 25% occasionally, 2% often. Of those who disagreed 71% never formally dissented. 
Stalfors et al  2007 
Establishment of diagnosis 
and treatment plan at first 
MDT meeting 
236/324 (73%) decisions possible at first meeting. Failures: lack of imaging 42%, extra staging information needed 30%, 
histological problems 7%, comorbidity information needed 6%, 16% more than 1 of above.  
Wood et al 2007 
Compliance with MDT 
decision 
20/201 not implemented (10%, 95% CI 6·3-15·2%) (9 co morbidity, 7 patient choice, 2 further clinical information at time of 
surgery) Odds ratio of discordance 4·9 for palliative intent (P= 0·002). Not significant for age or gender.  
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Not all decisions made in a MDT are implemented: decisions are not implemented in 1-16% 
of cases because of contradictory patient choice and treatments being inappropriate in view of 
comorbidities.(33;52;58;59;62;63) 
 
2.5.4 Information used to make decisions (Table 4) 
Physicians attending MDTs base their decisions almost exclusively on biomedical 
information. Clarke et al (40) and Wilson et al (41) studied the information used by 30 
urologists each in deciding upon a treatment option for patients with urological cancer. 
Prostatectomy was mostly decided on the basis of PSA, 10yr survival, and MRI/Lap stage. 
Radiotherapy+/-hormones was decided upon 10yr survival, PSA, and Gleason grade. Finally, 
decision for active surveillance/hormones was based on 10yr survival, MRI/Lap stage, and 
PSA. In Wilson et al‟s study prostatectomy was determined by digital rectal examination 
(DRE), stage, and PSA; radical radiotherapy was chosen based on Gleason grade, DRE, and 
patient age; and active surveillance/hormones based on age, DRE, and stage. Patient choice 
was used by a minority of urologists (seven of 30) in Clark et al, and was not used at all in 
Wilson et al. Similarly, Langenhoff et al found that colorectal surgeons base their decision-
making on patient age, whether metastases were unilateral or bilateral and the proximity of 
the lesions to major blood vessels.(42) Similarly biomedical information was found by Penel 
et al in their study of palliative intent.(43) Lanceley et al‟s and Kidger et al‟s qualitative 
studies confirm these findings: these researchers showed that decisions are made by 
physicians with little nursing input on the basis of biomedical information over patient-
related factors such as psychosocial situation and the patients‘ wishes.(56;57) Nursing 
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Table 4: Information used to make decisions 
Lead Author Theme Result 
Clarke et al 2007 
Information preference of Urologist 
for three treatments for prostate 
cancer. 
Cues used significantly for prostatectomy were PSA (n=27), 10yr survival (n=20), MRI/Lap stage (n=19);  
For radiotherapy+/-hormones were 10yr survival (n=12), PSA (n=12), Gleason grade (n=13);  
For active surveillance/hormones were 10yr survival (n=23), MRI/Lap stage (n=16), PSA (n=10) (all p<0.01, multiple 
stepwise linear regression analysis). 
Junnola et al 2001 
Information acquired to make 
decisions. 
Pain, family situation, pain medication, spread of cancer, psychosocial situation (in order of importance).  
Information guiding actions when 
making decisions 
Information from patient, knowledge and experience of nurse, medical diagnosis, nursing education, personal values (in 
order of importance). 
Kidger et al  2008 
Factors that influence decision 
making in the MDT 
(1) Unsystematic consideration of patient related factors (comorbidity, psychosocial situation, patient wishes), privileged 
role of disease/pathological information in decision making.  
(2) Variation in team members‘ role and level of participation in discussions, depending on their profession. 
Lanceley et al 2008 
To explore the process of decision-
making in MDT. 
(1) The team: 30+members. Meetings highly pressurised, crowded, swift and technical. Little time. Some members 
resented technicality. Meetings favoured traditional professional hierarchies. 
(2) The discussion: junior medical staff began discussion. This set a disease focussed discussion, excluding non-medical 
team members from contributing. Not open to challenge.  
(3) Psychosocial information: another form of knowledge concerning personhood, ethics and morality. Nurses were talked 
over and biomedical knowledge prevailed.  
(4) Union of medical and psycho-social information: when good knowledge of patients was present, the different strands 
were integrated. This gave an improved discussion. 
Langenhoff et al  
2007 
Information preference of surgeons 
when choosing from 4 treatments for 
colorectal cancer metastases. 
Patient age, extra hepatic spread, uni/bilobar disease and location of metastases in regards to large vessels all used 
significantly (all P<0·001, Chi squared). Number of metastases and size of largest lesion also correlated but less so.  
Penel  et al 2008 
To see which factors are associated 
with palliative treatment intent 
Factors significantly correlated with palliative intent- contraindication to general anaesthetic (P=0·001), head and neck 
location (P=0·017), visceral sarcoma (P=0·022), tumour >8cm (P=0·008), and presence of metastases (P=0·001) (Cox 
multivariate proportional hazards model). 
Wilson  et al  2007 
Information preference of Urologist 
for 3 treatments for prostate cancer. 
Cues used significantly for:  
Prostatectomy was digital rectal examination (DRE) (94%), stage (90%), PSA (84%); 
Radical radiotherapy was Gleason grade (44%), DRE (25%), Age (19%); 
Active surveillance/hormones were age (63%), DRE (60%), stage (53%) (All p<0.01, Spearman‘s correlation).  
Patient choice not used significantly by any consultant. 
65 
 
personnel, in contrast, typically prioritises information about the patients‘ symptoms, 
psychosocial and family situation.(44)
 
Interestingly, MDT discussions are rated very high 
when biomedical discussion is combined with a more holistic discussion of the patient as a 
human being. (56)  
 
2.5.5 Information interpretation and comparison of decision making by individuals 
with that of MDTs (Table 5) 
Three studies showed that the MDTs change the interpretation of information presented to the 
meeting. Chang et al (36) found that 4% of pathological specimens were reinterpreted; 
Ganesan et al (34) found that MDT discussion resulted in change to the diagnosis in more 
than half of the cases (52%); and Davies et al found that MDTs outperforms a range of other 
diagnostics tests, including CT, oesophageal ultrasound, and laparoscopic ultrasound in 
tumour staging.(55) However, two studies by the same research group showed no significant 
difference to individual or the group prognostications or survival predictions before and after 
MDT discussion.(54;71) 
 
Seven studies found that MDTs affect treatment decision in 2-52% of cases.(32-37) These 
studies did not show the reasons for changes, or whether decision-making improved. A study 
by Forrest et al shows that the number of patients being offered chemotherapy was 
significantly higher after the introduction of MDT (7% to 23%), and the proportion of 
palliative care fell (58% to 44%). The authors postulated that this finding could indicate that 
the MDT takes a more proactive approach to treatment than individual clinicians alone 
(although they note that other factors could also have contributed) (Table 4).(38) In addition, 
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Table 5: Information interpretation and individual vs. MDT decisions 
Lead Author Theme Result 
Acher  et al   2005 
Effect of MDT on treatment 
decision 
2/124 (2%) management changed as result of discussion. 
Bumm  et al 2007 
Effect of MDT on treatment 
decision 
36% of subset of 1545 decisions modified by MDT. No further information given. 
Chang  et al  2001 
Effect of MDT on diagnosis 3 of 77 (4%) pathological diagnoses changed by MDT. 
Effect of MDT on treatment 
decision 
32 of 77 (43%) decisions modified by MDT.  Of 32, 10 needed further workup, 3 had pathology re-evaluated 15 more 
conservative treatment given, 4 more invasive treatments. 
Davies et al  2006 
Effect of MDT meeting on 
accuracy of staging.  
T stage: oesophageal- MDT more accurate than CT (p<0·02, Chi-squared). N stage: oesophageal- MDT more accurate than CT 
(p<0·001, Chi-squared), Oesophageal ultrasound (EUS) (p<0·01, Chi-squared), Laparoscopic ultrasound (LUS) (p<0·01, Chi-
squared); gastric- MDT more accurate than CT (p<0·03, Chi-squared), EUS (p<0·02, Chi-squared), LUS (p<0·05, Chi-squared). 
Accuracy of treatment 
decision  
Incorrect treatment given: Oesophageal cancer: CT scans alone 42 of 94 (44.7%), EUS alone 31 of 94 (33%), LUS alone 11 of 28 
(39%), MDT discussion 17 of 94 (18.1%). Gastric cancer: CT alone 6 of 24 (25%), EUS 8 of 24 (33%), LUS 5 of 11 (45%), 
MDT 7 of 24 (29%). No effect sizes given. 
Forrest  et al  2005 
Effect of MDT on treatment 
decision 
Chemotherapy:  pre 7% v post 23% P=<0·001. Palliative care: pre 58% v post 44% P=0.045. Overall change in treatment 
P=0·003. 
Ganesan et al  2008 
Effect of MDT on diagnosis Change in diagnosis in 48/91 (52%) cases (Grading modifications in 34 cases, non-grading modifications in 14 cases). 
Effect of MDT on treatment 
decision 
20/91 (22%) decisions modified by MDT (Changed grading 9 cases, alterations in histopathology 3 cases, change to primary site 
8 cases). 
Gatcliffe et al  2008 
Effect of MDT on treatment 
decision 
 13/153 (8.5%) of decisions modified by MDT (change from pathology 6, radiology 2, staging 4, oncologist 1 case) 
Kee et al  2007 
Effect of MDT meeting on 
accuracy of individual 
clinician prognostication 
Mean difference after MDT discussion 0·007, (95% CI -0·014 to 0·001). No significant difference. 
Effect of MDT meeting on 
accuracy of group prognostic 
estimates. 
Mean difference after MDT discussion 0·01. No effect size reported. 
67 
 
Lead Author Theme Result 
Kee et al 2004 
Effect of MDT on treatment 
decision 
39% of decisions modified by MDT (no reason given). 
Effect of MDT on quality of 
clinician decision 
Combined mean net utility -0·00087 (95% Confidence interval -0·00487 to 0·00313). No significant difference. 
Effect of MDT discussion on 
clinician prediction of survival 
No significant difference between mean predictions of survival (P= 0·236)   or morbidity (P= 0·916) before and after MDT 
discussion (Wilcoxon Signed Rank Test). 
Newman  et al  2006 
Change in decision from MDT 
discussion 
48 of 149 (32%) decisions modified by MDT due to reappraisal in line with guidelines. 
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one study found that accuracy of staging with MDT at least as good as the individual 
modalities and in some cases better, but no effect size was reported.(55) No significant 
improvement in prognostication or survival prediction by MDT over individual clinicians‘ 
estimates were found in two studies that investigated them.(54;71) 
 
2.5.6 Teamworking and leadership in MDTs (Table 6) 
Time pressure and workload are key factors affecting the quality of the MDT work. Team 
performance is negatively affected by workload.(46) Time pressure is often observed in 
MDTs, rendering decision-making rushed (57) and lowering team-members‘ attendance.(48) 
Sidhom et al found that the biggest limitation of MDTs was when patients were not worked 
up enough prior to their case discussion.(61) Protected time for these meetings and 
preparation has been reported as a key improvement to MDT functioning.(49) 
 
One survey study has assessed team-members‘ views of the MDT environment.(61) Team-
members perceive the MDT as an environment in which optimal management plans are 
formulated, treatment is coordinated, and likelihood of error is reduced. In the same study, 
67% of Consultant/Attending-level team-members reported that they typically work in an 
open and free MDT environment. Comparing different professional groups, surgeons tend to 
be more content with the teamworking than other specialties.(61) However, the role of 
nursing personnel in these meetings appears to be limited.  A number of studies found that 
nurses bring the patient‘s views and psychosocial aspects of care to the MDT.(56;57;72) 
Nurses‘ views however are often ignored, and nurses do not speak at the meetings.(56;57) 
When they are actively involved, performance of the team is higher.(46) In addition to 
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Table 6: Teamworking and leadership in MDTs 
Lead Author Theme Result 
Amir  et al 2004 
Professional roles of Breast 
cancer nurses. 
(1) Role in ensuring the co-ordination, communication and planning of the team not recognised outside the team.  
(2) Role in making the bureaucracy respond to patients and family.  
(3) Role to assess patients' concerns and incorporate them into the plan.  
(4)  Confidence and humour (5) politically restricted compared to doctors. 
Butow  et al 2007 
Current practice of involving 
patients in MDT meetings:  
Only 12 of 300 (4%) healthcare professionals' work practice allowed for patient attendance.  
Involving patients in  
discussion of their own case 
126 of 135 (93%) patient advocates, 41 of 56 (73%) nurses, of 45 of 142 (32%) surgeons, 16 of 65 (25%) medical and 7 of 31 (24%)  
radiation oncologists thought it would benefit patients (Chi squared, P<0·001). 
Delaney  et al 2004 
Effect of telemedicine on non 
attendance at MDT meetings 
63% regularly attended face-to-face MDTM. Non attendance due to time commitments, schedule clashes, too few cases to make 
worthwhile.  
Haward et al  2003 
Evaluation of Leadership in 
breast teams in England. 
Positive correlates: a number of leaders (β=0·258, p=0·018). Negative correlates: one leader (β=-0·353, p=0·002), lack of leadership 
clarity(β=0·382, p=0·001), leadership conflict ( β=0·453, p=0·001), (all stepwise regression analysis) 
Team composition and self 
reported effectiveness 
Self-reported team effectiveness increased with team size (β=0·254, p=0·034), team diversity (β=0·428, p=0·001), and number of 
medical oncologists (β=0·243, p=0·044). Breast surgeons (p=0·05) and breast care nurses (p=0·01) associated with higher self-reports of 
effectiveness. Radiologists (β=0·235, p=0·035) and clinical oncologists (β=0·241, p=0·041) associated with lower self reports of team 
effectiveness. (all stepwise regression analysis) 
Team input and clinical 
performance 
Clinical performance correlated with proportion of breast cancer nurses (β=0·376, p=0·0003) (stepwise regression analysis), workload 
(β=0·331, p=0·009) (stepwise regression analysis), and proportion of new cases (r=0·262, p=0·045) (univariate analysis). Negative 
correlates: Number of hospitals team operated over (β=-0·342, p=0·011) (stepwise regression analysis). 
Kidger et al  2008 
Factors that influence decision 
making in the MDT 
(1) Unsystematic consideration of patient related factors (comorbidity, psychosocial situation, patient wishes), privileged role of 
disease/pathological information in decision making.  
(2) Variation in team members‘ role and level of participation in discussions, depending on their profession. 
 (3) Different pathways of discussion- quick and decisive, long and decisive, long with no decision. 
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Lead Author Theme Result 
Lanceley et al 2008 
To explore the process of 
decision-making in MDT. 
(1) The team: 30+members. Meetings highly pressurised, crowded, swift and technical. Some members resented technicality. Meetings 
favoured traditional professional hierarchies. 
(2) The discussion: junior medical staff began discussion. This set a disease focussed discussion, excluding non-medical team members 
from contributing. Not open to challenge.  
(3) Psychosocial information: another form of knowledge concerning personhood, ethics and morality. Nurses were talked over and 
biomedical knowledge prevailed.  
(4) Union of medical and psycho-social information: when good knowledge of patients was present, the different strands were 
integrated. This gave an improved discussion. 
Macaskill  et al 
2006 
Timing of MDT meetings 
attended 
Protection of time for MDT meetings: 28% protected session, 72% unprotected (51·5% lunchtime, 26·5% breakfast, 6·6% evening).  
Chairperson of MDT meeting Chair: surgeon 76·5%, radiologist 14%, rotating chair 5·9%.  
Improvements to MDT 
meeting 
78% wanted more time or protected sessions.  
Sidhom   et al 2008 
Limitations of MDTM:  Failure to adequately work patients up before discussion 69%, inadequate time and resources 45%.  
Discussion environment: 67% felt open and free. 49% radiation oncologists felt discussion environment suboptimal vs. 22% surgeons and 21% medical 
oncologists. (P=0·003). 
Perceived benefits of MDT:  Best management plan generated 61%, coordinated service delivery 18%, minimization of error 11%, good learning environment for 
participants 10%.  
Effect of patient attendance on 
understanding of legal 
position 
Where patients attend MDTs 63% understood legal position vs. 42% if patients not attending (P= 0·04, chi-squared). 
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nursing staff, generally larger and more diverse teams are associated with increased self-
reported effectiveness.(46)   
 
Regarding MDT leadership, surgeons tend to lead MDTs.(49) Haward et al found that having 
several leaders (not within one meeting) contributed to better teamworking, whereas having 
one stable leader makes team work deteriorate. Lack of clarity in leadership and conflicts also 
significantly impede teamworking.(46)
 
 
General practitioners were found to be generally satisfied with the way decisions were 
communicated, and most were happy not to take part in MDT discussions.(68) 
 
2.5.7 Patient involvement (Table 7) 
One Australian study found that only 4% of healthcare professionals‘ MDTs involve patients 
in their meetings. Most clinicians (surgeons, medical and clinical oncologists) were not keen 
to do so, whereas patient advocates and nursing personnel are significantly more positive 
about patient involvement.(70) 
 
Interestingly, Sidhom et al found that clinicians who included 
patients in the MDT had a significantly better understanding of their legal position compared 
to those who did not.(61) 
 
2.5.8 Technology: telemedicine and decision support systems (Table 7) 
Several studies have investigated various aspects of telemedicine in MDT meetings. A UK 
national survey in 2005 found that 30% of colorectal cancer teams (who responded) have 
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Table 7: Telemedicine and decision support systems 
Author Themes Results 
Davison et al 2004 
Change in resection rates before and after 
introduction of telemedicine 
Before telemedicine 14.7 resections/year. Post intervention 19/62 resections. No effect size. 
Change in time to resection after 
introduction of telemedicine 
Pre-telemedicine= 69 (SD 38); Post-telemedicine= 54 (SD 26). P>0·05 Student's T- test- No significant 
difference. 
Delaney et al 2004 
Effect of telemedicine on attendance of 
MDT meeting 
Face-to-face median 8 (4-10) vs. telemedicine median 10 (8-15). 
Effect of telemedicine on mean number of 
cases discussed at MDT meeting: 
Face-to-face 6 vs. telemedicine 4 (P<0·01, Student's T-test). 
Epstein et al 2006 
Extent to which regular use of web-based 
decision making tool affected MDT 
decisions. 
Treatment decision for adjuvant systemic therapy modified in 13 of 102 decisions (12·7%). 
Kunkler et al  2006 
Attitudes of clinicians to telemedicine for 
MDT meeting  
Pre-trial mean =96 (range 53-131, SD 19), after mean =93 (range 60-128, SD 20). 
Kunkler et al 2007 
Agreement of MDT decision with best 
practice guidelines. 
Face-to-face 116/116 (100%). telemedicine 136/137 (99%). 
Costs of service delivery as modified by 
cost avoidance due to telemedicine 
Cost neutral between 20-30 meetings per year. 
Satisfaction of MDT members with the 
quality of decisions 
No significant difference between telemedicine and face-to-face for appropriate sharing of decision on 
management, consensus on next steps in management or confidence in decision. 
Seroussi  et al  
2008 
To see whether decision tool reduced non-
compliance of decisions with clinical 
guidelines. 
Before introduction of decision tool: 179/226 (79·2%) compliant. After: 225/241 (93·4%) compliant. (P 
<0·0001 Fisher's exact test).  
Soukop et al 2006 Availability of telemedicine facilities. Videoconferencing facilities: available in 32 (30%), further 11 planning to acquire. only 17 used for MDT.  
Stalfors et al 2007 
Change in time to treatment for face-to-face 
vs. telemedicine 
Surgery: telemedicine= 19 days (5-34). Face-to-face = 14 days (5-59). Oncology: telemedicine= 38 (5-267). 
Face-to-face= 32 (3-229). No significant difference MWU test. 
Change in rate of treatment plan with 
telemedicine vs. without. 
Failure to reach a decision:  Face-to-face 69/234 (29%), telemedicine: 15/49 (31%). No effect size reported. 
73 
 
telemedicine facilities available.(65) A few studies have shown that decision-making that 
relies on telemedicine is not inferior to face to face decision-making,(51-53;74) whereas 
Delaney et al found telemedicine may improve attendance. This study, however, also showed 
that using telemedicine significant reduces number of cases discussed per meeting (from six 
to four).(48) Kunkler et al found that telemedicine can be cost-effective at 20-30 meetings per 
year.(51)  
 
Decision support is not used very often in MDTs, although there is evidence that they can 
improve care.(78) Seroussi et al found that compliance with clinical guidelines improved 
(79·2% to 93·4%) with the use of a decision tool.(77)  
 
2.6 Discussion 
2.6.1 Summary of results 
To the best of my knowledge this systematic review has looked at all the available literature 
concerning decision-making by healthcare professionals in cancer MDTs. The review has 
produced papers from ten countries around the world which confirms that this topic is of 
global significance.  
 
MDTs seem to make a difference to the outcome of decisions, compared with the decisions of 
individual clinicians. The literature shows the varied roles played by different team members 
within the MDT and that MDT decisions are sometimes not implemented, often because of 
insufficient information when a decision is made. This review has found that high-quality 
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decision making requires optimal support in the form comprehensive information at the point 
of decision-making, effective teamworking and leadership, protected time and good facilities. 
Use of telemedicine is increasing and can provide a cost effective way to improve attendance 
and synchronously present pathological and radiological information at different sites. 
 
2.6.2 Limitations 
There is an array of different outcomes being investigated and therefore only a small amount 
of research for any given cancer site (Table 2). This scarcity of research presents a complex 
issue for researchers and provides a limited evidence base on which clinicians can base MDT 
practice, presenting a challenge for future research. Although large, double-blind, randomised 
control trials are the gold standard of medical research, they may not be appropriate or 
feasible in this area. Larger prospective studies would reduce the risk of studies being under-
powered, a problem faced by several authors in my systematic review, and would help to 
eliminate bias.(54;55)  
 
This systematic review exposes several shortcomings in the literature on MDT decision 
making. The studies in this review were of variable quality and many were not able to give 
significance values or confidence intervals. The studies‘ methodological limitations probably 
reflect a pilot or feasibility status. Only one paper in this review examines activity of a local 
MDT.(32) Other studies are based at either teaching hospitals or specialist MDTs (often 
convened at city teaching hospitals), or are national surveys that do not draw the distinction 
between local and specialist/regional MDTs. This potential bias could arise because 
researchers, often based at teaching hospitals, may find it easier to study their institution‘s 
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own specialist MDT rather than a local MDT based elsewhere. Only one paper from India 
gives any indication of the work into decision-making in MDTs in the developing world.(34) 
MDTs may not be as widely practiced in the developing world, or research into MDTs may 
not be widely undertaken. There is also the possibility of publication bias towards research 
from these countries, and language bias given that I only selected papers published in 
English.  
 
2.7 Conclusion 
This Chapter summarised the current evidence surrounding decision making by MDTs across 
a range of specialities in multiple countries and has found that high-quality decision making 
in MDT meetings depends on a number of factors including comprehensive information at 
the point of decision-making, effective teamworking and leadership, protected time and good 
facilities. A recent national survey by the UK National Cancer Action Team suggests that 
many of these factors are relevant to healthcare professionals in the UK.(79)It is not known, 
however, whether these issues apply to professionals across all tumour types, or to particular 
tumour types, such as urology. It is important to explore which of the factors from the present 
Chapter healthcare professionals feel apply to their own clinical practice, and to which 
tumour types these issues are relevant. To this end, the following two Chapters describe 
analyses of the original data from the 2009 NCAT national survey(79) Chapter 3 explores 
areas of consensus and difference in opinion/perceptions between MDT members from 
different tumour types using data from closed survey questions. Chapter 4 uses health care 
professionals‘ own free text responses to questions that address the decision-making process 
in more depth.
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3 ANALYSIS OF A NATIONAL UK SURVEY ON 
MULTIDISCIPLINARY TEAM WORKING ACROSS 
DIFFERENT TUMOUR TYPES 
 
3.1 Chapter overview 
In this Chapter I analyse the responses of MDT members from a UK national survey to 
statements regarding MDT working, in order to assess consensus and difference across a 
range of tumour types. 
 
3.2 Introduction 
In the absence of empirical evidence about the characteristics of effective MDTs the National 
Cancer Action Team recently conducted a national survey of MDT members‘ perceptions of 
MDT working.(79)  Over 2000 MDT members responded to the survey which has enabled a 
working definition of MDT effectiveness to be developed. There was strong agreement about 
the components of effective MDT working in relation to various domains of teamworking, 
including aspects of the structure, resources and process of decision-making within cancer 
MDTs. The results from the 2009 NCAT survey were summarised in a report where 
descriptive comparisons were made of perceptions of MDT working across professional 
groups and tumour types but no statistical techniques were applied.(79) However, the 
underlying assumption that the basic model for MDT working is appropriate for all tumour 
types, including urology has not been validated.(80)  
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3.3 Aims 
The aim of the present Chapter is to empirically test this assumption regarding MDT working 
by applying appropriate statistical techniques to data from the national NCAT survey. 
Specifically, my objectives are to: 
1. Systematically analyse responses relating to the components of effective MDT 
working 
2. Identify areas of consensus and difference in opinion/perceptions between MDT 
members from different tumour types 
 
3.4 Methods 
3.4.1 The 2009 national NCAT survey  
The survey aimed to investigate MDT members‘ perceptions about effective MDT working.  
It was designed with input from a steering group consisting of 32 cancer professionals, 
including representatives from all core disciplines in cancer MDTs. Surveys were completed 
on-line between 30th January and 16th March 2009. The survey contained 131 statements 
which were rated on 1-4 Likert scales (1=strongly disagree, 4=strongly agree), along with 5 
additional multiple choice questions, all of which are included in the current analysis. In 
addition, there was a background section to collect information about respondents‘ 
demographics and current working practices and also some free text questions – these are not 
included in this paper. The domains of teamworking covered by the survey and analysed here 
are depicted in Figure 4.  
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Survey participants were recruited using a snowball sampling method via cancer networks, 
cancer service managers, the MDT coordinators forum and the Network Development 
Programme forum for Informatics. Participants were sent an introductory email with the web 
address of the survey, and were encouraged to circulate the details broadly amongst MDT 
members. A link to the survey was also provided on the National Cancer Intelligence 
Network website. Anonymity was assured and informed consent implied by completion of 
the survey. 
 
3.4.2 Participants 
Due to the focus on tumour type differences,  only respondents who were core or extended 
members of an MDT, and who worked in a single tumour type were included in analysis.  
The survey only enabled an ‗overall‘ opinion, rather than permitting respondents to give 
different responses for different teams/tumour types. Therefore the responses of those who 
work in more than one tumour type would be averaged across the different teams they work 
in, thus artificially reducing any difference that might occur between tumour types. In 
addition, members of tumour types with fewer than 100 responses were excluded to ensure 
all subgroup analyses were carried out on a statistically robust sample size. Included tumour 
types were breast, gynaecological, colorectal, upper gastrointestinal, urological, head and 
neck, haematological and lung.
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The team  Membership  
Attendance  
Leadership  
Team working & culture  
Personal development & training  
Infrastructure for Meetings  Physical environment of meeting venue  
Technology & equipment (availability & use)  
Meeting Organisation & 
Logistics  
Scheduling of MDT meetings  
Preparation prior to MDT meetings  
Organisation/administration during MDT meetings  
Post MDT meeting /co-ordination of service  
Patient-centred Clinical 
Decision-Making  
Who to discuss  
Patient-centred care  
Clinical decision-making process  
Team Governance  Organisational Support  
Data collection, analysis and audit of outcomes  
Clinical governance  
 
Figure 4: Domains of MDT working covered in the 2009 NCAT survey of cancer MDT members. Main 
headings are set out on the left with themes detailed on the right. 
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3.4.3 Analysis 
Following the NCAT report authors‘ recommendations, which were intended to render the 
analysis most meaningful, and also to simplify a very extensive dataset, responses were 
aggregated into agree/disagree categories (scale ratings 3 or 4=agree; scale rating 1 or 
2=disagree).(79) Three levels of analysis were undertaken. Firstly, statements for which the 
difference between the tumour group with the highest and the lowest percentage agreement 
was under 20% were treated as consensus. In these cases no further analysis was undertaken. 
Secondly, where the difference between the tumour group with the highest and the lowest 
percentage agreement was equal to, or more than 20%, the  nonparametric Kruskal Wallis test 
was applied to responses to each statement in order to explore differences  by tumour type.  
For each statement, a non-significant test result would indicate that responses were similar 
across tumour types, implying consensus. In these cases no further analysis was undertaken. 
A significant Kruskal Wallis test would indicate differences in perceptions across tumour 
types which were submitted to a third line of analysis.  For the third analysis, pair-wise 
comparisons were undertaken between the different tumour types using the nonparametric 
Mann Whitney U test. As in the previous analysis, non-significant Mann Whitney results 
between any two tumour types on pair-wise comparison would indicate consensus between 
the pair, whereas significant results would indicate differences in perception/opinion between 
specific tumour types. Bonferroni correction with nominal p<0.05 was used for multiple 
comparisons to minimise statistical bias (Type I error). All statistical analyses were 
performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).  
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3.5 Results 
3.5.1 Respondents 
Of 2054 respondents to the survey, 1141 met the criteria for inclusion in this analysis (were 
members of MDTs that only covered one tumour type and there were at least 100 respondents 
in the tumour type).  These included members of eight of the most common tumour types:  
Breast, Colorectal, Lung, Gynaecological, Head and Neck, Upper Gastro-Intestinal, 
Urological, and Haematological cancers, with the exclusion of skin, brain and CNS, sarcoma 
and children and young people due to sample size of less than 100. The professional groups 
of respondents within each tumour type are shown in Table 8. 
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Table 8: Responses of MDT members by professional group and tumour type 
 Respondents by tumour type (%) 
Professional  Group Bre Col Lun Gyn H&N UGI Uro Haem Total 
Surgeon 22 36 3 35 25 19 34 0 21 
Radiologist 15 2 3 4 2 2 1 2 5 
Histo/cytopathologist 4 1 2 5 3 0 2 1 2 
Oncologist 6 0 3 4 0 0 4 2 3 
Haematologist 0 0 0 0 0 0 0 53 8 
Other Doctor (Physician, GP etc) 2 1 41 4 3 15 0 6 9 
Palliative care specialist 0 0 0 1 1 1 0 1 0 
Clinical Nurse Specialist 29 42 32 32 28 37 37 21 32 
Nursing (other) 0 1 0 0 2 0 1 2 1 
Allied Health Professional 8 0 0 0 28 4 0 3 5 
MDT coordinator 10 16 14 11 8 21 19 7 13 
Other (admin/clerical and managerial) 2 1 1 3 1 1 1 2 1 
Total number 204 134 146 116 109 124 134 174 1141 
 
3.5.2 Consensus and differences across tumour types 
The responses to 116 of the total 136 statements were similar across tumour types (no 
significant difference across tumour types, as assessed by Kruskal Wallis tests and Mann 
Whitney U test). The remaining 20 statements showed significant differences between the 
responses of different tumour types (Table 9).  
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Table 9: Statements with significant differences in agreement/opinion between MDT members from 
different tumour types; Mann Whitney U Test; Significance level P≤0.001. 
Domain 
No 
Significant 
difference 
Significant 
difference 
The team Membership, attendance & Leadership 11 1 
Team working & culture 7 1 
Personal development & training 8 0 
Infrastructure for 
Meetings 
Physical environment of meeting venue 5 0 
Technology & equipment (availability & use) 17 0 
Meeting Organisation & 
Logistics 
Scheduling of MDT meetings 3 0 
Preparation prior to MDT meetings 5 3 
Organisation/administration during MDT meetings 6 3 
Post MDT meeting /co-ordination of service 5 0 
Patient-centred Clinical 
Decision-Making 
Who to discuss 1 2 
Patient-centred care 8 1 
Clinical decision-making process 8 9 
Team Governance Organisational Support 9 0 
Data collection, analysis , audit and clinical governance 23 0 
Total  116 20 
 
 
There were no differences in opinions between MDT members from the different tumour 
types regarding aspects of teamworking that related to the infrastructure for meetings, and 
team governance (Table 10). Significant agreement (i.e., no more that 20% difference 
between the highest and lowest percentage agreement across tumour types) was obtained for 
these domains.  
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Table 10: Statements showing consensus of opinion relating to infrastructure for meetings, and team 
governance 
Statement % Agreement 
 Median Min Max 
Infrastructure for Meetings  
Physical environment of meeting venue    
All attendees need to be able to view diagnostics from where they are seated 98 96 100 
A dedicated MDT meeting venue should be available 96 93 99 
Technology & equipment (availability & use)    
MDT meeting rooms should have equipment for projecting and viewing radiology images 100 99 100 
Meetings need to have access to retrospective images during the meeting 99 97 100 
MDTs need to be able to access retrospective pathology reports 98 97 100 
MDT meeting rooms should be connected to PACS 96 92 99 
Technology (availability and use) (is important / very important) 95 93 97 
MDT meeting rooms need facilities for projecting and viewing specimen biopsies 94 88 97 
Team Governance  
Organisational Support    
Professional support (i.e. from peers) for MDT working is important 99 97 100 
Organisational support (i.e. from employers) for MDT working is important 97 96 99 
Interactive electronic data systems should support MDT meetings 96 95 98 
Data collection, analysis , audit of outcomes and clinical governance    
If a patient chooses a treatment that is not in line with MDT recommendations this should be recorded 98 94 100 
MDTs should be responsible for collecting key information that directly affects treatment decisions  97 94 100 
MDTs should have processes to review audit data 97 92 100 
Internal audit should be used to confirm that treatment decisions match current best practice 97 92 100 
Being an MDT member is not solely confined to attendance at meetings 96 94 99 
MDTs must collect and use defined national minimum datasets (e.g. cancer registration) 96 93 98 
MDTs should be alerted to serious treatment complications or death in treatments 95 88 100 
Data collection, analysis and audit of outcomes (is important / very important) 92 88 95 
MDT should review treatment recommendations after notification of complications/ death in treatment 91 83 98 
There should be agreed guidelines for how an MDT operates, how members work together etc. 91 85 95 
Majority agreement of a treatment recommendation is acceptable 91 87 93 
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Similarly, significant consensus was obtained for most of the survey statements in the other 
domains, including characteristics of the team, MDT meeting organisation and logistics, and 
patient-centred clinical decision-making (Table 11). Within these three domains, however, 
there were also significant differences between tumour types for some statements – these are 
reported in detail in Table 12.      
 
 Regarding tumour types, haematology participants were consistently different from other 
tumours (involved in 8 of the 20 non-consensual statements), followed by lung participants 
(involved in 6 of the 20). Other tumour types showed fewer discrepancies from the general 
consensus. Regarding domains, tumour types disagreed in relation to circulating case 
summaries prior to the meeting (Breast, Colorectal and Lung did not agree) and not allowing 
late additions to the agenda (Colorectal and Lung did not agree). Both of these are aspects of 
meeting organisations and logistics. Moreover, disagreement was evident on whether a 
patient should be discussed in an MDT if no one is present who has seen the patient 
(Gynaecological and  Upper Gastro-Intestinal did not agree with this), which is an aspect of 
patient-centred decision-making care. Within the same domain, Haematology was an outlier 
in relation to several statements about the process of clinical decision-making in MDTs – 
including whether MDT discussion improves timeliness of care, patient choice, patient 
involvement, patient staging, and survival rates. Lung participants also contributed to three 
significant disagreements within this domain that related to palliative care processes, 
discussion of patients with recurrences, and oncologists making treatment decisions without 
MDT support for some patients.       
  
86 
 
Table 11: Statements showing consensus of opinion relating to the team; meeting organisation and 
logistics; and patient-centred clinical decision-making 
Statement % Agreement 
 Median Min Max 
The team  
 
 
Membership, attendance & Leadership 
   
Membership and attendance (is important / very important) 99 98 100 
Good leadership is a pre-requisite for effective teamwork within the MDT environment 98 96 100 
Leadership (is important / very important) 95 93 98 
Team working & culture 
   
Teamworking (is important / very important) 99 96 100 
The relationship between the Chair and the MDT coordinator is key to ensuring the meeting runs 
effectively 
92 87 95 
Personal development & training 
   
MDTs have an important role in sharing learning and best practice with peers 97 94 100 
MDTs provide an opportunity for education and learning for staff in all disciplines 96 91 99 
The MDT should contribute to the continuing professional development of all members 95 92 97 
Meeting Organisation & Logistics    
Scheduling of MDT meetings    
MDT members need allocated protected time (including travel time) to attend meetings 98 96 100 
Core members should attend for the full meeting and not just for the cases directly relevant to them 93 88 96 
Preparation prior to MDT meetings    
Preparation prior to MDT meeting (is important / very important) 97 92 99 
Preparation time for MDT meetings should be recognised in job plans 97 94 98 
The agenda and patient lists should be circulated prior to the meeting 97 91 99 
Information about patients to be discussed should be collated and summarised prior to the MDT 
meeting 
96 93 100 
All case notes/reports/images, past and present, should be available at the meeting 96 87 99 
Organisation/administration during MDT meetings    
Organisation/admin during MDT meeting (is important / very important) 98 96 100 
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Patient-centred Clinical Decision-Making  
Patient-centred care    
Patient demography and co-morbidities should always be considered 99 98 100 
Patient psychosocial, supportive and palliative care issues should always be considered 99 97 100 
Patients should be made aware that an MDT will be advising on their treatment/care 97 95 99 
(Effective MDT working results in) More co-ordinated patient care 96 88 99 
Patient views should always inform the decision-making process 96 92 99 
Patient views/preferences should be presented to the MDT meeting by someone who has met the 
patient 
96 93 98 
Patient-centred care/coordination of service (is important / very important) 94 88 97 
(Effective MDT working results in) Improvement to overall quality of care 94 86 98 
Clinical decision-making process    
Case management and clinical decision-making process  (is important / very important) 99 98 100 
MDTs should consider all clinically appropriate treatment options even if they cannot offer/provide 
them locally 
99 97 100 
Care plans should be communicated to other health professionals within a locally agreed timeframe 99 96 100 
(Effective MDT working results in) Improved clinical decision making 98 94 99 
A patient's suitability for trials should always be considered 98 94 100 
Standard pro-forma documentation should be used when electronic databases are not available 97 95 98 
Decisions should be documented in real time on a database or proforma 96 92 99 
(Effective MDT working results in) Evidence-based treatment decisions 95 91 98 
A minimum dataset of diagnostic information (pathology and radiology) should be presented for each 
patient 
94 86 97 
Standard treatment protocols for patients should be used whenever possible 94 89 97 
Formal protocols are needed to manage referral of patient cases between MDTs 91 83 95 
MDTs should always be notified if their treatment recommendations are not adopted 91 82 99 
(Effective MDT working results in) Improved treatment 90 78 95 
88 
 
Table 12: Statements with significant difference in opinion between MDT members across different 
tumour groups. 
Statements with differences  
Agreement by tumour type (%) 
Br CR Lun Gyn H&N UGI Uro Hem 
The team         
Leadership         
The same individual should chair the MDT meeting on a regular basis 74 82  89 80  92 87  80  72 
Teamworking & culture         
A good MDT can save you time elsewhere in the period between meetings 94 88 92 93 94 91 91 74 
Meeting Organisation & Logistics         
Preparation prior to MDT meetings         
All MDT core members need to do some preparation prior to the meeting 83  77  83  80  87  81  74 90 
Case summaries should be circulated prior to the meeting 50 50 54 69  77 67  58  65  
Late additions to the agenda should not be allowed unless clinically urgent 74  61 63 76  74  77  82 78  
Organisation/administration during MDT meetings         
What is the maximum length of time an MDT should last? (minutes) 105  75  75  105  75  90  105  105  
What is the optimum number of cases your MDT can discuss during a single meeting? 30  20  20  20  <15 20  20 20  
Patient-centred clinical decision-making          
Patient-centred care          
A patient's case should not be discussed unless someone is present who has been involved in 
assessing the patient 
65  68 71 57 82 53 64  83 
Clinical decision-making process         
MDT discussion results in Improved timeliness of tests/treatments 87 88 88 86 90 88 84 58 
MDT discussion results in Improved patient choice 76 66 70 65 74 65 71 41 
MDT discussion results in Improved patient involvement in decisions  73 59 57 57 71 65 59 34 
MDT discussion results in Increase in proportion of patients staged 71  78  93 88  95 78  64 53 
MDT discussion results in Improved survival rates at appropriate intervals 87 84 78  81 90 78  76  58 
Specialist palliative care representation is essential at every MDT meeting 20 53  69 45  63  67  30  21 
Specialist palliative care attendance is not needed if there are referral mechanisms  94 69  57 83  69  59 86  89 
All patients with recurrence/progressive disease should be discussed by MDT 92 94 67 87 98 85 79  81  
Oncologists should not make treatment decisions on patients with recurrence/ progressive 
disease without MDT support 
63 78 40 71  92 72 61  64  
Key: Br= Breast; CR= Colorectal; Gyn= Gynaecological; H&N= Head and Neck; UGI= Upper Gastrointestinal; Uro= Urological; Haem= 
Haematological. Colour coding= Figures in Red significantly lower than those in Green, Black are not significantly different to any other. 
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3.6 Discussion 
3.6.1 Summary of results 
This study aimed to systematically assess whether there exist tumour-based differences in 
definition of effectiveness of MDT working.  Consensus between team members from 
different tumour types was very high – the majority (116/136) statements were answered 
similarly regardless of tumour specialty of the respondent.  The differences of opinion I have 
revealed related to preparation for and organisation of MDT meetings, case selection and the 
clinical decision-making process (Figure 5). Regarding urology specifically, differences from 
other tumour types were found in only eight of 136 statements, and in each of these, urology 
only differed from one or two other tumour types, with no significant differences form the 
remaining tumour types. This study offers statistical evidence that MDT members from 
different tumour types across the UK are in reasonable agreement about what constitutes 
effective MDT working.  
 
3.6.2 Limitations 
The results of this analysis should be interpreted against certain limitations. The sampling 
method used for the survey involved snowballing so it is not possible to estimate the 
representativeness of responses with any confidence. However, the sample adequately 
represents respondents across core MDT members, common tumour types and a wide range 
of geographical locations throughout England. Team members were only able to give one 
response per statement, which meant that respondents who worked in multiple teams across 
different tumour types were not able report opinions relating to different teams. My analysis 
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had to exclude such team members and include only those who worked in one tumour type so 
that only data relating to specific tumour types was included. This imposes an inevitable bias 
on the sample as MDT members who commonly work across multiple tumour types 
including oncologists, radiologists and histopathologists, are underrepresented in this study. 
Future research should elicit the opinions of these professional groups to validate the results 
of this study. Moreover, professionals who work in more than one tumour type may provide 
interesting insights into the differences identified in this study by virtue of working in 
different and possibly contrasting teams.(79) In addition further work should be undertaken 
to investigate the views of healthcare professionals working in tumour types not included (i.e. 
those with fewer than 100 responses) in this analysis, in particular members of MDTs 
working with children and young people, who may need to work in a different way from 
those working with adult patients. 
 
3.7 Conclusion 
In this Chapter I have reported a rigorous analysis of responses to a recent NCAT national 
survey of MDT members‘ views of the characteristics of effective MDT functioning. My 
analysis reveals numerous areas of consensus across responses from members of different 
tumour types, including those from urology MDTs. Members from all common tumour types, 
including those of urology MDTs, expressed variation in some areas of teamworking and 
clinical decision-making. In Chapter 4 I will attempt to address issues of teamworking, 
decision-making and patient-centeredness, with an analysis of the responses of healthcare 
professionals to open-ended questions that address such domains within the same UK 
national survey. 
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Figure 5: Diagrammatic representation of domains necessary for effective MDT working, split into 
generic and tumour specific components. Generic components display consensus across different tumour 
types; tumour type specific components exhibit variation between tumour types. 
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4  PERCEPTIONS OF UK MDT MEMBERS ON 
FACILITATORS, BARRIERS AND PATIENT-
CENTEREDNESS IN MDTS 
 
4.1 Chapter overview 
In the present chapter I will analyse the responses of MDT members to the open-ended 
questions in the survey described in Chapter 3, to explore attitudes towards teamworking and 
patient-centeredness in MDT decision-making. 
 
4.2 Introduction 
A number of questions remain regarding MDT functioning, which have not been addressed to 
date. These include issues like how best to represent patient views in MDT meetings, how 
disagreements within the team should be dealt with, and what are the factors that impair good 
teamworking and team decision making in these meetings – including organizational factors 
(e.g., lack of time to prepare or attend the meeting), or more personal factors (e.g., lack of 
leadership skills in MDT chairs/leads). These issues can affect directly the process by which 
a MDT makes clinical decisions, and may contribute to some of the variability seen in MDT 
performance.(2;81) Therefore addressing some of these questions will equip MDTs with 
evidence on which to base their practice.  
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In addition to multiple choice and scale items, the NCAT survey described in Chapter 3 also 
included free-text responses, where participants could report their own views and perceptions 
on their MDTs. These responses are available in individual reports by professional group– 
however, a substantial number of them that relate to the key areas of teamworking and 
patient-centeredness in MDT decision-making were not analysed in the original work due to 
limitations of time and resources.(79) Systematic and scientific analysis of responses to these 
questions will help to fill gaps in the evidence, which are required to improve the standard of 
clinical decision-making in MDTs. Finding what is important to MDT members in relation to 
how their teams actually function and how they make patient-centred decisions can contribute 
to defining benchmarks for effectiveness of MDTs in these key domains.(80) Such 
benchmarks could then be used to augment current assessment methods (e.g., the ‗peer 
review‘ process), which do not address such issues.(3)  
 
4.3 Aim 
In Chapter 4 I have carried out a detailed qualitative analysis of the NCAT free-text 
responses, aiming to gain an in-depth understanding of effective teamworking in MDTs; the 
efficacy of decision-making by MDTs; and patient-centeredness of the MDT decision-
making process – all of these with particular reference to similarities and differences in views 
between different ‗core‘ professional groups. 
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4.4 Methods 
4.4.1 The 2009 National Cancer Action Team survey  
The 2009 National Cancer Action Team survey, as described in Chapter 3, contained both 
free-text and ‗closed‘ (Likert scale and multiple choice) questions. This Chapter focuses on 6 
free-text items that address the issues of teamworking and team decision-making in MDTs. 
The raw data for these items are publicly available 
(http://www.ncin.org.uk/cancer_type_and_topic_specific_work/multidisciplinary_teams/mdt
_development.aspx), but are yet to be analysed scientifically. These 6 questions fall in the 
following 3 categories:  
 Effective teamworking in MDT meetings: 
Q1: What makes an MDT work well together? 
Q2: What would help you to improve your personal contribution to the MDT? 
 Efficacy of decision-making: 
Q3: How should disagreements/split decisions over treatment recommendations be 
recorded? 
Q4: What are the main reasons for MDT treatment recommendations not being 
implemented? 
 Patient-centeredness of the MDT decision-making process: 
Q5: Who is the best person to represent the patient's views at an MDT meeting? 
Q6: Who should be responsible for communicating the treatment recommendations to 
the patient? 
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4.4.2 Data analysis  
2054 MDT members responded to the survey. For the purposes of the analysis, respondents 
were grouped into three categories: doctors (D), nurses along with allied healthcare 
professionals (N), and then MDT coordinators and non-clinical personnel (C). The analytical 
approach followed well-established standards in qualitative research to ensure validity and 
transparency.(82) First, all responses were analysed for content to identify emergent themes 
by two blinded coders (Lamb J & Strickland). Emergent themes were subsequently discussed 
between the coders, and two other members of the research team who did not have access to 
the data during the coding phase (i.e., they were blinded), one with background in medicine 
(Lamb B) and one with background in psychology (Sevdalis). Theme content was finalised at 
this stage, themes were tabulated, and verbatim quotes from respondents to validate and 
illustrate the themes were extracted. To simplify presentation themes reported by a very small 
minority of respondents (fewer than 5% of the total) are not presented in this Chapter. 
 
4.5 Results 
4.5.1 Respondents 
Of 2054 respondents to this survey, 1636 answered at least one of the questions included in 
this analysis, including 875 doctors (80% of those who participated overall); 502 nurses and 
allied healthcare professionals (81%); as well as 260 MDT coordinators and other non-
clinical MDT members (76%). The range of responses across all questions (i.e., minimum-
maximum number of responses) was 369-689 for doctors, 191−421 for nurses/allied health 
professionals and 93−202 for coordinators/non-clinical personnel. These numbers are 
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unusually high in qualitative research of the type reported here and ensure adequate ‗theme 
saturation‘ – in other words, adequate coverage of the key themes per question.  
 
4.5.2 Key Themes  
Tables 13 to 15 display detailed results for each of the questions across the 3 areas of interest, 
namely teamworking in MDTs (Table 13), team decision-making in MDTs (Table 14), and 
patient-centeredness of the decision-making process (Table 15). The tables include the most 
prevalent themes in descending order, the proportion of responses that fell within each one of 
them (%), and verbatim quotes to illustrate theme content.   
4.5.2.1 Effective teamworking (Q1 & Q2) 
MDT members recognise the need for adequate ‗non-technical‘ skills to ensure MDT 
meetings function well, including mutual respect, good communication and good leadership 
(Table 13, upper panel). Equally, institutional support from the hospital for the work of the 
MDT emerged as a key requirement, particularly among doctors– including MDT workload 
to be included in the job-plans of the team-members, lengthier meetings to ensure less rushed 
discussion and more time for pre-meeting preparation (Table 13, lower panel). MDT 
Coordinators/non-clinical personnel were less likely than either doctors or nurses to want 
more time for MDT working, but more likely to suggest that educational training days would 
improve their contribution, thereby revealing an existing training need for this group. 
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4.5.2.2 Efficacy of decision-making by MDTs (Q3 & Q4) 
Participants recognised that disagreements do occur, and the consensus across all of them was 
that such disagreements ought to be recorded. Doctors were overall more likely to suggest 
verbatim recording, whereas nurses and coordinators were of the view that noting 
disagreements in meeting minutes is sufficient. Acknowledging such disagreement within 
patient notes and also in discussions with patients also surfaced as aspects of the process of 
handling disagreements (Table 14, upper panel). Regarding lack of implementation of MDT 
decisions, lack of information derived from close contact with patients was reported as the 
main reason for decisions not being implemented (Table 14, lower panel). Interestingly, a 
smaller proportion of doctors than nurses or MDT coordinators responded that a direct lack of 
patient contact is the main reason behind non-implementation.  
 
4.5.2.3 Patient-centeredness of the MDT decision-making process (Q5 & Q6) 
Consensus emerged regarding who within the MDT is the key patient contact, with clinical 
nurse specialists and Consultants both cited most frequently. The view that whoever in the 
team knows the patient best, however, was also prominent (Table 15, upper panel). 
Respondents‘ views were equally consensual regarding which MDT member should be 
communicating the team recommendation to the patient: the Consultant in charge and the 
clinical nurse specialist emerged as the key members to carry out this task (Table 15; lower 
panel).  
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Table 13: Responses related to effective teamworking in MDT meetings (questions 1 & 2) 
 % Response  
 Rank Themes D N C Total Quotes 
Q1: What makes an MDT work well together? 
1 
Mutual respect & 
understanding 
50 64 44 54 
People are valued and their opinions taken seriously 
and considered” (N) 
2 
Enthusiasm & 
positivity 
22 14 27 21 “Enthusiasm, dedication, and hard work” (C). 
3 
Good 
communication 
11 29 29 21 
“On some occasions there has been difference of 
opinions but by good communications it is worked 
out” (C) 
4 
Sharing of 
common goals 
20 14 7 16 
“A clear operational policy which has been 
constructed with involvement from core members 
thus promoting shared common goals” (D) 
5 Good leadership 11 12 8 11 
“The Chair should endeavour to control controversy 
between members, and try and resolve problems” (N) 
6 
Patient-
centeredness 
5 6 8 6 
“All members here tend to focus on the patient's 
welfare and agree on the best pathway for each 
patient” (C) 
Number of respondents: 434 292 153 867  
Q2: What would help you to improve your personal contribution to the MDT? 
1 
Time recognized in 
job-plan to attend 
29 18 8 23 
“More time for MDT's- at present they are over 
lunchtime on a Friday, we have no radiology or 
histology staff” (N). 
2 
Educational 
training days 
7 14 39 14 
“Access to training within a multi-professional team, 
done as an MCT team away from the hospital 
environment” (N) 
3 
More time in 
meetings 
19 3 0 11 
“There are many issues that could be discussed at 
our MDT but there is no time” (D) 
4 
Time to prepare 
for meetings 
14 10 2 11 
“More preparation time recognized in my job plan. 
More support from my department in recognizing the 
importance of the MDTs” (D) 
5 
Organizational 
support 
10 11 15 11 
“More support from line managers who don't seem to 
have a basic understanding of the demands of the 
role” (C) 
6 
Stimulation by 
other team 
members 
2 17 8 7 
“We are a functional team and actively stimulate 
each other to work better” (N) 
Number of respondents: 369 191 93 653  
Note: D=Doctor, N=Nurse/Allied Health Professional; C=Coordinator/Non-clinical personnel 
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Table 14: Responses related to team decision-making in MDT meetings (questions 3 & 4) 
 % Response  
 Rank Themes D N C Total Quotes 
Q3: How should disagreements/split decisions over treatment recommendations be recorded? 
1 Record 91 85 83 88 Not specified 
2 
Document 
verbatim 
43 26 20 35 
“[Record] who recommended what and why. It is 
not appropriate to think of it as a 'majority verdict' as 
this does not necessarily reflect evidence base” (D) 
3 
Write in minutes 
of meeting 
19 44 45 30 
“[Record] within MDT minutes and patient records” 
(N) 
4 
Write in case 
notes 
10 26 10 15 
“Entered into notes via an MDT letter to the GP or 
referring Clinician” (C) 
5 
Tell patient about 
disagreement 
17 14 8 15 
“Both decisions should be recorded on the MDT 
outcome forms and then discussed with the patient 
along with the reasons why decisions were split” (N) 
6 
Record a 
consensus 
9 5 7 8 
“A consensus should always be aimed for, and in 
the rare event that there is significant dissent, the 
alternative treatment discussed should also be 
recorded if possible” (D) 
Number of respondents: 454 239 117 810  
Q4: What are the main reasons for MCT treatment recommendations not being implemented? 
1 
Lack of 
knowledge of 
patient’s views 
53 40 35 47 
“The patients’ preferences. Sometimes patients are 
discussed prior to being seen and when reviewed 
the patient has different wishes” (N) 
2 
Lack of personal 
contact with 
patient 
6 64 58 30 
“You cannot make a firm recommendation in many 
circumstances without seeing the patient yourself to 
assess the appropriateness of the treatment” (D) 
3 
Changing clinical 
picture 
19 3 4 12 
“A patient’s condition may deteriorate soon after the 
MDT and require emergency intervention by 
surgery or other treatment” (D) 
4 
Lack of 
knowledge of 
patient 
comorbidities 
17 4 3 11 
“Performance status stopping someone being fit for 
the treatment and this info not available at MDT” 
(N) 
5 
Incorrect clinical 
information 
14 3 2 9 
“If the incorrect information about the patient’s 
history was communicated at the MDT it changes 
what treatment they [the patient] could or could not 
have” (C). 
Number of respondents: 539 273 130 941  
Note: D=Doctor, N=Nurse/Allied Health Professional; C=Coordinator/Non-clinical personnel 
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Table 15: Responses related to team decision-making in MDT meetings (questions 5 & 6) 
 % Response  
 Rank Themes D N C Total Quotes 
Q5: Who is the best person to represent the patient's views at an MDT meeting? 
1 
Clinical Nurse 
Specialist 
68 55 65 63 
“The specialist nurse as they work closely with the 
patient and the patient’s family and form a 
relationship” (C) 
2 
Consultant in 
charge 
51 22 41 40 
“Ideally the physician with responsibility for their 
care” (D) 
3 
Whoever knows 
the patient best 
36 37 17 33 
“Variable, dependant on individual who knows the 
patient the best” (D) 
4 
Key-worker 
(other) 
16 15 9 15 
“Key worker or clinician who has had direct contact 
with the patient” (N) 
Number of respondents: 682 420 202 1,304  
Q6: Who should be responsible for communicating the treatment recommendations to the patient? 
1 
Consultant in 
charge 
68 68 75 69 
“The consultant who the patient is under the care of 
at the time of the management decision of the MDT” 
(C) 
2 
Clinical Nurse 
Specialist 
33 49 51 41 
“For some patients this information may be 
appropriately communicated by a specialist nurse” 
(D) 
3 
Key-worker 
(other) 
6 14 6 9 “Whoever is delegated as the key-worker” (N) 
4 
Whoever knows 
the patient best 
7 8 3 7 
“Whoever has had most meaningful contact - medic 
or nurse –may be different for different people” (N) 
Number of respondents: 689 421 202 1,312  
Note: D=Doctor, N=Nurse/Allied Health Professional; C=Coordinator/Non-clinical personnel 
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4.6 Discussion 
4.6.1 Summary of results 
In this Chapter I have analysed comments provided by over 1600 MDT members regarding 
effective teamworking in MDTs; efficacy of decision-making by MDTs; and patient-
centeredness of the MDT decision-making process. The key themes emerging in relation to 
effective teamworking were the importance of good relationships between team members, 
adequate non-technical skills (i.e., communication, leadership) and the need for support at an 
organizational level. In relation to team decision-making, recording of disagreements when 
they occur (and potentially letting the patient know), and the importance of having adequate 
information about the patient were key emerging issues. Finally, in relation to patient-
centeredness of MDT decision-making the key role of the clinical nurse specialists as patient 
advocates alongside the medical personnel, and the complementary role of nurses and 
Consultants in discussing team recommendations with the patient were key findings.   
  
4.6.2 Limitations 
Certain limitations must be applied to the results of this analysis. The method used to recruit 
the survey sample involved snowballing so it is not possible to be certain of the response rate, 
or how representative the sample is of the population of MDT members as a whole. 
Moreover, the total number of participants (to the survey and also to the free-text questions 
reported here), although large for this type of qualitative research, are certainly only a 
fraction of the thousands of healthcare professionals working in the 1500 MDTs in the UK. 
Taken together, these limitations do limit the generalisability of the findings. However, the 
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sampling was successful in representing respondents across core MDT members, from a wide 
range of geographical locations throughout England. Caution should also be used before 
extrapolating the results of this study to healthcare systems in other countries where MDT are 
in use, particularly concerning organisational factors that are likely locally different. Again, 
however, some of the issues revealed here (e.g., team skills, team-members to communicate 
with patients) are indeed found in other countries outside England and are increasingly 
reported in the literature.(83;84) 
 
4.7 Conclusion 
This Chapter provides in-depth understanding of elements of good teamworking and patient-
centeredness in clinical decision-making by MDTs in the UK. This Chapter supports the 
findings of Chapters 2 and 3 and reveals the importance of team-members‘ skills, as well as 
organizational support in having well-functioning teams that make recommendations for their 
patients that are implementable. The views of healthcare professionals support evidence in 
the literature that clinical decisions in MDT meetings are better when focussed on the patient, 
not just the disease. However, little is known about how patients want their needs and 
preferences to be represented in MDT meetings, which is an issue that I will explore in the 
next Chapter. 
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5 PATIENTS‟ VIEWS ON MDT WORKING IN CANCER 
CARE 
 
5.1 Chapter overview 
A phrase that has been frequently occurring in the Chapters so far is, ―Patient-centred‖. The 
idea of having the patient and their interests at the heart of cancer care, and indeed of any 
research project is integral to high quality healthcare services. The previous Chapters have 
explored the factors that affect the quality of teamworking and decision-making in MDTs 
across international literature, and from the perspectives of UK healthcare professionals. The 
current Chapter follows on from the previous and sets out to explore patients‘ perspectives on 
MDT decision making in order to ensure that any subsequent assessment tools or 
interventions capture that which is important to patients, as well as cancer teams. 
 
5.2 Introduction 
Patient-centred care is increasingly recognised as being integral to high quality healthcare 
services. The Manual for cancer Services requires regular assessment of patient satisfaction 
in several areas. However, little research has been carried out to assess what patients think of, 
or understand about the role of the MDT in cancer care.(3) To date, the evidence for what 
patients think of MDTs has been limited, and at present it is not clear whether their 
experience reflects the perceptions of healthcare professionals, researchers and policymakers. 
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5.3 Aims 
The aims of the study presented in this Chapter are to: 
1. Explore patients‘ understanding and experience of the purpose of an MDT 
2. Investigate patients‘ views on how they would like their views and preferences to be 
incorporated into MDTs decision-making 
3. Elicit patients‘ views on who they feel would be best suited to represent them, assuming 
that they themselves cannot or do not wish to attend meetings. 
4. Elicit patients‘ views on how they want the outcome of MDT decisions to be 
communicated to them and how they can be involved in decision-making with the MDT 
 
5.4 Methods 
5.4.1 Study design 
The aim of the study is to explore the perceptions and experiences of cancer patients 
regarding patient involvement in the clinical decision-making process by multidisciplinary 
cancer teams. Therefore, a qualitative method was employed, designed to enable detailed 
exploration of participants‘ experiences and opinions across a range of topics.(85-87) Themes 
covered on the topic guide were: 
 Patients‘ experience of cancer diagnosis and/or treatment 
 Awareness of the role and make-up of the multidisciplinary team (MDT) 
 Experiences of being treated by/ interacting with a cancer MDT 
 Information that is felt to be important for the MDT to consider 
105 
 
 Patient representation and attendance at MDT meetings 
 Communication of MDT outcomes to patients 
 Patient involvement in decision-making with the MDT 
 
5.4.2 Participants and setting 
Purposive sampling was used in order to recruit patients previously treated by MDTs, and to 
ensure a diverse sample that collects opinion from a range of social and cultural groups. 
Participants were recruited via local patient groups through group representatives (the patient 
information sheet is provided in Appendix 3). Two focus groups were organised due to time 
and resource limitations. Focus groups were planned to occur at NHS Trusts and last 
approximately two hours. Informed written consent was sought by all participants prior to 
participation. 
 
5.4.3 Data collection 
Focus groups were all conducted in person, the first by a psychologist (Brown) and a surgeon 
(Lamb), and the second by a surgeon alone (Lamb). The focus groups were recorded with a 
digital voice recorder. The researcher followed a semi-structured open-ended list of questions 
to obtain and explore participants‘ views on MDTs in cancer care. The question list has been 
developed by the research team (which includes a patient safety researcher, urological 
surgeons, a health psychologist, and an oncologist) based on the literature outlined in the 
introduction (the focus group topic guide is presented in Appendix 4).  
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5.4.4 Analysis 
Focus-groups were recorded and transcribed verbatim. Transcripts were then coded by one 
researcher with a surgical background (Lamb), before themes were checked for content by a 
second researcher with a psychological background (Brown). A Grounded Theory approach 
was used whereby a skeleton coding frame was devised based on the topic guide, and data 
were coded to those primary codes, then new codes were added as new themes emerged in 
the data. All codes were grounded in the data and quotes were extracted to support codes.(82) 
 
5.4.5 Ethical Approval 
Ethical approval for the study was given by the South East London Research Ethics 
Committee, and also locally by the R&D departments of the NHS Trusts concerned. 
 
5.5 Results 
5.5.1 Participants 
Two focus groups were held, the first in Essex in October 2010 that was attended by nine 
participants (1hr:45m), and a second in Surrey in August 2011 that was attended by six 
participants (1hr:30m). Demographic information of participants is given in Table 16.  
 
5.5.2 Patients‟ awareness and opinions of the MDT (Table 17) 
None of the participants in the first focus group and only two participants in the second focus 
group had heard of the MDT at the time of their treatment. Other participants reported that 
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they became aware of a team structure as their care progressed, and all found the idea of 
being treated by a team to be reassuring. Participants generally felt that a team approach to 
cancer care would mean that patients are offered a wider range of treatments than those 
provided by the clinician they might personally see. The phrase ―MDT‖ was not popular with 
group members, they felt it was jargonistic and did not reflect their understanding of the team 
and the team meeting. The term ―Case-conference‖ was preferred by participants. The 
majority of participants knew that surgeons, oncologists and nurses were MDT members, but 
there was little awareness of the professional groups of other team members. Participants felt 
that confronting a whole team would be intimidating, and they would prefer to have contact 
only with individual team members. Regarding the cases that might require MDT discussion, 
participants felt that inclusion criteria as they stand are reasonable. Participants were open to 
the idea of streamlining the MDT meeting by prioritising cases, or treating some straight 
forward cases by ‗chair‘s action‘, rather than a full discussion. 
 
Table 16: Characteristics of participants 
Characteristic Participants (N=15) 
Female 2 
Age group  
60-80 14 
>80 1 
Cancer type  
Prostate 11 
Breast 1 
Upper GI 2 
Sarcoma 1 
Ethnicity  
White British 15 
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Table 17: Patients‟ awareness of the MDT 
Theme Illustrative quote 
Initially not aware of MDT “Felt like a parcel being handed carefully along from one person to the other” (M,62) 
Aware of teamworking  
“I just assumed that these links exist, but I didn't know they existed formally and I don't think we were ever 
told as patients that there is an MDT team discussing” (M,83) 
Little knowledge of MDT membership “What makes up a case conference? Who is there? I don‟t know” (M, 73) 
Liked idea of being treated by a team 
“I think it would be a comfort to know that your case is being looked at by a group of professionals and they 
also have access to other areas outside” (M, 70) 
Knowledge of MDT would help decision-making 
“It would have stopped that niggle in the back of your mind that in the future thinking what would have 
happened if I had had the other treatment. This way you think a group of experts have gone over it” (M, 70) 
All cases need MDT discussion “What if someone points something out and says hold on and changes the plan” (M, 65) 
Prioritisation might be good “It‟s ok if you are 5th on the list, but what if you are number 40 on the list?” (M, 62) 
Simple cases can be sped through 
“[Simple cases could be treated by chair‟s action] as long as there is the option of stopping and saying hang 
on” (F, 71) 
 
109 
 
Table 18: What information patients want MDT to take into account when making clinical decisions 
Theme Illustrative  quote 
Primacy of pathology 
“The other doesn't come into play unless you've actually got the right diagnosis first. Everything else follows” 
(F, 71) 
Importance of assessment of fitness 
“It's [fitness] part of the picture. After all, if your heart's about to give out, there's no point in doing liver 
surgery because you probably wouldn't survive the op anyway” (F, 60) 
Importance of social factors “If people have got a wife or a husband and how fit they are can also be brought in” (F, 60) 
Importance of Patients‟ circumstances  
“I think we are in cloud cuckoo land, I don‟t think the patient other than the direct circumstances is going to 
be dealt with” (M, 74) 
Trust that MDT will know all they need to 
“Somebody attending the meeting will know my blood pressure, my heart, my diet, all the rest of it that makes 
me, and how it will best fit in to the various courses of treatment available” (M, 74) 
Nurse who gathers patient-centred information 
“But it's the nurse that sits with the patients and finds out what makes them tick and all about them and is 
therefore able to put the patient”  (M, 70) 
Experience of assessing fitness before surgery 
“I was asked to do exercises and run up and down stairs to see if I was fit etc, to see if I could cope.  And I 
think it wasn't specifically said to me that he was trying to assess whether it was worthwhile” (M, 60) 
Experience of being asked about social factors “I was never asked about family or anything else” (M, 79) 
Experience of seeing CNS 
“I was coming back for another one [endoscopy], and then the clinical nurse specialist got involved: family 
life, family history, and that's when it all started.  That was two weeks before surgery” (M, 70) 
Experience of comorbidities not being taken into 
account 
“I had recent inguinal hernia operation and there was a large mesh in the way. I didn‟t find out until the last 
minute that they had not realised I had a mesh. I was told well you can‟t have surgery now. I kept telling them 
and nobody seemed to take it into account” (M, 62) 
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5.5.3 Information that patients want the MDT to consider in decision-making (Table 
18) 
Members felt strongly that biomedical information, and pathology in particular, was the most 
important information to consider, and without this, it would be impossible to arrive at the 
correct diagnosis, or treatment. After information about the disease in question, participants 
felt that information about a patients‘ fitness and social circumstances were also crucial to 
ensure that decisions were appropriate. There was a mix between trust in the MDT, a feeling 
that they knew all they needed to in order to make good decisions, though others did not trust 
that MDT members would have the time or inclination to consider patients‘ preferences, or 
their individual circumstances. Regarding who might collect information on patients‘ 
circumstances and fitness, participants felt that the nurse was the easiest person to talk to and 
would be best able to gather this information. Patients had experienced assessment of their 
fitness, often by the operating surgeon. However, only one patient had been asked about 
family life, and those details were taken by the CNS between visits for endoscopy. One 
participant went further and said that he had tried telling his clinicians about his comorbid 
conditions that may complicate surgery, but that he was not listened to until just before 
surgery, which was subsequently cancelled causing considerable distress.  
  
5.5.4 Opinion about attending/representation in MDT meeting (Table 19) 
Several participants felt that they could potentially be directly involved in their own case 
discussion, and that their personal contribution would add value to the decision-making 
process. However, there were others who felt that their presence in the MDT meeting would 
inhibit full and frank discussion of their case by MDT members, as well as being distressing 
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to themselves. In addition, some participants thought that the MDT members would know 
everything that was relevant, and as such, their participation would not add any benefit. 
 
Participants were unanimous in their opinion that the nurse was the member of the MDT with 
whom they had the best relationship and who would be best placed to ascertain information 
on their social circumstances, personal views, and even information of a more intimate 
nature. By virtue of the fact that the CNS has a good relationship with patients, most 
participants felt that in the absence of the patients in the MDT meeting themselves, the CNS 
was the team member best placed to act as a patient advocate. One participant raised the point 
that all team members should have the patients‘ best interest in mind and should do their best 
to act in the patients‘ best interest, an idea to which other participants gave their approval. 
Another participant discussed whether the CNS should have a formal role as patient advocate, 
with the official responsibility of representing patients‘ views and circumstances in meetings. 
 
The occurrence of hierarchies in the MDT meeting was discussed, and in particular the way 
in which this limited the input of nurses. Participants all found this concerning, but many felt 
that this style of teamwork was outdated, and was changing with the increasing recognition 
that CNS played a unique and valuable contribution to the MDT meeting. 
 
Participants felt strongly and unanimously that patients‘ cases should only be discussed if 
someone was present who personally knew the patient.  Many participants were incredulous 
at the idea of being discussed without being known. Someone raised the idea that if there was 
no team member who knew them present, they would rather delay case discussion until 
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someone they knew was present. This idea was supported by the majority of other 
participants.  
 
Participants were generally not keen on the idea of having a patient representative in the 
MDT meeting. They felt that such a role would be too demanding for the individual, and may 
be unpopular with patients and team members should they misrepresent the patient, or the 
opinion of the team. Participants did not give much support for the involvement of their GP 
as their representative in meetings, largely as they do not have close relationships to an 
individual GP, as was the case in previous times. 
 
5.5.5 Opinion about receiving information from MDT meeting (Table 20) 
There was variation in the amount of information that participants thought patients would 
want following discussion of their case at the MDT meeting. All participants wanted to be 
informed of the outcome of meetings, some wanted only to be informed of the decision, 
where as others wanted to be given details about different possible options as well as the 
presence of any differing opinions from team members, or any disagreement. Several 
participants articulated that the outcome of the MDT meeting should be tailored to the 
preferences of the individual patient, as some would want choice and information, but others 
would want a more paternalistic and prescriptive approach. Where choice over possible 
treatments might exist, it was felt that members of the MDT with particular treatment 
expertise might not be able to give a balanced view of all the different options available. In 
that instance, the view was raised that it would be best to discuss options with the respective 
practitioners in sequence, to get a balanced view. This opinion was countered by other 
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participants who felt that it would be best to talk to an MDT member, such as the CNS, who 
did not have a particular treatment expertise, but who could give a balanced overall picture of 
the pros and cons. This opinion was strengthened by the trust that participants had in the CNS 
they knew, and the ease with which they could talk to them. 
 
Participants reported a range of experiences regarding being given information about 
diagnosis and treatment. Experiences ranged from being given little information on a variety 
of options, to a good amount of information on a single option, to a single option with no 
information. There did not seem to be an association between the amount of information 
patients were given about their diagnosis and treatment, and their satisfaction with the 
treatment they received. The only criticism came from patients who had not been prepared to 
be given information about the diagnosis and found it very distressing and therefore difficult 
to take in, and those patients who found that there was no continuity of care, so they did not 
have the rapport with the clinician who was giving them information, which made it difficult 
to interpret.  
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Table 19: Opinion about attending/representation in MDT meeting 
Theme Illustrative quote 
Don‟t want to go to own MDT discussion 
“I do think there is a place for a patient to attend and I can't see why a patient can't be bound by the same 
confidentiality as the professionals”  (F, 65)) 
Patients can contribute to meetings “The patient can actually add in value to the discussion, not just tick the box” (M, 70) 
Patients cannot want to contribute to decision-
making 
“Beyond going what the options are, I'm not entirely sure what one would have to contribute” (M, 83)) 
Concerned that presence would disrupt 
discussion 
“My problem is if I'm sitting there and I'm putting the professionals off frank discussion”  (F, 65) 
Timing of MDT meeting difficult “I don't think you're in the right frame of mind when you're diagnosed” (M, 62) 
Relationship with the CNS 
“You can talk [to the CNS] about anything and everything, she knows more about us than we do, or our 
partners do” (M, 60) 
All MDT members should speak for patients 
“I think the nurse is the patient advocate in that group.  But they should all have the patient's benefits at 
heart” (F, 71) 
Have a specific role for the patient advocate 
“It's quite an interesting idea to actually make the nurse the person who assesses and informs the person's 
personal and social circumstances...you should have somebody who's responsible actually for saying” (M, 
83) 
Surgeons dominating meetings, CNS not 
speaking 
“That's a worry and I think it probably does happen in some places where the surgeon is the prima donna and 
it's not worth upsetting them or whatever” (F, 71) 
Role of CNS as patient advocate 
“Every patient and I think most clinicians accept how valuable they are...they will have more confidence to be 
the patient's spokesperson, if you like, on the MDT if the patient themselves doesn't want to be there” (F, 71) 
Importance of knowing patient  “If they don‟t know me how can they make decisions about me?” (M, 74) 
Importance of personal knowledge of patients 
“If I needed to and they were going to have an MDT, I shall now ask who's going to be there and if I don't 
approve, 'No, no.  I'll wait until next week.'” (F, 65) 
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Table 20: Opinion about receiving information from MDT meeting 
Patient representative on MDT not popular 
“It would be extremely demanding...That volunteer has only got to come back to the patient with one false 
misconception of what was discussed and the whole lot would be thrown into turmoil” (M, 60) 
Theme Illustrative quote 
Communication important “Keep me informed and do what you have to do” (M, 73) 
Amount of choice should be tailored to patient “It's part of the assessment whether the patient is going to be stressed out by being offered choice” (M, 83) 
Specialist should give own information 
“Well, if it's essential surgery, I think it needs to be the surgeon.  If it's chemo or radio or something like that, 
then probably the oncologist, in conjunction with the nurse” (M, 70) 
Concern that patients are not given whole 
choice 
“The surgeon could be biased in favour of this particular treatment, and the radiotherapist and the 
oncologist, too” (M, 74) 
CNS unbiased 
“The nurse is so valuable because they don't have the same biases, perhaps, as the surgeon and the 
oncologist” (M, 83) 
CNS easy to talk to 
“Nurse is person in whole NHS I sit down and actually talk to. I get the impression that surgeons are busy 
and clock watching.  Nurses give the impression of having more time” (M, 65) 
Experience of CNS giving information 
“She [the CNS] came to me and she did advise she'd spoken with [the surgeon] on this account, „and this is 
the procedure we will recommend.'  I had a booklet given me” (M, 60) 
Experience of sufficient time to decide 
“I was given three options and told go away and think about it. I made my mind up and went back some time 
later and said this is what I want” (M, 79) 
Experience of insufficient time to decide 
“I was actually told by the oncologist that you either have radiotherapy or you have the operation. I must 
have your answer in the next hour” (M, 74) 
Experience of  not being given real choices 
“In my case the surgeon was hell bent on taking it out. Although I was told of other options he did not expand 
on them because it wasn‟t his thing” (M, 73) 
Experience of lack of preparation 
“They're up there and I was down there and it hadn't crossed anybody's mind...I was on my own.  I wasn't 
asked to bring anybody.  So that would be my criticism” (M, 74) 
Experience of lack of continuity of care 
“When I was diagnosed I went back and forth and saw a different registrar each time. There was no 
continuity” (F, 65) 
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5.5.6  Patients‟ role in decision-making after the MDT meeting (Table 21) 
Participants generally agreed that any decision-making at the time of diagnosis was very 
difficult on account of the news being overwhelming. Some participants intimated that they 
would rather have a clinician that they trusted to make decision for them, than to make 
decisions for themselves, though others said they would rather decide themselves. 
Participants felt that patients should be able to make decisions with the help of carers and 
family, and that if a choice was available the patient should also be supported by members of 
the MDT to come to a decision that was tailored to their circumstances. When making 
decisions about different treatments, participants said that as well as considering factors such 
as the side effects of different treatments, issues such as the reputation and location of 
potential treating hospitals would be important. Regarding factors that had helped participants 
to make decisions in the past, some had spoken to friends who had similar experiences, where 
as others were put in touch with past patients by the clinician treating them. In both cases, 
Participants said that talking to other patients was helpful, and that they would also talk to 
their GP to get advice. Participants thought that the amount of weight the MDT opinion 
carried would depend on the unanimity of any recommendation, and that although 
disagreement within the MDT might make decision-making more difficult for them, they 
would rather be informed.  
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5.6 Discussion 
5.6.1 Summary of results 
The present study gives an initial picture of what patients think about MDTs, and how they 
want to be represented and included in the decision-making process. Awareness about the 
MDT among participants was low, but they found the idea reassuring. Participants felt that is 
was important to consider all relevant information- biomedical, psychosocial as well as 
preferences, although their experience showed that this was not always the case. While 
participants were not keen on attending their own case discussion, they felt that they could 
contribute indirectly via the CNS, who by virtue of the close relationship with patients had a 
special role in gathering information and could act as an advocate in the MDT meeting. 
Participants felt that it was important that cases were only discussed when there were 
members present who knew the patient; otherwise they thought it would be preferable to 
delay discussion. Participants felt that it was important that they were well supported when 
being given diagnoses and treatment options, including impartial and clear information from 
a range of sources, with adequate time to decide.  
 
5.6.2 Limitations 
The results of this study are subject to certain limitations. The sample size in this study is 
small and therefore may not be representative of the population in general. However, pilot 
qualitative work does not generally require large sample sizes, and in the present study 
saturation point was reached, suggesting that the sample size was sufficient. Participants may 
not be representative of the population as a whole, and there were a minority of women 
participating in the study, although participants were selected from diverse locations and 
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Table 21: Opinion/experience of patients‟ role in decision-making after the MDT meeting 
Theme Illustrative quote 
Effect of certainty of MDT on trust  
“And if the MDT says, 'We're all absolutely certain that now's the time for surgery,' for example, then I would 
probably go along with it because they've obviously come to an informed decision” (M, 83) 
Patient should be able to choose if choice exists 
“Provided the patient, and maybe the carer, which in this case was his daughter, are told the whole scene.  
Then they can make a choice”  (M, 74) 
Would rather be given a choice of treatments 
“I'm not taking the drug to which I am entitled; I chose not to take it, at the moment, anyway.  I don't want the 
side effects and I discussed it with the oncologist and the surgeon and the radiologist...they gave me that 
choice” (F, 65) 
Experience that decision making at diagnosis 
impossible 
“At that point when you are given the diagnosis that you have got cancer, you don‟t hear anything else, 
you‟re not really listening to anybody else, and a s far as you‟re concerned that‟s it- you‟re dead”  (M, 74) 
Often did not want a choice, wanted best option. “He gave me options. I said, „what do you think is best? You tell me.‟” (M, 74) 
Patient-centred information important in 
decision making 
“I took other little things into considerations when deciding between surgery and radiotherapy. I was told 
certain hospitals offering surgery didn‟t have good reputations for cleanliness. Also my wife can‟t drive, so is 
there a bus service to the hospital? It‟s an important consideration” (M, 79) 
Experience of being offered choice 
“My friends said you want it done with keyhole. So I asked my man and he said I don‟t do it but if you want it 
done I can send you to someone who can do it” (M, 74) 
Speaking to other patients was useful 
“I was able to phone David and ask him what the operation was like and speak to somebody who'd been 
operated upon about 100 years ago and he's still answering the phone”  (M, 63) 
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social groups in order to access opinion from different parts of society. Future research might 
examine the views of a larger range of patients across different social groups before 
generalisations can be made with any certainty. 
 
5.7 Conclusion 
In this Chapter I have begun to explore the views and experiences of patients who have been 
treated by MDTs regarding these teams and the way they interact with patients. Although the 
study itself was exploratory in nature, it has served a valid purpose. Firstly, to the best of my 
knowledge, this was the first study to elicit the views of patients about their treatment by 
MDTs, and as such brings new evidence to this field of research and practice. In doing so this 
study also brings out several areas that require further in depth exploration, including how 
patients are included and represented in the decision-making process. Secondly, this Chapter 
places the interests of patients at the core of this thesis. This Chapter will be able to inform all 
subsequent Chapters and ensure that they are based on patient-centered evidence. Now that I 
have assessed the current evidence base (Introduction and Chapter 2) and gathered the views 
of MDT health care professionals (Chapters 3 and 4) and patients (this Chapter) I can begin 
to focus in on some of the issues raised in the preceding Chapters in more depth with 
members of urology MDTs. In doing so I will be able to confirm whether such issues are 
relevant to their working lives and assess how they affect the quality of decision-making. 
This will be the focus of Chapter 6. 
6 BARRIERS, FACILITATORS, AND OPPORTUNITIES FOR 
IMPROVEMENT OF TEAMWORK AND TEAM 
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DECISION-MAKING IN MULTIDISCIPLINARY CANCER 
TEAM MEETINGS 
 
6.1 Chapter overview  
In order to begin to improve performance in urological MDT meetings, issues that have 
arisen in the Chapters so far must be explored and defined in more depth.  Chapters 3 to 5 
have confirmed that the evidence presented in the Introduction and Chapter 2 is relevant to 
patients and members of MDTs across different tumour types in the UK. Following on from 
that, Chapter 6 reports a qualitative exploratory study to explore teamworking issues in more 
depth with core members of Urology MDTs. 
 
6.2 Introduction 
Although MDTs provide a means of enhancing patient care,(1) the team decision making 
processes can be variable.(46) Chapter 2 has systematically examined the current evidence 
base, and demonstrate that there are many factors that affect the quality of cancer MDTs. The 
present study aimed to evaluate in depth whether the experiences of members of Urological 
MDTs from a range of professional groups reflected the issues raised in the literature.  
 
6.3 Aims: 
Specifically, the aims of this study are: 
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1. To explore the experiences and attitudes of MDT members towards information use, 
discussion, leadership and team decision making in MDTs 
2. To evaluate what MDT members see as the positive aspects of MDT working, and 
suggestions for any improvements. 
3. To assess whether such findings are applicable to all core MDT professionals, or 
affect individual members more than others. 
 
6.4 Methods 
6.4.1 Protocol development 
This was a prospective, qualitative, semi-structured interview study. I used qualitative 
methodology and an interview based approach to gain a deep understanding of the factors 
that affect decision making in urological MDTs, where people feel there are problems, and 
what people think can be done to improve the quality of the process.(82;88) An interview 
protocol was developed and piloted in iterative phases to ensure feasibility and adequate 
content. It was then distilled into a topic guide (Appendix 5). This explored participants‘ 
opinions on the following issues: MDT attendance, information presentation, case discussion, 
leadership, reaching a decision and general benefits, challenges and improvements to MDT 
meetings.  
 
6.4.2 Participants 
I carried out semi-structured individual interviews with a purposive sample of MDT members 
from Urological, Oncological, Nursing and MDT Coordinator backgrounds. The sample was 
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drawn from MDTs across England who had taken part in a Bladder Cancer Training day, run 
by the Pelican Cancer Foundation. Participation was voluntary and informed consent was 
obtained. Anonymity was ensured throughout the study.  
 
6.4.3 Procedure 
Each interview lasted approximately 20 to 40 minutes. All interviews were audio-taped and 
transcribed verbatim (an example transcript is presented in Appendix 6). Transcripts were 
cross-checked with the original recordings to ensure accuracy.  
 
6.4.4 Data analysis 
After an initial period of familiarisation, during which transcripts were read and re read to 
ensure full immersion in the data, I analysed each of the interviews for content to identify 
emergent themes. A sample of interview transcripts (20%) from each professional group 
(chosen at random) was then coded independently by another member of the research team 
(Pinto), with a background in psychology and qualitative methodology. The interview 
protocol was used in this phase to aid the coding process. Finally, emergent themes were 
reviewed by me and another researcher (Arora) with a surgical background to identify key 
strands. The level of coding agreement between researchers was evaluated.(88) 
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Table 22: MDT interview protocol 
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6.5 Results 
Nineteen members of the Urology MDT were recruited using a purposive sampling technique 
(5 Consultant Urologists, 5 Consultant Oncologists, 5 Clinical Nurse specialists and 4 MDT 
Coordinators). These specialities were chosen as they are core members of the Urology MDT 
and have direct patient contact (Urologists, Oncologists, CNS) or a pivotal role in 
administering the MDT (MDTC) and all are involved in team working and decision making 
in the MDT. Interviews took place face-to-face (n=4) and via telephone (n=15) between 
October 2009 and April 2010. 
 
6.5.1 Coding category reliability 
Tables 23 to 26 list the main findings for each key question of the interview protocol (i.e. the 
items mentioned), the number of participants who mentioned each item, and an exemplary 
quote. 
 
I examined the correlation between myself and the second coder (Pinto) for a randomly 
selected sample of one each of Urologist, Oncologist, CNS and MDTC for the number of 
items that each of them identified per interview. High correlations would imply similar 
coding across researchers and, therefore, adequate reliability of the coding. The correlations 
were high for the whole interview: r=0.870, p<0.001, and for all six questions: MDT 
attendance: Pearson‘s r=1.00; information presentation, r=0.95, p<0.001; case discussion: 
r=0.94, p<0.001; leadership: r=0.61, p=0.006; reaching a decision: r=0.84, p<0.001; and 
general benefits, challenges and improvements to MDT meetings: r=0.67, p<0.001. 
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Therefore, my background did not affect theme extraction from the transcripts. In the 
following sections, data relating to key themes is summarised and supported by verbatim 
quotations. The code letter suffixed to each quotation refers to the MDT members‘ 
professional group of Urologist (U), Oncologist (O), CNS (C), and MDTC (M). 
 
6.5.2 MDT Working 
Fourteen of 19 participants reported that they attend a satisfactory number of Urological 
MDT meetings. The remainder managed to attend some, but not all of the MDT meetings 
they were expected to attend. Having protected time (10 of 19) was associated with being 
more likely to attend the MDT (2(1)= 5.63, p=0.018). However, for others meetings were 
often held outside core hours, ―[the MDT meeting is] before the day starts so it‘s an 
additional hour to the day‖ (U4). For some, though, there was a direct clash: ―I can‘t do both 
[the MDT and Clinic]...And my priority obviously has to be the oncology outpatients‖ (O3).  
 
6.5.3 Information presentation (Table 23) 
Some participants reported that the radiological images were one of the most positive aspects 
of the MDT, others having specialist Uro-radiologists present at meetings. Dissatisfaction 
occurred as a result of an inability to view radiological images across sites via 
videoconferencing, and because of non-attendance of radiologists.  Pathological information 
presented was usually satisfactory. Opinion was more divided about the adequacy of 
presentation of information about the comorbidities of patients. Participants felt generally that 
comorbidities had an important bearing on decision-making, but approximately half of 
participants felt that they were not adequately discussed. An oncologist echoed the opinion of 
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several participants saying, ―Sometimes important parts of the cases are not necessarily in the 
disease but the comorbidities.  They‘re often skipped over so it can make meeting decisions 
less meaningful‖ (O2). Several participants said that often although information about co-
morbid conditions was enquired about, no one at the MDT meeting had personal knowledge 
of the patient, which could cause a problem. 
 
Table 23: Adequacy of presentation of information in MDT meetings  
Adequately 
presented? 
N/19 Representative Quote 
Case history  
Yes=12 
It‘s the consultant usually, will likely present his own 
cases (U3) 
No=7 
It depends...we have to have the notes in the clinics so 
that we can go back and double check (O4) 
Radiological 
images  
Yes=12 The most positive aspect is having radiology (O3) 
No=7 
A lot of the time we‘re just working off reports, which is 
obviously not adequate (U3) 
Pathology 
slides  
Yes=7 
Very often yes, there‘s an agreement not to discuss every 
G2, G1 TCC (O2) 
No=12 
If there‘s anything really interesting he will actually put 
these slides up (N2) 
Comorbidity, 
psychological 
and social 
problems 
Yes=10 
The patient‘s social, domestic or psychological 
circumstances may have a bearing on what we would 
recommend (U4) 
No=9 
If you‘re asking whether they‘re [comorbidities] 
discussed on the majority of patients, no they‘re not (U3) 
Patients‟ 
wishes 
Yes=11 
If they [the patient] have a strong preference then, yes, 
we normally would say (N3) 
No=8 Not overall, not generally speaking (U4) 
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Presentation of patients‘ wishes evoked strong reaction from participants. Poor presentation 
often came down to lack of personal knowledge of the patient. Where patient wishes were 
known, it was often down to the nurses to gather and present this information – despite there 
being a reluctance to do so. One of the Nurses went further to say that in the past he had been 
reprimanded for discussing treatment with patients before the MDT had made a decision.  
 
6.5.4 Case discussion 
The most common professional group that contributed to the discussion about treatment 
options was Urologists (15/19), followed by Oncologists (10), CNS (7), Pathologists (7), 
Radiologists (6) and MDT Coordinators (1). Most participants felt that the discussion was not 
balanced equally across groups, and sometimes not open. One Urologist felt that poor 
attendance led to one sided discussions: ―Often it‘s just the urological consultants...other 
people who may have an input are often absent‖ (U3). Even when others were present at the 
MDT, it was felt that Urologists dominated discussions: ―Anyone can [contribute]...but 
normally in reality I think the urologist very often they‘re almost decided the management 
strategy.  You‘ve got to say, hang on a minute, if you really don‘t want that to happen‖. It 
was recognised that different members of the MDT contribute to the discussion in different 
ways, and some participants encouraged multidisciplinary discussion: an Urologist said, ―The 
nurses are encouraged to give us information...they often they know a patient‘s wishes... and 
they often know about home circumstances‖ (U2). However, this was not the case for all 
participants, with one in particular becoming disillusioned at the process, ―I never get an 
opportunity to speak at that meeting, if I have, or in the past when I have tried to speak at that 
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meeting you're more or less told it's not my place to question a consultant's opinion, and 
really then you just think well what's the point in me coming?‖ (N3).  
 
6.5.5 Leadership (Table 24) 
Participants felt that the combination of interpersonal and clinical attributes was important, 
and that an ideal chair would possess both. 
 
Table 24: Ideal qualities/role of a MDT chairperson  
Ideal qualities/role 
of a chair 
N/19 Representative quote 
Time management 8 
 To try to ensure the thing runs to time...Time can be really 
important (O2) 
Gathering 
opinions 
6 
The role of a chair really is to ensure that all voices are heard 
(N1) 
Leadership 6 As a leader it is having to take charge (M3) 
Forming a plan 5 
If there‘s any sticking points, to be able to make a casting 
decision (M2) 
Clinical 
experience 
5 
Without clinical knowledge it would be very difficult, 
because you are dealing with difficult complex patients (U2) 
Camaraderie 4 
We all trust each other and I think the chair...doesn‘t need to 
be terribly, terribly formal (O1) 
Facilitation 2 I think to facilitate the actual meeting (N3) 
Respect of peers 2 They need to be well respected within their team (U2) 
Coordinate 
meeting 
1 
The ideal role of the chair is to try and coordinate the 
meeting (N4) 
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6.5.6 Reaching a decision (Table 25) 
Nine out of 19 participants reported that there were occasions where it was not possible for 
the MDT to reach a recommendation that could be presented to the patient, but that this was 
in a minority of cases. The most commonly reported barrier to reaching a clear treatment 
recommendation was lack of clinical or staging information and as such, the MDT 
Coordinator was crucial to ensuring that patients were only discussed when all the necessary 
information was available. The second most common barrier to reaching a decision is lack of 
personal knowledge of the patient, or the patients‘ comorbidities. 
 
6.5.7 Benefits, and potential improvements to MDT meetings (Table 26) 
Camaraderie and consensus was the most commonly reported positive aspect of MDT 
working with all team members working towards common goals. The second most 
commonly reported benefit was the clinical discussion, particularly with input from various 
specialities. Although mentioned as good points by some, preparation for MDT meetings, IT 
and videoconferencing, attendance; and patient-centredness were all suggested as areas of 
MDT working that needed to be improved. The most commonly reported improvement to 
MDTs was more time: not only time in meetings, but also time in job plans to attend. Better 
case selection was seen both as a way of reducing time pressure and avoiding boredom. 
Several MDT members reported that the MDT would benefit from working in a more 
structured way, with ground rules that MDT members adhered to. 
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Table 25: Barriers to reaching a clear treatment plan in MDT meetings  
Barriers to 
reaching a clear 
treatment plan 
N/19 Representative quote 
Lack of clinical or 
staging information 
11 
Patients are re-discussed because the MDT may say, well 
we need another scan or we need further information or...a 
biopsy or something else (U2) 
Lack of personal 
knowledge of 
patient 
5 
If you‘ve never met them [the patient], I think that does 
hamper the discussion and sometimes you can‘t come to a 
proper decision (O3) 
Lack of information 
on comorbidities 
3 
Often that [deferring to another meeting] will be because 
it‘s a very complicated patient ...somebody who‘s got 
complex comorbidities that again you need the notes to be 
able to assess it (O4) 
Poor attendance 3 
Our one big problem is getting people, getting everybody 
there every week (U1) 
Disagreement 3 
Sometimes there‘s disagreement over what the best course 
of action to take is between the consultants (M2) 
Complex cases 1 
70% of cases include a treatment plan...it [failing to make a 
plan] is really about information, complexity of case (U3) 
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 Table 26: Positive aspects of MDTs and aspects requiring improvement  
 N/19 Representative quote 
Positive aspects of MDTs 
Camaraderie and 
consensus 
5 
We all feel very comfortable...which is why I think it works 
well (O1) 
Clinical discussion 4 
Probably the best part of the process is the clinical discussion 
(N1) 
Attendance of 
specialists 
3 
It‘s [MDT meeting] very well attended in the sense that we 
always have pathological cover, radiological cover, and 
oncological cover (U1) 
High standard of care 2 
The patients clinically are managed well in that good, sound 
clinical decisions are discussed and ultimately formulated 
(N1) 
Patient-centred 2 
We know the patients well, their morbidities, their preferences 
(U3) 
Efficiency 1 They‘re quite fast, I think just that it‘s more organised (M1) 
Preparation 1 
I think the fact that we prepare all our cases before the MDT 
(N3) 
Videoconferencing  
facilities 
1 
With the hospitals, 20 to 30 miles apart, so the good AV, the 
high quality AV facilities help us (U1) 
Aspects of MDTs requiring improvement 
More time 5 More time. Our meetings are far too short (M3) 
Working in a more 
structured way 
4 
When everybody‘s chipping in it gets quite heated ...I think 
there should be more set rules (M1) 
Better preparation 3 
I think the time for the specialist MDT is adequate, it‘s just 
the preparation by all departments is not good enough (U3) 
Better case 
selection/fewer cases 
3 
Bring to the specialist MDT those cases that are actually 
clinically problematic, which would cut it down tremendously 
(U4) 
Improved IT and 
videoconferencing 
3 The video link up could be better (M2) 
Better attendance 2 
Better time management of all individuals that should be at 
the MDT, i.e. allowing them time to attend the MDT (U3) 
More patient-centred 2 
I think the patient‘s views need to be represented a bit more 
(N4) 
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6.6 Discussion 
6.6.1 Summary of results 
Through my exploration of the experiences and attitudes of four groups of core members of 
cancer MDTs from six teams across England and Wales I have drilled down into some of the 
key areas affecting the performance of cancer MDTs. The high inter rater reliability confirms 
that the coding used in this study is an accurate representation of the information from the 
interviews, and that my results are robust. I found that over a quarter of those I interviewed 
were not able to attend the MDT as often as they would have liked, and that there was an 
association between not attending and not having protected time in the job plan to attend. 
Lack of protected time also resulted in longer working days for those able to attend. Members 
perceived case history as well presented, but that problems with equipment and attendance 
reduced the quality of presentation of radiological and pathological information which led to 
reduced satisfaction with meetings. Information on the comorbidities of patients, and any 
choice they had expressed was often glossed over, which was compounded by lack of 
personal knowledge of patients, or non-attendance of someone who knew the patient at the 
meeting. The discussion environment was not one of equality. Participants reported that 
discussions were dominated by surgeons, even by their own admission, but often because 
other professionals were absent. Nurses sometimes felt that they were marginalised. 
Participants across professional groups felt that personal qualities of leadership and 
facilitation as well as clinical experience were necessary for an effective MDT chair. The 
main reasons that it was not always possible to reach an effective outcome were lack of 
clinical information, lack of personal knowledge of patients, and poor attendance at meetings. 
Overall, MDT members were positive about MDT working and reported the main benefits 
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were improved team-working and input from specialists. Improvements to MDTs could come 
from more time- both at meetings and in job plans to attend; improved case selection and 
working in a more structured way. 
 
6.6.2 Limitations 
These results should be interpreted against certain limitations. The views of my sample of 
urology MDT members may not represent the views of all MDT members within their 
groups, or of other professional groups in the MDT. However, I have interviewed four of the 
core groups within cancer MDTs, and my sample covered a wide geographical area; District 
General Hospitals and teaching hospitals; local and network MDTs allowing some 
generalisability of my findings. Also although I only looked at the Urology MDT, which is 
only one specific site within the whole of cancer, I have no reason to believe that this differs 
from any other cancer MDT. Importantly, the findings of this study are consistent with those 
of the National Cancer Action Team in the UK, mentioned above, who surveyed 2054 MDT 
members, covering all major cancer specialities including urology.(79) Finally, these results 
are based on self-reported data, which are subject to potential recall bias. In order to be sure 
of the integrity of the results, more objective evidence (e.g. observational data) is needed to 
confirm the findings of this study. 
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6.7 Conclusion 
This study has begun to explore in depth some of the issues relating to information use, case 
discussion, teamworking, and decision making by MDTs. I have found that MDT members 
view MDTs positively, however a range of improvements are possible, aiming to maximize 
the quality of service and therefore enhance patient care. So far, Chapters 3 to 6 have relied 
on self-reported data, which are by their nature subjective. In Chapter 7 I apply the principles 
of observational assessment to MDT working and develop a systematic and objective method 
of assessing performance in cancer MDT meetings. 
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7 DEVELOPMENT AND EVALUATION OF MDT-MODe- A 
TOOL FOR THE OBSERVATIONAL ASSESSMENT OF 
TEAM DECISION-MAKING IN UROLOGICAL 
MULTIDISCIPLINARY CANCER TEAMS 
 
7.1 Chapter overview  
My first two Chapters have critically evaluated the existing evidence base on team decision-
making in cancer MDTs, revealing various technical and non-technical factors affecting the 
performance of cancer MDTs. Chapters 3 and 4 have explored similar themes on a national 
level across multiple tumour types and between different professional groups, whilst Chapter 
5 found that such issues are found to be important to patients as well as health care 
professionals. The previous Chapter has taken the findings that have emerged from preceding 
Chapters and have explored in depth MDT members‘ views on how their teams function. In 
the current Chapter I have taken a step towards quantifying the performance in the MDT 
meeting with the development and evaluation of an objective, observational measure of 
teamwork and team performance in Urological MDTs. 
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7.2 Introduction 
Outside cancer MDTs, in the past 10 years there has been significant interest and an ever 
expanding evidence base on the description, assessment and improvement of teamworking 
and team performance across a range of healthcare specialties. Within healthcare, surgery and 
anaesthesia are the specialties that pioneered the research on team skills – including 
developing reliable and valid tools for assessment and feedback, and using simulation-based 
training to improve team performance.(18;23-25)   Building on such existing research on 
team performance in other healthcare specialties, it might be possible to construct a robust 
(i.e., reliable and valid) and feasible observational tool to assess the quality of teamworking 
in cancer MDTs. Such a tool might then be used to address the existing gap in understanding 
how cancer teams function. 
 
7.3 Aims 
The specific objectives of the study are: 
1. To construct a robust tool for systematic assessment of MDT team performance 
2. To assess which aspects of MDT team performance can be validly and reliably assessed 
by observers 
3. To assess usability of the tool by clinical and non-clinical observers (including observers‘ 
learning curves, i.e., whether observers‘ reliability improves as their volume of 
observations increases) 
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7.4 Methods 
7.4.1 Tool development 
To ensure content and face validity, tool development proceeded in two Phases.  
In Phase 1, the evidence base on teamworking and team decision making in cancer MDTs 
was reviewed (see Chapter 2) to ensure that the assessment tool captures all relevant aspects 
of teamworking and team decision-making in Urological MDTs. The key aspects of team 
functioning that emerged are as follows:  
 information presentation to the team: coverage of all relevant domains for all patients in 
the discussion list 
 team leadership: aspects of effective and ineffective leadership and on MDT decision-
making 
 team decision-making processes: level of involvement of different professional groups; 
ability to reach and implement a decision  
 
Phase 2 involved the modification of an existing validated tool that assesses quality of 
teamwork to include the themes of cancer team functioning that emerged from Phase 1. The 
Observational Teamwork Assessment for Surgery (OTAS), a validated structured 
observational tool for use in operating theatre teams was chosen as a basis for urological 
cancer team observation.(19;89) In OTAS, behaviours of operating theatre team members are 
scored by an observer (surgeon, or psychologist) on Likert scales with reference to pre-
defined anchor behaviours that are objective (i.e., observable). Two experts (one Consultant 
Urologist (Green), and a Patient Safety expert (Sevdalis)) converted the themes from Phase 1 
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into behaviours to be used in cancer teams. The behaviours that were included in the cancer 
team assessment tool were: presentation of information (radiological, pathological, 
comorbidities and social factors), performance of the chair, and contribution to team 
decision-making of MDT members (Urologists, Oncologists, Radiologists, Pathologists, and 
Clinical Nurse Specialists). Five-point Likert scales (1= lowest to 5= highest) were 
introduced to score the behaviours. Specific, observable anchors were provided for each 
behaviour, which were also derived from Phase 1. The tool is depicted in Figure 27.   
 
7.4.2 Cases  
Data were collected across 112 cancer patients discussed in three different MDTs of three 
separate hospitals in England by a total of 78 team-members. The observed MDTs were 
general Urology MDTs. Cases covered tumours of the bladder, kidney, prostate, testis and 
penis, as well as discussion of benign cases.  
 
7.4.3 Procedure 
I and a psychologist researcher with expertise in observing healthcare teams (Wong) sat in 
and observed the MDT meetings. The researchers were introduced to the teams, informed 
consent was sought by team-members, and it was explained to participants that the aims of 
the observation was to develop and validate an observational tool (the participant information 
sheet is provided in Appendix 7). The observers used the tool to rate team decision-making 
for every patient discussed in the attended meetings. The observers were kept blinded to each 
other‘s ratings throughout data collection. At the end of the observation period, data were 
collated for statistical analyses.    
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Table 27: MDT-MODe scoring sheet (this page) and behavioural anchors (next page) 
 Information Discussion OUTCOME 
# Site point Hx X-ray Path Psy/soc/ comorbid Patient 
view 
Chair Surg Phys Oncolo Nurse Radiolo Histopath MDTC Y/N Free text 
1                   
2                   
3                   
4                   
5                   
6                   
7                   
8                   
9                   
10                   
11                   
12                   
13                   
14                   
15                   
16                   
17                   
18                   
19                   
20                   
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History 5 Fluent, comprehensive case history Psycho-
social 
5 Comprehensive first-hand knowledge of patients‘ personal 
circumstances, social and psychological issues. 
3 Partial case history 3 Vague first-hand knowledge or good second-hand knowledge of 
personal circumstances, social and psychological issues. 
1 No patient case history 1 No knowledge of personal circumstances, social and 
psychological issues. 
x-ray 5 Radiological images Co-
morbidity 
5 Comprehensive first-hand knowledge of past medical history 
and performance status 
3 Radiological information from a report/ account 3 Vague first-hand knowledge, or good second-hand knowledge 
of past medical history or performance status 
1 No provision of radiological information 1 No knowledge of past medical history or performance status 
Pathology 5 Histopathological information from pathologist Patient‟s 
views 
5 Comprehensive first-hand knowledge of patient‘s wishes or 
opinions regarding treatment 
3 Histopathological information from a report/account 3 Vague first-hand knowledge, or good second-hand knowledge 
of patient‘s wishes or opinions regarding treatment 
1 No provision of Histopathological information 1 No knowledge of patient‘s wishes or opinions regarding 
treatment 
Chair 5 Good leadership enhanced team discussion and decision 
making 
Members 5 Clear contribution of speciality. 
3 Leadership neither enhanced or impeded team discussion 
and decision making 
3 Contribution inarticulate or vague 
1 Poor/inadequate leadership impeded team discussion and 
decision making 
1 No contribution 
Point Pre Rx Pre treatment Decision Y Clear treatment decision 
Post 
Rx 
Post treatment N No decision/ Decision deferred 
R Recurrence/ surveillance 
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7.4.4 Data analyses 
Descriptive statistics (mean and median; standard deviation (SD) and range) are reported for 
behavioural ratings. Differences in ratings of the various behaviours were assessed 
statistically using the non-parametric Kruskal Wallis test. All behaviours were assessed 
against the scale midpoint (3), which indicates average quality, using one sample t-test. Tool 
reliability was also assessed statistically. In order to demonstrate reliability, two kinds of 
agreement between observers must be shown. Firstly, it must be demonstrated that there is 
adequate correlation between the scores awarded by the observers across cases. This was 
assessed statistically using Intraclass Correlation Coefficients (ICC) and 95% confidence 
intervals for each behaviour observed. The ICC is a useful correlation coefficient for making 
comparisons between observations.  It is frequently used in the assessment of consistency of 
quantitative measurements made by different observers measuring the same quantity e.g. 
comparing the weight of two objects, rather than comparing the height and weight of the 
same object.(90) Secondly, agreement between observers also entails no significant 
differences in the average score per behaviour awarded by each observer. This analysis 
demonstrates whether one observer is using the tool more leniently (or harshly) that the other. 
This was assessed via comparison of the two observer‘s average scores for each observed 
behaviour. Non-parametric Mann Whitney U tests were applied to these scores to determine 
significant differences in the scoring. Finally, to assess improvement in tool utilisation over 
time, observed cases were grouped into cohorts of 10 and ICC calculated for each cohort. 
Improving ICCs would demonstrate learning curves in tool usage by the observers.  
All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, 
USA). Significance was taken at the 0.05 level, and Bonferroni correction was used to correct 
for multiple tests.  
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7.5 Results 
Descriptive information on the meetings observed is given in Table 28. Between 16 and 34 
cases were discussed at each meeting. The meetings were busy, with an average 19 cases 
discussed per hour (average of 3.2 minutes spent on team discussion per case) (Table 28).  
 
Table 28: Descriptive data of MDT meetings observed 
Observation session 
Number of cases 
observed 
Meeting duration 
(minutes) 
Team-members in 
attendance 
1 20 60 10 
2 25 60 21 
3 17 60 16 
4 16 60 20 
5 34 120 11 
Total 112 360 78 
Mean 22.4 72 15.6 
Median  20 60 16 
 
7.5.1 Ratings of quality of information presentation and team members‟ contributions  
Table 16 summarises the observers‘ ratings. Both observers (surgeon and psychologist) rated 
the various aspects of information presentation and team-member contribution in the same 
rank order – in other words, aspects of teamworking that were rated higher/lower by the 
surgeon were also rated higher/lower by the psychologist. Significant differences were 
observed in the ratings of the various behaviours, both in terms of information presentation 
and also in relation to team-members‘ contributions (Kruskal Wallis, P<0.05). This means 
that the observers rated some behaviour significantly higher than others.  
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Regarding the quality of presented information to the team, case history presentation was 
rated highest by both observers (observers‘ mean=3.93, SD=0.89), followed by Radiological 
information (observers‘ mean =3.56, SD=1.72) and Pathological information (observers‘ 
mean =3.03, SD=1.27). Regarding each team-member‘s contribution, Urologists were scored 
highest (observers‘ mean 4.05, SD=1.26) and clinical nurse specialists lowest (observers‘ 
mean=1.60, SD=1.07), with other team-members in between (Ps<0.05).  
 
Ratings were also submitted to a one-sample t-test, to test whether they were significantly 
different from the scale midpoint (3). Given the scale length and anchors, ratings significantly 
higher than 3 indicate good teamworking; significantly lower than 3 indicate poor 
teamworking; and non-significant differences indicate moderate teamworking (always in 
relation to the scale‘s average anchor for each behaviour). This analysis demonstrated that the 
contribution of Urologists and the behaviour of the Chair, as well as presentation of case 
history, and of radiological information were rated above moderate (P≤0.001), 
Histopathologists and Clinical Nurse Specialists were rated below moderate (P≤0.001), and 
presentation of histopathological information, Oncologists and Radiologists were rated 
moderate (P=0.78; P=0.77; P=0.09 respectively).   
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Table 29: Observers‟ ratings across all categories 
 
Observer 1  
(surgeon) 
Observer 2  
(psychologist) 
Statistical 
significance
#
  
ICC‡ 
 Mean Range Mean Range P value† ICC 95% CI P value 
Information 
presentation to 
team 
History 3.67 1 - 5 4.20 1 - 5 <0.001 0.68 0.53 - 0.79 <0.001 
Radiological 
information 
3.52 1 - 5 3.61 1- 5 0.702 0.84 0.76 - 0.90 <0.001 
Pathological 
information 
2.85 1 - 5 3.20 1 - 5 0.039 0.31 
-0.44 - 
0.55 
0.039 
Team-
members‟ 
contribution to 
team 
discussion 
Chairperson 3.50 1 - 5 3.29 1 - 5 0.168 0.52 0.31 - 0.67 <0.001 
Urologists 4.26 1 - 5 3.85 1 - 5 0.017 0.69 0.54 - 0.78 <0.001 
Oncologists 3.04 1 - 5 2.88 1 - 5 0.447 0.71 0.56 - 0.81 <0.001 
Radiologists 2.83 1 - 5 2.74 1 - 5 0.771 0.82 0.73 - 0.88 <0.001 
Histopathologists 2.03 1 - 5 2.15 1 - 5 0.679 0.86 0.79 - 0.90 <0.001 
Clinical Nurse 
Specialist 
1.63 1 - 5 1.58 1 - 5 0.738 0.87 0.80 - 0.91 <0.001 
Note: Bonferroni correction applied to all statistical tests. Statistically significant results following Bonferroni correction highlighted in boldface; 
#
Mann Whitney U 
test; † average difference between observers (see text); ‡ICC- Intraclass Correlation Coefficient. 
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7.5.2 Inter-rater reliability  
Reliability was assessed via examination of average differences between the two observers‘ 
ratings of the various behaviours, as well as ICCs for each one of the behaviours. Table 16 
summarises the observers‘ ratings, as well as ICCs. Obtained ICCs (Marked ‡ Table 16) were 
good both for the rating of quality of information presentation as well as for the ratings of 
individual team-members‘ contributions to the team. ICCs were very high (0.70+) for five of 
the nine assessed behaviours, and adequate for rating of case history (0.68) and rating of 
Urologists (0.69). Rating of the quality of presentation of histopathological information only 
reached poor reliability (0.31), indicating that perhaps this aspect of the meeting cannot be 
assessed robustly by a non-clinician. Finally, quality of contribution of the Chairperson could 
certainly improve (0.52) – these findings and their implication for team assessment are 
revisited in the Discussion.   
 
Analyses of average differences in the scoring between the two observers (marked † in table 
16) revealed a promising pattern, with no significant differences between them in eight of the 
nine categories. This suggests that the tool allows both observers to score consistently, 
without one being significantly more or less lenient than the other. The single behaviour 
where differences were obtained was case history presentation, where the surgeon observer 
gave significantly lower scores than the psychologist.  
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7.5.3 Observers‟ learning curves 
Figure 6 displays inter-observer ICCs for cohorts of 10 cases in each category of observation. 
The plots are annotated with a solid line at ICC=0.00 and a dotted line at ICC=0.70. 
Reliability coefficients should be read as follows:  
 
 Observations below the solid line (≤0.00) indicate serious disagreement, and 
potentially inability of a non-clinical observer to agree with a surgeon on that aspect 
of an MDT 
 Observations between the solid and the dotted line (≥0.00 and ≤0.70) indicate some 
agreement between surgeon and psychologist observers 
 Observations above the dotted line (≥0.70) indicate very good agreement between 
surgeon and psychologist observers 
 
The two observers showed good agreement (i.e., most coefficients consistently above the 
dotted line) in their assessment of Clinical Nurse Specialists, Radiologists and 
Histopathologists. From the other behaviours, improvement (i.e., an increasing number of 
points above the dotted line as the volume of observations increased) was noted in the 
assessment of case history, and Oncologists. Assessment of Urologists and radiological 
information showed a more mixed pattern, with some good agreement, but not consistent 
improvement over time. Finally, the observers did not reach adequate agreement for the 
presentation of histopathological information and the contribution of the Chair (majority of 
data points below the dotted line, with some of them below the sold line cut off).  
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Closer inspection of the plots reveals a consistent ―dip‖ across most behaviour ratings in 
Cohort 4. This cohort consists of observations carried out in meeting, in which 21 MDT 
members discussed 25 patients. This was the highest rate of case discussion with the greatest 
number of participants included in these observations, and it occurred relatively early in the 
observers‘ learning curve. The increased difficulty of observing such an intense meeting may 
have reduced the reliability of the observation.  
 
 
Figure 6: Graphs depicting learning curves for ICCs between observers      
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7.6 Discussion 
7.6.1 Summary of findings  
The study has demonstrated that robustly constructed observational metrics can reliably be 
used by medical and non-medical observers to assess a range of aspects of MDT performance 
– including the quality of information presentation to the team, and the contributions to team 
decision-making of the core members of the MDT. With the exception of the rating of the 
performance of the MDT Chair, the two observers statistically agree on their average ratings 
of quality of information presentation and team-members‘ contribution. Moreover, adequate 
to good reliability was obtained in the assessment of seven of the nine aspects of the MDT 
performance (presentation of history and radiological information; contribution of Urologist, 
Oncologist, Radiologist, Histopathologist, and Clinical Nurse Specialist). The observers were 
less reliable in their assessments of the Chair‘s contribution, or of the quality of presentation 
of histopathological information, which need further discussion. Finally, a range of learning 
curves were obtained in the aspects of the teams that were overall reliably rated: ratings were 
consistently reliable for Clinical Nurse Specialists, Radiologists and Histopathologists (no 
learning curve evident); improved over time for Oncologists and presentation of case history 
(learning curve evident); and showed a mixed pattern for Urologists and presentation of 
radiological information (no learning curve evident).  
 
7.6.2 Limitations 
These findings are subject to certain limitations. First of all, the sample of MDTs observed 
was rather small and therefore potentially unrepresentative of urology MDTs in general. 
Although this is a fair criticism, it is important to note here that three different hospitals were 
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recruited in the study and the variation in the number of cases discussed and length of team 
discussion time implies that these MDTs were mixed and thus likely representative of the 
wider population. Observations and reliability analyses could have been biased by the 
presence of a non-medically trained observer, who cannot evaluate presentation of clinical 
information. The unsystematic presentation of information and contribution to team 
discussion that was often witnessed made data capture difficult particularly for the 
psychologist observer.  Information on pathology or radiology was often presented within the 
case history, making it difficult for a psychologist to tease out. However, the presence of the 
psychologist observer did not compromise the reliability of most of the observations. 
 
7.7 Conclusion 
Healthcare providers and policy makers are seeking cost-effective and decentralised ways for 
healthcare teams to self-monitor and improve their performance. Developing robust 
assessment tools for MDTs, of which observational metrics are one part, is the first step to 
providing teams with a robust tool kit to assess and improve how they work. In this study I 
have piloted a robust observation tool and demonstrated content validity, face validity and 
feasibility. This alone, without further interventions (like team training, team building, or 
others) can help to highlight problems and issues in a systematic and transparent manner – 
such that some teams will be able to resolve these issues internally. Other teams may require 
further support, in the form of training or other interventions.(25) This observation measure 
may therefore provide the first phase in a staged approach to assessing and improving 
teamworking within MDTs. In the following Chapter I attempt to further validate MDT-
MODe and assess how it compares to team members‘ own ratings of their performance. If 
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successful, such a comparison might also provide some cross-validation for the self-reported 
data presented in Chapters 3 to 6. 
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8  CROSS-VALIDATION OF ASSESSMENT METHODS OF 
TEAMWORK AND CLINICAL DECISION-MAKING IN 
MDT MEETINGS 
 
8.1 Chapter overview 
The previous Chapter described the process of developing and the initial evaluation of an 
evidence based tool for the observational assessment of team decision-making at MDT 
meetings. Although I have demonstrated that the tool can be used reliably, further validation 
is difficult as there are no existing validated tools with which the tool can be compared. In the 
present Chapter I assess validity by comparing objective ratings using MDT-MODe with 
team members own self-assessments. 
 
8.2 Introduction 
In this Chapter I report a study to cross-validate expert observational assessment of cancer 
MDTs against the same teams‘ self-assessment of their team performance and clinical 
decision-making. High agreement between observation and self-report would show good 
concurrent validity.(91) In addition, systematic, statistically evaluated agreement between an 
expert observer‘s assessment of MDT functioning and the team‘s own self-assessment would 
show that teams have self-insight, and therefore can regularly assess themselves without 
constant need for external assessors. In contrast, significant discrepancies between a team‘s 
self-assessment and an assessors‘ evaluation of the same team would show that external 
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assessors are required for team assessment and feedback for cancer MDTs, with the relevant 
cost and resource implications.  
 
8.3 Aims 
The aims of this Chapter are: 
1. To develop an evidence based survey tool with which teams can assess their own 
performance in MDT meeting team decision-making 
2. To recruit teams to self assess their performance in MDT meeting team decision-
making 
3. To observe the same teams in MDT meetings and assess their team decision-making 
using MDT-MODe 
4. To cross-validate assessment methods through comparison of the  results of 
observational- and self-assessment 
 
8.4 Methods 
8.4.1 Observational tool development 
The development of the observational tool has been reported in the previous Chapter. 
 
8.4.2 Survey tool development 
A 29-question survey was developed in three iterative phases to ensure robustness and 
feasibility. Specifically, the tool sought to demonstrate:(89) 
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 content validity: the survey should capture all relevant aspects of teamworking and 
team decision-making in MDTs  
 face validity: the survey should be perceived as relevant and comprehensive by expert 
MDT team members     
 feasibility: the survey should be feasible to complete in that the questions/items ought 
to be understood easily and uniformly by the intended respondents, and the tool 
should not take too long to complete     
 
Aiming to achieve these properties, in Phase 1, I reviewed and extracted key themes from the 
literature on MDT decision-making and its efficacy. The main themes were the quality of the 
discussion at the MDT meeting (enough time; coverage of all relevant issues for all patients 
in the discussion list), MDT leadership (aspects of effective and ineffective leadership; 
impact of effective/ineffective leadership on MDT decision-making process), and MDT 
decision-making processes (level of input by different professionals; coverage of clinical and 
psychosocial aspects of the decision).  
 
In Phase 2, the themes that were extracted in Phase 1 were discussed within the research team 
and a long-list of relevant questions was formulated for potential inclusion in the survey. To 
ensure adequate domain coverage and feasibility, three experts blinded to Phase 1 contributed 
to Phase 2: one Consultant Urologist (Green), one Consultant Oncologist (Payne) and a 
Patient Safety Expert (Sevdalis). The selected questions mirrored the themes that were 
extracted in Phase 1. 
154 
 
Finally, in Phase 3, the draft survey tool was piloted with five clinicians, nurses, and 
psychologists with expertise in survey development and validation to ensure feasibility 
(adequate question comprehension and reasonable length of time taken to complete survey). 
A few amendments were carried out as a result of this Phase, resulting in the final version of 
the tool for data collection. 
 
The final survey (Appendix 8) incorporated multiple choice questions, questions answered on 
Likert rating scales (1=Never, 2=Not often, 3=Sometimes, 4=Half of the time, 5=Usually, 
6=Nearly always, 7=Always), and open-ended questions, in which participants freely 
recorded their views. The questions covered in detail participants‘ work practices, the 
frequency of presentation of different types of information at MDT meetings, the frequency 
of contribution of different healthcare professionals to the MDT discussion, leadership of the 
MDT, and decision-making by the team. Participants‘ demographic information was also 
captured.  
 
8.4.3 Cases 
Participants were recruited between September-November 2009 across multiple hospitals in 
England. Potential participants were recruited in numbers that reflected the representation of 
different specialties within typical MDTs in order to ensure comparability between 
observational and self-assessment data.(79) Participating MDT members were sent an 
electronic invitation letter to the study. Those who accepted were asked to fill out an 
electronic survey via freely available software (http://www.surveymonkey.com). Following 
completion of the survey I visited the participating MDTs to carry out the observational 
155 
 
assessment of teamworking and team decision-making. I used the previously developed and 
validated observation tool, MDT-MODe to rate team decision-making for every patient 
discussed.(92) I had calibrated my ratings with a psychologist observer (Wong) in a previous 
set of observational assessments (i.e., the ratings showed good inter-rater reliability), (See 
Chapter 7 (92)) and was kept blinded to the team-members‘ self-assessments throughout data 
collection. Institutional and ethical approvals to carry out the study were obtained and oral 
informed consent was provided by team-members prior to data collection.  
 
8.4.4 Data analyses 
To ensure comparability between numerical ratings on the observation tool and participants‘ 
self-reported surveys, all data were first standardized to scores ranging from 0 to 1 and 
expressed on a percentage scale (0-100%). Higher scores indicate higher quality of case 
presentation at the MDT and higher quality of team discussion. Mean, standard deviation 
(SD) and range (min-max) are reported for all ratings. The rank ordering of the quality of 
various aspects of the case discussion (i.e., which aspect was better discussed) was analyzed 
using the non-parametric Jonckheere-Terpstra test.(93) This test allows the agreement 
between the observer‘s and self-reported rank orderings to be statistically compared. Cross-
validation of the observational and self-report assessments was carried out statistically using 
non-parametric Spearman‘s correlations (Rho). Significant positive correlations between 
observations and self-reports would provide evidence for adequate consistency between the 
two, and hence concurrent validity for both assessment methods. To visually demonstrate 
correlations between tools, the data were also plotted on scatterplots. All statistical analyses 
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were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Significance was 
taken at the 0.05 level.  
 
8.5 Results 
Preliminary data were collected across 164 cancer cases discussed in five different MDTs in 
England by a total of 67 team-members. Cases were presented by a range of MDT members, 
predominantly Consultant Surgeons and Oncologists. The majority of the time for each case 
was taken with information presentation, and often discussion occurred concurrently with 
presentation of information. Descriptive information on the participating MDTs is given in 
Table 22. Self-report assessments were undertaken by Nurses, (N=16), Surgeons (N=11), 
MDT Coordinators (N=10), Radiologist (N=5), Oncologists (Medical and Radiation; N=3), 
and Pathologists (N=2) with a 70% response rate.  
 
Table 30: Summary of participating MDTs 
Observation 
session 
Number of cases 
observed 
Meeting duration 
(minutes) 
Team-members in 
attendance 
Number of surveys 
completed 
1 48 120 9 6 
2 43 120 16 16 
3 41 120 15 7 
4 25 120 18 9 
5 7 20 9 9 
Total 164 500 67 47 
Mean 33 100 13 9.4 
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8.5.1 Quality of information presentation and team members‟ contributions: 
observational and self-assessments 
Table 31 and Figure 7 summarise the ratings from the observation and self-report 
assessments. 
 
Table 31: Descriptive data for observer‟s assessment and teams‟ self-assessment of team performance by 
category 
Component Observer‟s assessment (%) Teams‟ self-assessment (%) 
 Score SD Min Max Score SD Min Max 
Quality of 
information 
presentation 
to team 
Case history  56 23 0 100 75 21 17 100 
Radiological 53 45 0 100 75 25 0 100 
Histopathological 40 31 0 100 65 31 17 100 
Comorbid, psycho-
social 
18 30 0 100 58 25 17 100 
Patients‘ views 9 25 0 100 56 29 0 100 
Quality of 
team-
members‟ 
contribution 
to team 
discussion 
Surgeons 84 24 0 100 93 15 17 100 
Oncologists 43 41 0 100 88 18 17 100 
Radiologists    33 42 0 100 81 22 17 100 
Histopathologists  23 36 0 100 81 23 17 100 
Nurses  9 25 0 100 54 35 0 100 
MDT Coordinators  0 0 0 0 41 37 0 100 
Note: scores range from 0 to 100%. Higher scores indicate higher quality of presentation and higher quality team 
discussion 
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Figure 2: Bar graphs displaying mean scores for information presentation and contribution to 
case discussion for observational and self-report data 
Both the observer and the MDT members rated the various aspects of information 
presentation, and team-member contribution in the same rank order. Regarding the quality of 
information presentation to the team, both the observational assessment and participants‘  
self-assessments concurred that case histories and radiological information were best 
presented and that, in contrast, patients‘ views and comorbidities/psychosocial issues were 
least well covered (Observed: Z=14.80, P≤0.001; Self-report: Z=3.70, P<0.001; Jonckheere-
Terpstra test). Regarding the contribution of MDT members to case discussion, Surgeons and 
Figure 7: Bar graphs displaying mean scores for information presentation and contribution to case discussion for 
observational and self-report data 
159 
 
Oncologists were found to make the greatest contribution, both by participants‘ self-reports 
and the observational assessment. Both assessment methods found that the contribution of 
Nurses and MDT Coordinators to case discussions were the least frequent (Observed: 
Z=20.00, P≤0.001; Self-report: Z=8.10, P<0.001; Jonckheere-Terpstra test). Regarding the 
variability of ratings, there was no significant relationship between the mean and the SD for 
the observational data (Spearman‘s rho= 0.224; p=0.508). For self-report data, as the mean 
rating increased there was a corresponding reduction in the SD (Spearman‘s rho= -0.922; 
p<0.001). 
 
8.5.2 Agreement between observational and self-report assessments 
Table 32 summarizes Spearman‘s Rho correlations between observer and self-assessments 
for each MDT. The median correlation was Rho=0.74, indicating very good agreement 
between observer‘s ratings and self-reported scores. Correlations were high for MDT 4 
(Rho=0.91), MDT 3 (Rho=0.76) and MDT 2 (Rho=0.74), and adequate for MDT 1 
(Rho=0.66) and MDT 5 (Rho=0.67) – all significant (P<0.05 or lower).  
 
Figure 8 depicts scatterplots displaying mean scores from observational and self-report data 
for each category of assessment by MDT. The dotted line shows a perfect correlation of 1.0; 
the solid line is the line of ‗best fit‘ of the data on each plot. At lower scores there is 
increased deviation from the line of perfect correlation, indicating that participants scored 
themselves higher than the observer rated them. The lines converge at higher scores, which 
implies that for better-completed aspects self-report scores fell into line with scores of the 
external assessor. 
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Table 32: Spearman‟s rho correlation coefficients between observer‟s assessments and self-assessments of 
team performance across MDTs 
MDT Rho Statistical significance  
1 0.66 P=0.027 
2 0.74 P=0.010 
3 0.76 P=0.007 
4 0.91 P<0.001 
5 0.67 P=0.039 
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8.6 Discussion 
8.6.1 Summary of results 
My results demonstrate that observational and self-assessment metrics can be used to reliably 
assess teamworking and clinical decision-making in MDTs. Overall positive correlations 
between the observational and self- assessments were adequate to strong across all MDTs 
with the pattern of self-reported results mirroring those of the observer. The overall pattern of 
results seen in this study reflect previous research, where it can be seen that bio-medical 
information is more comprehensively presented than  patient-centered information, and that 
nursing MDT members often have little overt involvement in team decision-
making.(81;92;94;95) The peripheral role of nurses in clinical decision-making reported here, 
both through observational and self-report data, is a concern.  
 
8.6.2 Limitations 
These findings are subject to certain limitations. Firstly, the sample of MDTs observed was 
small and may not be representative of MDTs in general. However, the variation seen in the 
characteristics of meetings (e.g. case load, attendance) implies that MDTs in the study were 
mixed and likely representative of the wider population. Furthermore, the proportion of 
respondents from particular specialties reflects that of MDTs nationally in the UK.(79) 
Secondly, the present study examined urology MDTs only, and whilst I have no reason to 
believe that the nature of teamworking or decision-making processes differs between 
specialties, further research is needed to discover whether my findings are applicable across 
Figure 8: Scatterplots of observational ratings vs. self-reported scores for each assessment category by MDT 
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tumour types. Use of both self-report and observational methods of assessment in five 
different MDTs from across England, in conditions that realistically reflect the environments 
in which these teams work, demonstrates the usability of these tools for assessing team 
performance. 
 
8.7 Conclusion 
The study reported in this Chapter provides cross-validation evidence for observational and 
self-report assessments of cancer MDT teams and demonstrates that MDT-MODe is valid and 
reliable for use in MDT meetings to assess the quality of team decision-making. Chapters 7 
and 8 have suggested that factors other than team behaviours, such as the organisation of 
meetings, time for discussion, and attendance may influence decision-making behaviour. In 
the next Chapter I will investigate the effects of these on decision-making.  
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9 A STUDY OF FACTORS THAT AFFECT THE EFFICACY 
OF CLINICAL DECISION-MAKING IN MDT MEETINGS 
 
9.1 Chapter overview  
The first two Chapters of this thesis have described how organisational factors, as well as 
behavioural factors, can have an effect on MDT working. Chapter 4 also found the 
scheduling, caseload and timing of meetings to be an area of significant variability between 
urology and other specialities. It follows that such characteristics should be investigated to 
provide a more complete picture of team decision-making in MDT meetings. In the current 
Chapter I describe a study of the effect of organisational factors on decision-making 
behaviours using MDT-MODe. In addition, I will compare results with the ability of the team 
to reach a decision, which was discussed in Chapter 3 as an indicator of decision-making 
quality.  
 
9.2 Introduction 
Providing good patient care requires that the process of decision-making in the MDT meeting 
is also of high quality. Previous Chapters have shown that this depends on access to 
comprehensive information at the point of decision making, attendance of core team 
members, good teamworking and effective leadership. In addition, there is some evidence 
that organisational factors can affect MDT working.(46;84;96) From my experience of MDT 
meetings so far, and discussions with those working in MDTs factors such as the number of 
MDT members present, the timing of meetings, number of cases, and whether cases are at the 
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start or end of meetings also appear to have an effect on the quality of case discussion and 
decision-making. Neglecting to appreciate the effects of such factors could provide an 
incomplete picture of decision-making in the MDT, and failing to account for them might 
confound the results of any study to assess the effect of interventions designed to improve 
MDT decision-making. 
 
9.3 Aims 
The aims of the study reported here are to prospectively assess the relationship between the 
quality of the presented information, contribution to discussion of team members, team size, 
case positioning, and timing and the ability to reach clinical decisions using the MDT 
assessment tool developed and validated in Chapters 8 and 9. 
 
9.4 Method 
9.4.1 Study setting 
A prospective observational study took place between Dec 2009 and Jan 2010 at Whipps 
Cross University Hospital (WXUH), which provides pelvic and complex urological surgery 
for a population of approximately 1 million in north east London. WXUH has a local MDT 
meeting, at which all cases of suspected or confirmed cancer are discussed.  Certain cases of 
complex or high risk disease (Table 33) are referred from surrounding hospitals to the 
Specialist MDT at WXUH and are discussed at the specialist MDT meeting, which takes 
place at WXH once a week with referring sites linked via videoconference. 
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Table 33: Table outlining which patients must be discussed at the specialist MDT 
Organ Criteria for referral 
Prostate Eligible for radical therapy 
Bladder Eligible for radical therapy, G3, CIS 
Kidney Nephron sparing surgery 
Testis All 
Penis All 
Ureter Eligible for Radical therapy 
 
9.4.2 Cases and Participants  
During the study period, all local and specialist cases at seven MDT meetings were observed 
and included in the study. Members of the MDT in attendance included urological surgeons, 
clinical and medical oncologists, specialist and research nurses, radiologists, pathologists, and 
an MDT coordinator. Ethical approval for the study was given by the South East London 5 
Research Ethics Committee. Oral informed consent was given by team-members. 
 
9.4.3 Assessment tool development 
Data collected on features of team decision-making in the MDT meeting was collected using 
MDT-MODe, the development of which was discussed in detail in Chapter 7.(92)  
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9.4.4 Data collection 
The study was a prospective observational study. Using MDT-MODe I collected data on: 
 Meeting characteristics: whether a decision was reached for each case; the number of 
team members in attendance; the profession of team members in attendance; the start 
and end times of meetings. 
 Team behaviours:  
a) Quality of information from case history, radiological and pathological 
investigations, on comorbidities, psychosocial issues and the patients‘ views 
b) Observed quality of contribution to team decision-making of the Chair, Surgeons, 
Oncologists (Medical and Radiation), Radiologists, Pathologists, Nurses and 
MDT Coordinators (MDTCs)  
 
9.4.5 Statistical analysis 
Values for the mean, 95% confidence intervals, standard deviation, and Pearson‘s correlation 
are reported for outcomes and meeting characteristics and results tabulated. All statistical 
analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). 
Significance was taken at the 0.05 level.  
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9.5 Results 
298 local and specialist cases were assessed over seven MDT meetings. Table 34 presents 
descriptive data for meeting characteristics. Table 35 presents data on each domain of MDT 
meeting assessment (information and professional contribution) as well as information score, 
contribution score and decision score for each MDT meeting. Figure 9 displays mean values 
and 95% confidence intervals for each domain across specialist and local MDT cases. 
Overall, a clinical decision could be reached in 254 of 298 cases (85%) of the cases 
discussed. In the forty four cases where decision could not be reached, reasons included 
insufficient radiological information (n=16), inadequate pathological information (n=12), 
inappropriate referral to the MDT meeting (n=11), lack of clinical notes (n=3), and non-
attendance of team members (n=2). 
 
Table 34: Meeting characteristics 
  Cases per meeting Time per case Members attending 
MDT meeting N Mean SD Mean SD Mean SD 
Local 103 15.5 3.5 02:15 00:23 8.4 1.7 
Specialist 195 29.9 5.5 02:32 00:24 12.3 1.6 
Total 298 24.9 8.4 02:26 00:25 11.0 2.5 
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Figure 9 Bar charts displaying ratings for each domain of information (light grey bars) and professional 
contribution (dark grey bars) observed across the study. Specialist MDT cases are displayed in the upper 
panel, and local MDT cases in the lower panel. The dotted line represents the scale midpoint.
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Table 35: Descriptive statistics for domains of the observation assessment tool for each MDT meeting observed (range= 1–5) 
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   Mean (SD) 
1 13 28 
3.29 
(0.87) 
2.78 
(1.67) 
2.95 
(1.16) 
1.34 
(0.76) 
1.34 
(0.76) 
1.17 
(0.77) 
12.88 
(6.00) 
3.15 
(0.48) 
4.59 
(1.07) 
1.56 
(1.38) 
1.00 
(0.00) 
2.61 
(1.96) 
2.41 
(1.90) 
1.00 
(0.00) 
16.32 
(6.79) 
0.88 
(0.33) 
2 18 24 
3.40 
(0.91) 
2.52 
 (1.80) 
2.29 
(1.37) 
1.50 
(1.15) 
1.50 
(1.15) 
1.07 
(0.46) 
12.29 
(6.85) 
3.14 
(0.52) 
4.05 
(1.32) 
2.31 
(1.63) 
1.31 
(0.75) 
2.31 
(1.76) 
2.07 
(1.67) 
1.00 
(0.00) 
16.19 
(7.66) 
0.83 
(0.38) 
3 9 10 
3.16 
(0.76)  
2.79 
(1.65) 
3.21 
(0.85) 
1.37 
(0.68) 
1.37 
(0.68) 
1.37 
(1.12) 
13.26 
(5.76) 
3.05 
(0.23) 
4.58 
(1.02) 
2.11 
(1.59) 
1.95 
(1.22) 
2.16 
(1.77) 
2.16 
(1.77) 
1.00 
(0.00) 
17.00 
(7.61) 
0.95 
(0.23) 
4 15 32 
3.04 
(1.04) 
2.34 
 (1.52) 
2.66 
(1.26) 
1.43 
(1.02) 
1.43 
(1.02) 
1.11 
(0.52) 
12.00 
(6.37) 
3.38 
(0.57) 
4.51 
(1.02) 
1.74 
(1.50) 
1.23 
(0.70) 
1.91 
(1.64) 
1.89 
(1.66) 
1.00 
(0.00) 
15.68 
(7.08) 
0.83 
(0.38) 
5 21 30 
3.37 
(1.13 
2.71 
 (1.74) 
2.57 
(1.15) 
2.04 
(1.37) 
2.04 
(1.37) 
1.47 
(1.14) 
14.20 
(7.90) 
3.82 
(0.68) 
4.00 
(1.64) 
1.98 
(1.53) 
1.04 
(0.28) 
1.86 
(1.59) 
1.12 
(0.62) 
1.00 
(0.00) 
14.82 
(6.34) 
0.69 
(0.47) 
6 13 34 
3.40 
(0.97) 
2.89 
 (1.67) 
2.87 
(1.08) 
2.13 
(1.44) 
2.13 
(1.44) 
1.38 
(1.03) 
14.81 
(7.63) 
3.91 
(0.58) 
4.77 
(0.84) 
2.02 
(1.62) 
1.09 
(0.58) 
3.11 
(2.00) 
2.30 
(1.84) 
1.00 
(0.00) 
18.19 
(7.47) 
0.96 
(0.20) 
7 19 32 
3.25 
(1.00) 
2.25 
 (1.52) 
2.65 
(1.25) 
1.41 
(0.96) 
1.41 
(0.96) 
1.27 
(0.87) 
12.25 
(6.56) 
3.70 
(0.70) 
3.98 
(1.56) 
2.63 
(1.90) 
1.22 
(0.88) 
1.51 
(1.32) 
1.92 
(1.62) 
1.00 
(0.00) 
15.96 
(8.00) 
0.73 
(0.45) 
Mean 15 27 
3.29 
(0.98) 
2.59 
 (1.65) 
2.70 
(1.20) 
1.63 
(1.16) 
1.63 
(1.16) 
1.26 
(0.87) 
13.10 
(7.03) 
3.45 
(0.54) 
4.32 
(1.30) 
2.06 
(1.63) 
1.20 
(0.70) 
2.19 
(1.78) 
1.94 
(1.64) 
1.00 
(0.00) 
16.16 
(7.59) 
0.84 
(0.35) 
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9.5.1 Correlations between domains and outcome measures 
Values for Pearson‘s r across each domain of the observed data, and each outcome measure 
are displayed in Table 36. Decision score was positively correlated with case history, 
radiological and pathological information, and the contribution of surgeons and radiologists. 
There was a positive correlation between information score and each category of information, 
as well as with the contributions of surgeons, oncologists and radiologists. Contribution score 
was positively correlated with the contribution of each professional group except for MDT 
coordinators. There were also positive correlations between contribution score and 
information from case history, radiological, pathological and patients‘ views. Decision score, 
information score and contribution score were positively correlated with each other. 
 
9.5.2 Correlations between meeting characteristics and outcome measures  
Pearson‘s r values for correlations between meeting characteristics and outcome measures are 
presented in Table 37. Case number (i.e. cases occurring towards the end of the meeting) was 
associated with less time per case, a lower number of members present at the meeting, and 
lower scores for all three outcome measures: information score, contribution score and 
decision score. Specialist MDT meetings were positively correlated with the number of cases 
per meeting, the amount of time per case, and the numbers of team members present, as well 
as information score and contribution score. The number of cases per meeting was associated 
with higher numbers of team members present, and the better information and contribution 
scores, but a lower amount of time per case. Time per case was positively correlated with 
contribution score. The number of team members present was associated with higher scores 
for both the information and contribution score. 
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Table 36: Correlations for components of the observational tool and outcome measures 
 
 Information components Contribution components Scores 
 
 Radiological Pathological Psychosocial Comorbidities 
Patient 
view 
Chair  Surgeons Oncologists Nurses Radiologists Pathologists 
MDT 
Coordinator 
Decision 
score 
Information 
score 
Contribution 
score 
In
fo
r
m
a
ti
o
n
 c
o
m
p
o
n
e
n
ts
 
Case history 0.246** 0.147 0.172* 0.172* 0.070 -0.015 0.382** 0.285** 0.099 0.198** -0.004 – 0.285** 0.538** 0.359** 
Radiological 1.000 -0.018 0.141 0.141 0.044 0.076 0.371** 0.307** 0.012 0.676** -0.084 – 0.191** 0.595** 0.555** 
Pathological  1.000 -0.128 -0.128 0.034 -0.002 0.336** -0.026 0.003 0.003 0.521** – 0.334** 0.280** 0.319** 
Psychosocial   1.000 1.000 0.085 0.003 0.105 0.108 0.023 0.117 -0.110 – 0.034 0.702** 0.114 
Comorbidities    1.000 0.085 0.003 0.105 0.108 0.023 0.117 -0.110 – 0.034 0.702** 0.114 
Patient view     1.000 0.034 0.092 0.177 0.097 -0.019 -0.060 – 0.097 0.332** 0.121** 
C
o
n
tr
ib
u
ti
o
n
 c
o
m
p
o
n
e
n
ts
 
Chair      1.000 0.039 0.124 -0.022 0.102 -0.077 – -0.010 0.038 0.133 
Surgeons       1.000 0.243** 0.111 0.309** 0.081 – 0.583** 0.456** 0.649** 
Oncologists        1.000 0.126 0.159* -0.097 – 0.149* 0.308** 0.579** 
Nurses         1.000 0.051 0.033 – 0.107 0.069 0.308** 
Radiologists          1.000 -0.071 – 0.239** 0.417** 0.626** 
Pathologists           1.000 – 0.119 0.047 0.361** 
MDT 
Coordinator 
           – – – – 
S
c
o
r
e
s 
Decision 
Score 
            1.000 0.309** 0.423** 
Information 
score 
             1.000 0.537** 
 Key: *=P≤0.01, **=P≤0.001. 
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Table 37: Correlations for meeting characteristics and outcome measures 
N=298 Specialist /local 
Cases per 
meeting 
Time per case 
Members 
present 
Information 
score 
Contribution 
score 
Decision score 
Case number -0.759** -0.483** -0.468** -0.557** -0.300** -0.371** -0.153* 
Specialist / local 1.000 0.813** 0.329** 0.750** 0.371** 0.433** 0.123 
Cases per meeting  1.000 -0.212** 0.635** 0.318** 0.292** 0.034 
Time per case   1.000 1.25 0.092 0.163* 0.134 
Members present    1.000 0.348** 0.433** 0.150 
Information score     1.000 0.537** 0.359** 
contribution score      1.000 0.471** 
Key: *=P≤0.01, **=P≤0.001. 
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9.6 Discussion 
9.6.1 Summary of results 
My results suggest that the ability of an MDT to reach clinical decision is associated with 
improved information quality, specifically, improved information form case history, 
radiological and pathological investigations, improved contribution of team members, and 
with cases that are discussed closer to the beginning of the meeting.  Higher quality of 
information and team contribution are themselves associated with specialist cases, cases at 
the beginning of meetings, larger team size, higher numbers of cases per meeting, and longer 
case discussions. 
 
9.6.2 Limitation 
The results of this study should be interpreted in the light of certain limitations. Firstly, the 
sample of MDT meetings observed comes from a single MDT and may not be representative 
of MDTs in general. However, the sample size is large and the cases referred to the specialist 
and local MDTs are drawn from a large population which is more likely to be representative 
of the UK in general.  Secondly, the present study is set in a urology MDT, and whilst there is 
evidence that the nature of teamworking and decision-making is similar across common 
tumour types, further research is needed to discover whether my findings are applicable to 
different surgical oncology specialities. 
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9.7 Conclusion 
The present Chapter offers an objective and scientific analysis of the factors that affect 
teamworking and decision-making in MDT meetings- not just behavioural factors, but 
organisational factors too. This is the first study of MDT working to demonstrate a 
quantitative relationship between the way teams work together, the information they have 
available to them and their ability to make clinical decisions. I have also provided the first 
analysis of the effect of MDT meeting organisation on clinical decision-making. Taken 
together, these results reinforce the importance of good MDT working in the delivery of high 
quality cancer care- the care given to patients can only be as good as the clinical decision-
making process that underpins it. It now remains to develop an intervention to address some 
of the factors that I have so far described in an attempt to improve decision-making and 
teamworking in urological MDT meetings. This is what I have done, and I report it in 
Chapters 10 and 11. 
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10 DEVELOPMENT AND EVALUATION OF MDT-QUIC: A 
CHECKLIST TO SUPPORT DECISION-MAKING IN 
CANCER MULTIDISCIPLINARY TEAM MEETINGS  
 
10.1 Chapter overview  
My thesis so far has set out to identify behavioural and organisational factors that influence 
team decision-making in MDT meetings, and to construct a robust tool to objectively assess 
the decision-making process. These objectives have been met and in the current Chapter I 
begin the process of developing and evaluating an intervention that, by addressing issues that 
I have previously identified, might improve team decision-making. The subsequent Chapter 
will describe the implementation and testing of the intervention described here as part of 
multi-component intervention in a urology MDT meeting over a period of 16 months. 
 
10.2 Introduction 
Previous Chapters have demonstrated that there is currently no standardized method of 
conducting MDT meetings, and case discussions can be rapid, highly pressured and 
unstructured.(92;97) The average length of time of case discussion have ranged from just 
over two, to three minutes, and input from nurses was lacking.(92;97) In addition, 
information on patients‘ views, psycho-social aspects of care, and patients‘ comorbidities was 
consistently under-considered in clinical decision-making.(97;98)  
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In the light of this evidence, it is conceivable that standardizing the discussion process might 
improve the overall quality of clinical decision-making for cancer patients by ensuring 
minimum quality requirements for information presentation and participation of team 
members. One means of standardizing processes and improving quality that has been 
successfully used across a number of industries is the checklist.(99) Checklists are 
inexpensive tools that can be used in complex, high intensity fields of work, to improve 
safety and accuracy of service delivery by reducing human error.(100) Checklists vary from 
the prescriptive (the algorithm for CPR), to those that are just a mnemonic list (an equipment 
list for a procedure), leaving the method of implementation to the clinician.(101;102) They 
can be used as guidance during a task, or for post hoc verification that certain tasks have 
already been performed.(100) There are limitations to the utility of checklists - they can be 
difficult to enforce, and may be perceived to undermine autonomy, skill or knowledge.(99) In 
addition, organizations can suffer from checklist fatigue, where the increasing number of 
checklists becomes a nuisance, rather than a benefit.(99) However, strong evidence now 
exists that demonstrates robust improvements in healthcare processes and outcomes where 
checklists are employed, including in critical care units to reduce infections and length of 
stay, in anaesthetics to reduce communication error, and recently by the WHO to improve 
safety in surgery.(103-106) 
 
10.3 Aims 
In order to overcome such barriers to implementation a checklist must be developed in a user-
driven and evidence-based manner.(100;101) The aim of the research reported here is to 
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develop an intervention to standardize and improve the quality of case discussion and clinical 
decision-making in MDT meetings. My specific objectives are: 
 To develop an intervention based on the best evidence of quality improvement in 
MDTs and checklist development, with input from experts and key user groups 
 To evaluate the content and face validity of such an intervention with key user groups 
in order to validate the checklist for use in MDT meetings 
 
10.4 Methods 
10.4.1 Checklist development (Figure 10) 
To ensure content and face validity, checklist development was undertaken in three Phases.  
Phase 1 consisted of a review of the literature on clinical decision-making in cancer MDTs in 
order to ensure that the tool captures all salient aspects.(81) The key aspects of optimum 
clinical decision-making that emerged, to be included in the intervention are:  
 presence of all core team members, including those who know the patients to be 
discussed 
 coverage of all relevant domains of information for all patients  
 involvement of different professional groups 
 ability to reach and implement a decision  
 
In Phase 2, in order to validate the aspects that emerged from Phase 1, comparison was made 
with data from empirical studies of team decision-making in MDT meetings.(92;97;98) The 
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comparison confirmed the importance of the factors listed in Phase 1 for comprehensive 
clinical decision-making.  
 
In Phase 3 the evidence base on checklist design in healthcare was reviewed. Experts in 
human factors/safety (Sevdalis and Vincent) and cancer MDT working (Green and Lamb) 
converted the list of features from Phases 1 and 2 into a feasible preliminary decision-support 
tool, or checklist for use in MDT meetings. Features of the checklist included: 
 presentation of checkpoints in a logical and functional order reflecting the flow of 
real-time MDT case discussion(100;101) 
 minimum information necessary to cover the major checkpoints, whilst allowing team 
members the freedom to use their own judgement(100;101) 
 clear, bold fonts and clear colouring(100;101) 
Upon completion of this study, the preliminary checklist was modified to take into account 
feedback from the evaluation process.(100) The final version of the checklist is depicted in 
Figure 11. 
 
10.4.2 Checklist evaluation 
10.4.2.1 Participants 
Participants were recruited between October 2010 and April 2011. Recruitment was 
purposive in order to ensure representation of professional groups who have clinical contact 
with patients, namely surgeons, specialist nurses, oncologists, as well as MDT coordinators.  
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Participants were recruited from national forums and a regional cancer network within 
England, and were asked to forward the invitation to their colleagues in order to maximize 
the sample size. 
 
 
Figure 10: Flow diagram illustrating the process of development and evaluation of the MDT Quality 
Improvement Checklist (MDT-QuIC) 
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10.4.2.2 Procedure 
MDT members were sent an electronic invitation to fill out an electronic survey via freely 
available software (http://www.surveymonkey.com). Some questions were answered on a 5-
point Likert scale (1=completely disagree, 3= neither agree nor disagree, 5=completely 
agree), some were multiple choice, and others required free text responses. The survey 
consisted of an evaluation of the concept of the checklist for structuring MDT discussions 
(content and face validity), an evaluation of potential use and users of the checklist 
(feasibility), a section for suggestions for improvements to the checklist, and capture of 
demographic information (the survey tool is presented in Appendix 9). The experimental 
protocols were approved by the appropriate institutional review committee and meet the 
guidelines of their responsible governmental agency. The final version of the checklist 
(Figure 11) took into account all of the feedback provided by participants.  
 
10.4.2.3 Data analyses 
Descriptive statistics are reported for each element of the evaluation (median, minimum, 
maximum; or percentage and 95% confidence intervals).  Differences in ratings of 
professional groups (surgeons, oncologists, nurses, MDT coordinators) were assessed 
statistically using the Kruskal Wallis test. Where significant differences were obtained, pair-
wise comparisons to look for specific differences between professional groups were carried 
out using the Mann Whitney U test. In addition, elements evaluated on a 5-point Likert scale 
were assessed against the scale midpoint (3) using one sample t-tests. All statistical analyses 
were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Significance was 
taken at the 0.05 level, and Bonferroni correction was used to correct for multiple tests. 
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Figure 11: MDT-QuIC following the development and evaluation process 
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10.5 Results 
10.5.1 Characteristics of participants 
Participants included 38 surgeons, 40 oncologists, 62 nurse specialists and 35 MDT 
coordinators. 73% of participants worked only in urology, with 27% also working in other 
specialties. 42% of respondents were male, 33% chaired their MDT, 87% had attended over 
100 MDT meetings, 55% attended the MDT meeting at a major cancer centre, and 45% were 
electronically linked into a MDT meeting from a satellite hospital. There was no significant 
difference between healthcare professionals working only in urology, and those also working 
in other specialties for any of the survey items.  
 
10.5.2 Current practice at MDT meetings 
54% of participants already had some structure to their MDT meetings: 58% used a 
proforma, 28% had an electronic patient record, and 14% used both. 80% of respondents 
thought that a more structured way of discussing cases at the MDT meeting would aid the 
team‘s decision-making. 
 
10.5.3 Potential uses of the checklist 
Table 38 and Figure 12 display results for the evaluation of the potential uses for the 
checklist. The use of the checklist during the MDT meeting as a memory aid to guide 
discussions, and as a checklist to structure discussions were most popular. Most respondents 
also thought that the checklist could be used prior to the MDT meeting to gather and record 
information, or afterwards to comprehensively record the MDT outcome and decision-
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making process. There was no significant difference between the responses of different 
professional groups (Kruskal Wallis test).  
 
Table 38: Responses of participants to the question, “How should the checklist be used?”. Selection of 
more than one answer was permitted 
How should the checklist be used? 
 
95% confidence 
interval 
KW Test 
Yes (%) 
Lower 
bound 
Upper 
bound 
P 
As a memory aid to guide discussion                   60.7 51.4 69.6 .531 
As a check-list to structure discussion 
for each case 
57.3 46.9 65.4 .867 
With the MDT proforma to help 
prepare cases           
55.6 46.0 64.5 .565 
With the MDT outcome to structure the 
record          
53.8 43.3 61.9 .876 
None of the above                                     6.0 1.7 10.6 .556 
KW Test: Kruskal Wallis Test. Significance level P<0.01 after Bonferroni correction for multiple 
comparisons 
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Figure 12: Graph showing the percentage of respondents who answered „Yes‟ to statements regarding 
possible uses of the checklist. Error bars represent 95% confidence intervals 
 
Table 39: Responses of participants to the question, “Who should be responsible for using the checklist?”. 
Selection of more than one answer was permitted. 
Who should be responsible 
for using the checklist? 
 
95% confidence 
interval 
KW Test 
Yes (%) 
Lower 
bound 
Upper 
bound 
P 
MDT Chair                       70.1 60.7 77.9 .000* 
MDT Coordinator                 54.7 45.1 63.7 .000* 
All MDT members 37.6 28.7 46.8 .031 
Nurses                          12.8 6.9 19.5 .567 
Surgeons                        7.7 2.9 12.9 .701 
Oncologists                     6.0 1.7 10.6 .696 
Radiologists                    3.4 0.1 6.9 .036 
Pathologists                    1.7 -0.7 4.2 .045 
None of the above               2.6 -0.4 5.6 .220 
KW Test: Kruskal Wallis Test. *=Significant at P<0.006 level after Bonferroni correction. 
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10.5.4 Potential users of the checklist 
Table 39 and Figure 13 display results for the evaluation of the potential users of the checklist 
in MDT meetings. The most popular choices were the MDT chair, the coordinator, followed 
by the whole team. There were significant inter-professional differences for two of the 
questions. Regarding whether the MDT Chair should use the checklist, significantly more 
nurses (79% yes, 69-89 95% CI) and surgeons (66% yes, 50-82 95% CI) than oncologists 
(33% yes, 17-48 95% CI) or MDT coordinators (26% yes, 10-41% 95% CI) gave a positive 
answer (all P<0.003 on pair-wise comparison, Mann Whitney U Test). Second, regarding 
whether the MDT coordinator could use the checklist, significantly more nurses (89% yes, 
81-97 95% CI) than MDT coordinators (46% yes, 28-63 95% CI), or oncologists (38% yes, 
22-53 95% CI); and significantly more surgeons (71% yes, 56-86 95% CI) than oncologists 
gave positive answers. 
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Figure 13: Graph showing the percentage of respondents who answered yes for each professional group 
to the question of who should be responsible for using MDT-QuIC 
 
10.5.5 Attitudes to checklist 
Table 40 and Figure 14 display results for participants‘ attitudes to the checklist. The median 
responses to all but one of the statements were significantly positive, i.e., statistically higher 
than the scale midpoint of 3 (all P<0.001, single sample T-test). The only response which 
failed to reach significance level was to the item ‗[the checklist] would allow me to 
contribute more to the MDT‘ (median=3, Neither agree nor disagree). Moreover, some 
significant differences between professional groups in three statements were found. Nurses 
agreed significantly more (median=4, range=3–5) than surgeons or oncologists (both 
median=4, range=1–5) that the checklist was easy to use (P=0.001, and P<0.001 respectively, 
Mann Whitney U test). Nurses‘ belief that the checklist would allow them to contribute more 
to the MDT (median=4, range=1–5) was significantly more positive than that of the surgeons, 
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oncologists or MDT coordinators (all median=3, range=1–5) (all P<0.001, Mann Whitney U 
test). Nurses were also more positive towards introducing the checklist to the MDT they 
attend (median=4, range=1–5) compared to oncologists (median=3, range=1–5).  
 
Table 40: Responses of participants to statements regarding their attitudes towards the checklist. 
Participants were asked to rate their agreement with each statement on a 5-point Likert scale 
(1=completely disagree, 3= neither agree nor disagree, 5=completely agree). 
The checklist... 
   T-test 
KW 
Test 
Median Min Max P P 
Is a good idea 4.0 1.0 5.0 .000* 0.061 
Is easy to use 4.0 1.0 5.0 .000* 0.000* 
Would improve the way my 
MDT runs 
4.0 1.0 5.0 .000* 0.149 
Would make the MDT more 
patient-focused 
4.0 1.0 5.0 .000* 0.019 
Is something that I would like 
to introduce in the MDTs I 
attend 
4.0 1.0 5.0 .000* 0.001* 
Would allow me to contribute 
more to the MDT 
3.0 1.0 5.0 .013 0.000* 
KW Test: Kruskal Wallis Test. *=Significant at P<0.008 level after Bonferroni correction 
 
188 
 
 
Figure 14: Graph showing median response by professional group to statements regarding participants‟ 
attitudes towards the checklist (1= strongly disagree; 2= disagree; 3= neither agree nor disagree; 4= 
agree; 5= strongly agree). Error bars represent 95% confidence intervals 
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10.6 Discussion 
10.6.1 Summary of results 
This is the first study to develop and evaluate a checklist as a tool to support clinical 
decision-making in cancer MDTs. The development process ensures that the checklist is 
evidence based, validated with expert opinion, and evaluated by users. My evaluation data 
suggest that team members from across disciplines are positive towards the concept and 
content of the checklist as a tool to support decision-making, although nurses envisage a 
greater improvement to their personal contribution than other groups.  
 
10.6.2 Limitations 
The interpretation of the findings of this study is subject to certain limitations. The sample 
used in this study was small, and included only four professional groups. The study sample 
may not therefore be representative of MDT members in general. In addition, the sampling 
method used for the survey involved snowballing, which means that the response rate of 
those invited to participate cannot be determined. However, the oncologists, nurses and MDT 
coordinators who participated were recruited from national forums, and surgeons from a 
regional cancer network, and as such represent those core MDT members who have contact 
with patients, from a range of locations throughout the UK. The majority of participants 
practiced only in urology, which means that the checklist remains to be evaluated fully for 
use in MDTs in other specialties. Although in Chapter 4 I suggest that urology MDT working 
may not differ from that in other major tumour types, further replication of these results with 
more team members across more tumour types should be undertaken to clarify the 
generalisability of the results.  
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10.7 Conclusion 
In Chapter 11 I have developed MDT-QuIC, an evidence-based checklist for use in MDT 
meetings, which has been validated by key user groups. Respondents of all professional 
groups that participated were positive about the checklist. Teams may benefit from 
integrating the checklist with current MDT structures, such as electronic patient records, or 
proformas used to prepare cases for discussion, to ensure that clinical decision making is 
comprehensive and patient-cantered across the whole care pathway. In the following Chapter 
I use the checklist as described here as the basis for a multi-component intervention designed 
to improve decision-making, information quality and teamworking in the urology MDT 
meeting. 
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11 A MULTI-COMPONENT INTERVENTION TO IMPROVE 
THE QUALITY OF UROLOGICAL MULTIDISCIPLINARY 
TEAM DECISION-MAKING 
 
11.1 Chapter overview 
In previous Chapters I have described the development and validation of a tool to assess 
performance in MDT meeting decision-making, and an intervention to attempt to improve 
such decision-making. In the present Chapter I will describe a study that builds on my work 
so far and attempts to assess the effect of a series of quality improvement interventions on 
decision-making in a urology MDT meeting over a period of approximately 16 months. 
 
11.2 Introduction  
One method of improving healthcare quality that has been successful in areas that require 
interventions on multiple fronts is the use of multi-component interventions.(107;108) Such 
initiatives are composed of multiple interventions each based on the best available evidence. 
The collection of interventions is designed to be introduced together with the hypothesis that 
as a whole they can improve the quality of care more than the sum of the individual 
components. Such an approach has the advantage of allowing several interventions to be 
introduced over a shorter time scale with fewer resources required for implementation or 
assessment.(109;110) To this end, my research team has developed and evaluated a series of 
quality improvement initiatives for use in MDT meetings to enhance the quality of decision-
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making, information availability and teamworking. The bundle of interventions consists of 
four stages, each designed to complement the previous and based on the best available 
evidence: 
 Team training: face to face didactic lecture on the evidence for effective clinical 
decision-making in MDT meetings (Appendix 10) 
 Introduction of MDT-QuIC: introduction of team to a previously developed and 
evaluated checklist to support decision making in MDT meetings (MDT-QuIC), to 
use as team saw best (See Chapter 10).(111) 
 Enhanced use of MDT-QuIC: Use of checklist to improve preparation of information 
for MDT meeting, as well as supporting decision-making in meeting, with a team 
member devoted to populating summaries for each case. 
 Written guidance: emailed to local team and network highlighting evidence for best 
decision-making. 
A previously validated tool for assessment of the quality of clinical decision-making and 
team working in urological MDTs was used to assess the effect of the QI bundle on the 
decision-making and behaviours of the MDT during meetings (MDT-MODe). MDT-MODe 
was shown in Chapters 8 and 9 to be valid and reliable for use in urological MDT meetings 
by medical and non-medical assessors.(92;97) 
 
11.3 Aims 
The aim of this study is to prospectively evaluate the effect of an evidence based quality-
improvement bundle on the quality of decision-making and teamworking in a urological 
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MDT. I hypothesise that the implementation of such an intervention will increase the efficacy 
of decision-making and improve information quality and teamworking. 
 
11.4 Methods  
11.4.1 Study setting 
The study took place between December 2009 and April 2011 at Whipps Cross University 
Hospital (WXUH), which provides pelvic and complex urological surgery for a population of 
approximately 1 million in north east London where local and specialist cases are discussed 
at the MDT meeting, which takes place at WXH once a week with referring sites linked via 
videoconference. 
 
11.4.2 Cases and Participants  
During the study period, 36 MDT meetings were observed. All observed cases, both local and 
specialist were included in the study. Members of the MDT in attendance included urological 
surgeons, clinical and medical oncologists, specialist and research nurses, radiologists, 
pathologists, and an MDT coordinator. Ethical approval for the study was given by the South 
East London Research Ethics Committee. Oral informed consent was given by team-
members. 
 
11.4.3 Study design 
The study was a prospective intervention study. A period of baseline observations 
(01/12/2009–26/01/2010) was followed by the implementation of the intervention (Figure 
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15). The baseline observations allowed the observer to become accustomed with the MDT 
meeting and the team to become accustomed to the presence of the observer, hopefully 
minimising the Hawthorn effect. During the baseline observation the MDT underwent certain 
changes including changes to the IT and videoconferencing system, and change of venue for 
meetings. Consequently, the baseline period is split into two, so that any effect of the changes 
to infrastructure could be assessed. The individual components of the intervention were 
introduced sequentially so as not to overwhelm the team before introduction of the next part. 
 
 
Figure 15: Timeline of study interventions and observation periods 
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11.4.4 Interventions 
 Team training (31/08/2010): a session consisting of a 30 minute slideshow followed by 
interactive questions and discussion was conducted for all MDT members (10 fellows or 
residents, 3 specialist nurses, 5 consultant/attending surgeons, and 1 MDT Coordinator). 
The programme included an introduction to the idea of quality improvement in the MDT 
meeting with detailed presentation of the evidence for improved clinical decision-making 
in MDT meetings (Appendix 10). 
 MDT-QuIC (19/10/2011): MDT-QuIC (see Chapter 11) is an evidence based checklist to 
support clinical decision-making in MDT meetings.(111) The checklist was introduced to 
the team, who decided to use the checklist to structure information presentation for each 
case. 
 Enhancement of MDT-QuIC (16/11/2010): In order to enhance the use of the checklist, a 
member of the research team trained one of the clinical fellows to use MDT-QuIC to 
prepare case summaries in advance of the MDT meeting. The Clinical fellow then spent 
one morning each week collating results, going through case notes, ensuring that patients 
were appropriately referred for the following MDT meeting.  
 Written guidance (01/02/2011): Guidance on how to optimise the use of MDT-QuIC was 
written by the research team and emailed to all members of the MDT. The guidance was 
drawn from a review of the evidence on care management decisions in MDT meetings 
and applied to situations that they encountered in their everyday practice, setting out how 
team members could draw the optimal clinical information required for MDT decision-
making.  
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11.4.5 Data collection 
I collected data using MDT-MODe (see Chapter 8).(92) Measures included:  
a) Information score derived from rating of the quality of information from case 
history, radiological and pathological investigations, on comorbidities, psychosocial 
issues and the patients‘ views (MDT-MODe) 
b) Contribution score derived from the observed quality of contribution to team 
decision-making of the Chair, Surgeons, Oncologists (Medical and Radiation), 
Radiologists, Pathologists, Nurses and MDT Coordinators (MDTCs) (MDT-MODe) 
c) Decision score derived from whether a decision was reached on each case. This 
was objectively assessed from the Chair‘s action, which is recorded by the MDT 
coordinator in the meeting minutes 
I also gathered data on the number and profession of team members in attendance, as well as 
start and end times of meetings. Inter-rater reliability was assessed for Information Score and 
Contribution Score at the beginning and the end of the study over a total of seven MDT 
meetings by psychologist observers trained in the observation of teamwork, and blind to the 
surgeon observer‘s ratings (Wong and Brown) and was found to be excellent (ICC 
0.719−0.951, all P<0.001). 
 
11.4.6 Outcome measures 
The primary outcome measure for the study was Decision Score – i.e. the proportion of cases 
for which a decision could be made (range 0–1, converted to a percentage). Secondary 
outcome measures were Information Score (the sum of the scores for the six different 
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information types, range 6–30, converted to a percentage for ease of comparison); and 
Contribution Score (the sum of the scores for contribution of the seven different professional 
groups, range 7–35, converted to a percentage for ease of comparison). 
 
11.4.7 Covariates 
Organizational characteristics of MDT meetings (including the number and profession of 
team members in attendance, start and end times of meetings, and number of cases per 
meeting) were expected to have an effect on the outcome measures. These data were 
collected and used as covariates, which were controlled for in the analyses.  
 
11.4.8 Statistical analysis 
Mean and standard deviation (SD) are reported for all outcomes and meeting characteristics. 
Analysis of Covariance (ANCOVA) fitted as a series of linear models was used to assess the 
impact of each intervention phase upon the outcome measures, through statistical comparison 
with the first baseline period.  Linear or Logistic Regression procedures were used according 
to the nature of the outcome being assessed. A series of covariates (see above) were entered 
in each model as a preliminary step in the analysis, to control for variability in key 
organizational features of each MDT meeting.  Linear modelling was carried out to identify 
which interventions were independent predictors of each outcome measure. The individual 
effects of the intervention components were assessed according to the significance of the 
change in variance that occurred with the addition of each intervention over that of the study 
baseline when controlling for effects of the covariates. Statistical significance was set at 
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P<0.05. Results for meeting characteristics and each outcome measure were tabulated. All 
statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). 
 
11.5 Results 
1421 local and specialist cases were assessed over 36 MDT meetings. Table 41 presents 
descriptive data for meeting characteristics. Table 42 presents descriptive statistics for the 
primary and secondary outcome measures.  
 
Table 41: Data on characteristics of meetings 
  
Number of 
cases 
Meeting duration Time per case 
Members 
attending 
MDT meeting N Mean SD Mean SD Mean SD Mean SD 
Specialist 884 24.6 8.7 01:01:11 00:17:51 00:02:29 00:00:26 11.3 1.9 
Local 537 14.9 6.4 00:26:04 00:11:24 00:01:45 00:00:31 8.2 1.6 
Total 1421 39.5 11.2 01:27:16 00:22:38 00:02:13 00:00:28 10.1 2.3 
 
11.5.1 Inter rater reliability 
Table 42 presents data for inter rater reliability. Intraclass correlation coefficients for the 
beginning of the study are good for both information score and contribution score, and at the 
end are excellent for both. 
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Table 42: Interrater reliability analysis 
Assessment 
point 
Outcome 
Observer 1 
(surgeon) 
Observer 2 
(psychologist) 
ICC 
  Mean Range Mean Range ICC 95% CI 
Start 
Information score 3.38 1 - 5 3.72 1 - 5 0.719
**
 0.64–0.78 
Contribution score 2.93 1 - 5 2.79 1 - 5 0.842
**
 0.81–0.87 
End 
Information score 2.70 1 - 5 2.75 1 - 5 0.912
**
 0.90–0.94 
Contribution score 2.68 1 - 5 2.68 1 - 5 0.951
**
 0.94–0.96 
Note: ICC= intra-class correlation coefficient. 
**
=significant at P<0.001 level. 
 
Table 43: Table presenting data for each primary outcome measure across each intervention period 
Intervention 
added 
Cases 
Decision score 
(Range 0–100) 
Information score 
(Range 6–30) 
Contribution score 
(Range 7–35) 
 N 
Mean 
(SD) 
% 
Mean 
(SD) 
% 
Mean 
(SD) 
% 
Baseline A 298 
82.21 
(38.30) 
82.21 
13.10 
(3.76) 
29.60 
16.22 
(3.82) 
32.95 
Baseline B 169 
85.80 
(35.01) 
85.80 
12.96 
(3.82) 
28.99 
16.69 
(4.09) 
34.62 
Team training 139 
78.42 
(41.29) 
78.42 
13.78 
(4.22) 
32.43 
17.63 
(4.26) 
37.95 
MDT-QuIC 186 
77.42 
(41.92) 
77.42 
 
14.87 
(4.21) 
36.94 
18.23 
(4.06) 
40.11 
Enhanced 
MDT-QuIC 
301 
85.05 
(35.72) 
85.05 
 
14.57 
(3.84) 
35.76 
17.92 
(3.78) 
39.00 
Written guidance 328 
92.68 
(26.08) 
92.68 
 
15.21 
(3.65) 
38.40 
18.68 
(3.17) 
41.71 
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11.5.2 Decision Score 
Decision Score rose over the course of the study from 82.2% to 92.7% (Table 43, Figure 16). 
Decision Score showed positive correlations with both Information Score (r=0.298, range 
0.177–0.418) and Contribution Score (r=0.348, range 0.104–0.506) (Table 44). A weak 
positive correlation was found between Decision Score and time per case (Table 44). 
Analysis using a linear model revealed that the change in variance in Decision Score 
explained by the combination of team training, the use of MDT-QuIC, and enhancing MDT-
QuIC with training was significant, showing that these interventions were associated with 
significant improvement in Decision Score when compared to the score at baseline A. 
Addition of written team guidance had further a significant effect on variance in Decision 
Score (Table 45).  
 
11.5.3 Information score 
Over the course of the study the mean Information Score increased from 29.6% to 38.4% 
(Table 43, Figure 16). Correlational analysis revealed a positive association between 
Information and Contribution Scores. Information Score was lower for cases discussed later 
in the list, and higher with more cases per meeting, more time per case and more team-
members present, although these correlations were weak (Table 44). Linear statistical 
modelling revealed that a combination of team training and the introduction of MDT-QuIC 
were associated with a significant change in variance in Information Score, showing that 
these interventions were associated with significant improvements in this outcome over the 
baseline level. Enhancing the use of MDT-QuIC with training, and written team guidance 
explained further variance (Table 45). 
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11.5.4 Contribution score 
Over the entire study the mean Contribution Score rose from 32.9% to 41.7% (Table 43, 
Figure 16). Like Information Score, Contribution Score was lower for cases discussed later in 
the list, and higher with more cases per meeting, more time per case and more team-members 
present (Table 44). Linear statistical modelling showed that team training and MDT-QuIC 
were together sufficient to significantly change the variance in Contribution Score over the 
baseline level, suggesting that such interventions are associated with significant improvement 
in Contribution Score. The addition of training for MDT-QuIC, and then dissemination of 
written team guidance gave additional change in variance in Contribution Score (Table 45).  
 
Figure 16: Graph showing Decision score, Information score and Contribution score across intervention 
periods. 
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Table 44: Table displaying Pearson‟s r correlations for outcome measures and organisational 
characteristics of MDT meetings 
 Decision score Information score Contribution score 
Decision score 1.000 0.298
*
 0.348
*
 
Information score – 1.000 0.544
*
 
Contribution score – – 1.000 
Case number -0.016 -0.249
*
 -0.261
*
 
Cases per meeting -0.026 0.174
*
 0.198
*
 
Time per case -0.078
*
 0.124
*
 0.112
*
 
Number of members 
present 
0.029 0.193
*
 0.222
*
 
Note: 
*
=P<0.05 
 
Table 45: Regression analysis (linear model) of the effect of each additional part of the quality 
improvement intervention on each outcome measure 
Intervention 
added 
 
Decision Score 
 
Information Score 
 
Contribution Score 
Chi-
Squared 
OR 95% CI ∆R2 ∆F ∆R2 ∆F 
Baseline B 0.000 1.00 0.49–2.07 .000 0.034
A
 .000 0.086
 A
 
Team training 0.259 0.82 0.38–1.77 .013 6.399
*B
 .010 5.051
*B
 
MDT-QuIC 0.038 0.95 0.58–1.56 .042 24.238
*C
 .075 48.756
*C
 
Enhanced 
MDT-QuIC 
4.330
*
 2.07 1.04–4.14 .019 13.027*D .028 20.679*D 
Written 
guidance 
5.146
*
 1.94 1.08–3.49 .072 55.262*E .079 69.174*E 
Note:
 *
P<0.05. OR= odds ratio; CI=confidence interval; ∆R2= R2 change; ∆F=F change.  
A
Df1=1, Df2=438; 
B 
Df1=1, Df2=430; 
C
 Df1=1, Df2=477; 
D
 Df1=1, Df2=592; 
E
 Df1=1, Df2=619 
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11.5.5 Decision failure 
Figure 17 and Table 46 display data on cases where decision was not possible across each 
stage of the study. At each phase of the study, inadequate radiological and pathological 
information accounted for the greatest proportion of decision-failures. Failures appear to 
increase most noticably following team training and MDT-QuIC, due to an increase in 
inadequate radiology and pathology, which then subside in the final part of the study. 
 
 
Figure 17: Area chart presenting data for cases with decision failure. The coloured areas represent the 
percentage of cases where decisions could not be reached across each phase of the study. Each colour 
represents a different reason for the decision failure.  
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Table 46: Analysis of decision failure 
Intervention 
added 
Cases 
Decision-
failure 
Reason for decision-failure 
 N 
N 
(%) 
Inadequate 
pathology 
Inadequate 
radiology 
Lack of notes Staff absence 
Inappropriate 
referral 
Inadequate 
clinical 
information 
Technology 
failure 
Lack of 
time 
Baseline A 298 
44 
(14.8) 
4.0 5.4 1.0 0.7 3.7 0.0 0.0 0.0 
Baseline B 169 
22 
(13.0) 
2.4 4.1 2.4 1.2 3.0 0.0 0.0 0.0 
Team training 139 
28 
(20.1) 
4.3 4.3 1.4 0.7 0.0 2.9 6.5 0.0 
MDT-QuIC 186 
38 
(20.4) 
6.5 9.1 0.0 1.6 0.0 1.6 0.0 1.6 
Enhanced 
MDT-QuIC 
301 
40 
(13.3) 
3.3 6.0 1.3 1.0 1.0 0.0 0.3 0.3 
Written 
guidance 
328 
24 
(7.3) 
2.1 4.0 0.0 0.0 0.6 0.3 0.0 0.3 
 
11.6 Discussion 
11.6.1 Summary of results 
Over the course of the study, the introduction of a multi-stage intervention designed to 
improve MDT team decision-making was associated with a significant increase in the ability 
of the MDT to make decisions on cases discussed, as well as improvements in the quality of 
information, and team contribution to decision-making. This study provides further evidence 
to support the association between information quality, team contribution and the ability to 
reach management decisions on cases discussed at the MDT meeting. These results lend 
support to the use of measures of decision-making efficacy, information quality and 
teamworking as indicators of MDT performance, and suggest that by improving such metrics, 
teams may improve the way they work. 
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11.6.2 Limitations 
The results of this study should be interpreted in light of certain limitations. Firstly, the lack 
of a control group makes it difficult to attribute causation to the introduction of the quality 
improvement bundle its self, rather than to other factors. In our analysis we have controlled 
for the effects of meeting characteristics known from previous research to affect information 
quality and team decision-making. Secondly, the sample of cases included in the study comes 
from a single MDT and may not be representative of MDTs in general. However, the large 
sample size drawn from a population of approximately one million suggests that our results 
might be representative of the UK in general.  Thirdly, the present study is set in a urology 
MDT, which means results may not be generalisable to MDTs treating other tumour types. In 
Chapter 3 I have suggested that many aspects of MDT working are similar across common 
tumour types, but further research is needed before we can be confident that our findings are 
applicable to different surgical oncology specialities. 
 
11.7 Conclusion 
As the first study to prospectively assess the effect of a quality improvement bundle on the 
effectiveness of the MDT decision-making process, and as such, the results are encouraging. I 
have found further evidence of the importance of comprehensive clinical information, and 
good teamworking on clinical decision-making, and that such factors can be improved by 
relatively simple interventions. Further work is needed to assess the effect of quality 
improvement bundles on other measures of MDT performance that take into account patient 
outcomes, patient-centredness, and team member satisfaction. 
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12 GENERAL DISCUSSION 
 
12.1 The problem 
Although there was evidence that arranging cancer services into multidisciplinary teams may 
improve outcomes and reduce complications for patients, and even improve the working lives 
of healthcare professionals, there had been little research into how MDTs worked together 
and made decisions. Existing research that did examine the decision-making process and how 
team members interacted was largely qualitative and descriptive.(56;57) In parallel, in other 
healthcare fields, researchers were building an evidence base for how the performance of 
teams could be objectively measured, assessed and improved.(23;24) When I started this PhD 
in May 2009, my aim was to apply the approach that had been successfully used in surgery, 
anaesthesia and other specialities to the field of decision-making in MDT meetings. In the 
chapters of this thesis I have described how I have attempted to scientifically and 
systematically study this field by critiquing the existing evidence, defining current practice, 
exploring the attitudes of healthcare professionals and patients, developing tools to assess 
teams and using these tools to measure the effect of evidence based interventions on the 
quality of decision-making in MDT meetings. In the final Chapter I present an overview of 
my findings, review the main limitations of my work and discuss some possible implications 
of this work for future research and clinical practice. 
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12.2 Overview of thesis findings 
This thesis has reported a series of studies that have explored, measured and improved 
teamwork and team decision-making in urology multidisciplinary cancer teams. I started with 
a narrative review of the literature on team decision-making in healthcare, with a focus on 
cancer care and a systems approach to set out a conceptual framework to help rationalise the 
many factors that affect this process (Chapter 2). In Chapter 3 I conducted a systematic 
review of the evidence for clinical decision-making in cancer MDTs, which takes stock of the 
existing evidence, and focuses on specific factors that affect decision-making by MDTs. In 
Chapters 4 and 5 I analysed data from a national survey that explores the views of MDT 
members from different professional groups across a range of tumour types.  Chapter 4 used 
non-parametric analysis and pairwise comparisons to analyse consensus and difference 
between tumour types for a range of statements. In Chapter 5 I used qualitative methods to 
analyse free text responses to the survey data that related to teamworking and patient-
centeredness in MDT decision-making. I then used the themes that arose in Chapters 2 to 5 as 
a framework for qualitative exploration of the experiences and views of patients through a 
focus group study in Chapter 6, and of members of urology MDTs with an interview study in 
Chapter 7. A combination of the evidence base, and the experiences of healthcare 
professionals and patients were used in Chapter 8 to inform the development of an 
observational assessment tool, with demonstration of inter-rater reliability between medical 
and non-medical observers, as well as learning curves for each domain of assessment. In 
Chapter 9 the validity of the observational tool was then tested through cross-validation 
against the self-assessment of MDT members using an evidence based survey tool. In 
Chapter 10 I used the validated observation tool, MDT-MODe to assess the relationship 
between decision-making efficacy, organisational factors, information availability and team 
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members‘ contribution in a prospective experimental observational study. Having built up a 
picture of the factors that were important for decision-making in MDT meetings, and 
equipped with a tool to measure this process, Chapter 11 described the development of MDT-
QuIC, an intervention to improve decision-making in MDT meetings and its evaluation with 
key user groups. Finally, in Chapter 12 I reported a 16 month long prospective study using 
MDT-MODe to evaluate a multistage intervention, which included MDT-QuIC, to improve 
the quality of decision-making. 
 
12.3  Thesis findings by aim: 
Aim 1: To review and evaluate the evidence-base for team decision-making by 
multidisciplinary cancer teams 
Evidence from the quality and safety literature suggests that cognitive processes and 
behaviours of healthcare professionals (individually and as teams), and organisational factors 
can affect decision-making. Chapter 1 took a broad approach in its examination of all 
available evidence relevant to decision-making in cancer care. Overall, I found little evidence 
linking the existence of MDTs to oncological outcomes, and no research found convincing 
evidence of an effect on survival. Most research specific to MDTs has looked at the effect of 
MDTs on various measures of process, whether it is the ability to reach a decision, the quality 
of the decision, a change in decision or whether a decision is implemented. The systems 
approach provides a structured way of thinking about such measures of performance and 
identifies many of the factors that affect the quality of the process. The main findings of 
Chapter 1 were that decision-making requires people with the appropriate skills and 
information attend meetings and present, discuss and make decisions based on all relevant 
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information. The next step taken towards fulfilling my aim was my systematic review, 
reported in Chapter 2, which looked more specifically at the available literature concerning 
decision-making by healthcare professionals in cancer MDTs. Studies were generally of low 
quality and numerous endpoints were used, preventing synthesis of results. Of the evidence 
that was reviewed in this Chapter, much of it suggests that MDTs make a difference to the 
outcome of decisions, compared with those of individual clinicians. Changes to decisions 
came from reinterpretation of diagnostic information, or change to the choice of treatment, 
although evidence for improved decision-making was lacking. The literature shows the varied 
roles played by different team members within the MDT: different professionals use different 
information when making decisions, in particular that medical team members focus on 
biomedical information about the disease, and nurses tend to focus on information about the 
patient as a person, and how their illness affects their lives and families. Often hierarchies 
operate which result in the exclusion of certain team members, most frequently nursing and 
allied healthcare professionals. There is evidence that when teams cannot reach decisions it is 
often due to inadequate radiological or pathological information at the point of decision-
making. Concerning the implementation of decisions, failure of decisions to be implemented 
is related to the changing clinical picture, or when patients‘ comorbidities renders the 
decision clinically inappropriate, or the patient chooses to go against the recommendation of 
the MDT. Use of telemedicine is increasing and can provide a cost effective way to improve 
attendance and synchronously present pathological and radiological information at different 
sites. High-quality decision making requires optimal support in the form comprehensive 
information at the point of decision-making, effective teamworking and leadership, protected 
time and good facilities.  
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Aim 2: To assess the views and experiences of health care professionals regarding 
decision-making in MDT meetings 
The study presented in Chapter 3 aimed to systematically assess whether there exist tumour-
based differences in definition of effectiveness of MDT working.  Consensus between team 
members from different tumour types was very high – the majority (116/136) statements 
were answered similarly regardless of tumour specialty of the respondent.  No differences 
between tumour types were found the physical environment of meeting venues, technology or 
equipment, or the type and level of support required at an organisational level or aspects of 
team governance. The differences of opinion that I revealed related to preparation for and 
organisation of MDT meetings, case selection and the clinical decision-making process. 
Regarding urology specifically, differences from other tumour types were found in only eight 
of 136 statements, and in each of these, urology only differed from one or two other tumour 
types, with no significant differences form the remaining tumour types. This study offers 
statistical evidence that MDT members from different tumour types across the UK are in 
reasonable agreement about what constitutes effective MDT working. In Chapter 4 I analysed 
comments provided by a national sample of over 1600 MDT members regarding effective 
teamworking in MDTs; efficacy of decision-making by MDTs; and patient-centeredness of 
the MDT decision-making process. The key themes that emerged in relation to effective 
teamworking were the importance of good relationships between team members, adequate 
non-technical skills (i.e., communication, leadership) and the need for support at an 
organizational level. In relation to team decision-making, recording of disagreements when 
they occur (and potentially letting the patient know), and the importance of having adequate 
information about the patient were key emerging issues. Finally, in relation to patient-
centeredness of MDT decision-making the key role of the clinical nurse specialists as patient 
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advocates alongside the medical personnel, and the complementary role of nurses and 
Consultants in discussing team recommendations with the patient were key findings. In 
Chapter 6 I explored in depth using qualitative interviews the experiences and attitudes of the 
core members of urology MDTs from six teams across England and Wales, which confirmed 
the findings of preceding Chapters.  The main reasons that it was not always possible to reach 
an effective outcome were lack of clinical information, lack of personal knowledge of 
patients, and poor attendance at meetings. Overall, MDT members were positive about MDT 
working and that improvements to MDT meetings could come from more time for meetings, 
improved case selection and working in a more structured way.  
 
Aim 3: To evaluate the views of cancer patients in order to inform subsequent studies 
and ensure this research is patient-centred 
Although Chapter 5 described a small study, it gave an initial picture of what patients think 
about MDTs, and how they want to be represented and included in the decision-making 
process. I found that awareness of the MDT among participants was low, but they found the 
idea reassuring. Participants in the study felt that it was important for teams to consider all 
relevant information- biomedical, psychosocial as well as preferences, although their 
experience showed that this was not always the case. While I found that participants were not 
keen on attending their own case discussion, they felt that they could contribute indirectly via 
the CNS, who by virtue of the close relationship with patients could act as an advocate in the 
MDT meeting. Participants felt that it was important that cases were only discussed when 
there were members present who knew the patient; otherwise they thought it would be 
preferable to delay discussion.  
212 
 
Aim 4: To scientifically develop and evaluate objective assessment tools for use in 
urology MDT meetings 
In Chapter 7 I developed, used and assessed the inter-rater reliability of a tool to assess the 
quality of teamwork and decision-making in MDT meetings (MDT-MODe). The study 
demonstrated that this observational assessment tool can reliably be used by medical and 
non-medical observers to assess the quality of information presentation to the team, and the 
contributions to team decision-making of the core members of the MDT. Reliability was 
adequate or good across seven of the nine aspects of the MDT performance, and less reliable 
in assessments of the Chair‘s contribution, or of the quality of presentation of 
histopathological information. Learning curves were mixed showing that raters could learn to 
use the tool for assessing most aspects of decision-making within 100 cases. In Chapter 8 I 
then attempted to validate MDT-MODe through cross-validation with MDT members‘ self-
reported performance. Firstly, the results of this study demonstrated that observational and 
self-assessment can be used reliably to assess teamworking and clinical decision-making in 
MDT meetings. Furthermore, the pattern of self-reported results showed a positive 
correlation with those of the observer. In Chapter 10 MDT-MODe was used to assess the 
relationship between the ability of an MDT to reach a decision and information and 
contribution quality and organisational factors. The results suggest that the ability of an MDT 
to reach clinical decision is associated with improved information quality, specifically, 
improved information form case history, radiological and pathological investigations, 
improved contribution of team members, and with cases that are discussed closer to the 
beginning of the meeting.  Higher quality of information and team contribution are 
themselves associated with specialist cases, cases at the beginning of meetings, larger team 
size, higher numbers of cases per meeting, and longer case discussions. The overall pattern of 
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results seen in Chapters 7 to 9 was consistent and reflected those of previous Chapters, where 
it was seen that bio-medical information is more comprehensively presented than patient-
centered information, and that nursing MDT members often have little overt involvement in 
decision-making in the MDT meeting. 
 
Aim 5: To develop and evaluate an intervention to improve decision-making in urology 
MDT meetings 
In Chapter 10 I presented a study to develop and evaluate a checklist as a tool to support 
clinical decision-making in cancer MDTs. The development process, which involved input 
from the evidence described in Chapters 1 and 2 as well as input from experts in cancer care 
and quality and safety, ensured that the checklist had content and face validity, and was 
feasible. My evaluation data suggested that team members from across disciplines are 
positive towards the concept and content of the checklist as a tool to support decision-
making, although nurses envisage a greater improvement to their personal contribution than 
other groups. The checklist, MDT-QuIC, was tested in Chapter 11 as part of a staged 
intervention, designed to improve MDT team decision-making. Introduction of the 
programme of interventions, which was comprised of team training, use of a checklist, 
training in the checklist and written guidance for the team, was associated with a significant 
increase in the ability of the MDT to make decisions on cases discussed, as well as 
improvements in the quality of information, and team contribution to decision-making. The 
pattern of results required some interpretation, and it was not clear from the results how long 
each stage of the bundle takes to bed-in and take effect.  The main reason for decision failures 
appears to be an increase in the number of cases without adequate pathological or 
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radiological information. Interestingly, although not reaching significance level, the decision 
score decreased with the introduction of training and the checklist. One possible explanation 
for the drop in decision score may be that by enlightening the team about the necessity of 
comprehensive information for good decision-making, they become critical and despite some 
improvement in information score, are less happy to make decisions without adequate 
information. It was not until enhanced MDT-QuIC, when a team member is trained to collate 
results, prepare summaries and assess which cases are appropriate for discussion during that 
the decision score showed a significant improvement, an effect that was sustained with 
introduction of written guidance. The staged quality improvement intervention trialled in this 
study (team training, the introduction and demonstration of a checklist, and written team 
guidance) were designed to ensure that the MDT have the tools necessary to make high 
quality decisions, and not to replace the judgment of healthcare professionals. This study 
suggested that information quality and team contribution are associated with and necessary 
for the ability of the team to reach management decisions on cases discussed at the MDT 
meeting. These results lend support to the use of interventions designed to improve decision-
making efficacy, information quality and teamworking as means of improving the way MDTs 
work and therefore improving the care that teams are able to give to patients.  
 
12.4 Limitations 
12.4.1 Limitations of evidence base  
There are several limitations in the evidence base for improving MDT working. The review 
presented in Chapter 1 utilises literature on teamworking and team skills in cancer care as 
well as other domains of healthcare. Many parallels can be observed between teams in 
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different domains of healthcare, and one might expect that evidence from one might be 
applicable to another. However, Chapter 2 shows that the weight of evidence from empirical 
studies in decision-making in cancer MDTs is limited. 37 studies were included in my 
systematic review, which are a small number given the number of tumour types covered and 
the range of outcomes surveyed. The median quality score for quantitative papers was nine of 
18 (range 3-15) and for qualitative papers was 13 of 24 (range 9-14). One randomised control 
trial was included in the review along with ten non-randomised control trials, most with a 
pre-and post design. Other systematic reviews that I have referenced during this thesis have 
also found limitations in the quality of studies to be a limiting factor in this field of research.  
In addition, other factors including novel treatments, technology and service changes have 
evolved in parallel and it is difficult to unpick the specific effects attributable to MDT 
working in itself. However, as I have pointed out previously, in the UK, prospective trials 
aiming to robustly evaluate the effectiveness of working as an MDT cannot be carried out, as 
MDT working is now ubiquitous having been mandatory for a number of years. This means 
that much of the research on MDT working from recent years is ‗behind the curve‘ in terms 
of UK healthcare. Such research is certainly useful in other countries where MDT working is 
not mandatory and will allow other healthcare providers to decide whether they wish to 
organise their cancer services as the UK has done. Indeed, it is encouraging that a recent large 
retrospective study assessing the impact of MDT working on breast cancer outcomes in 
Scotland found that there were significant improvements in survival and other clinical 
outcomes.(112) What is more relevant to patients and healthcare professionals in the UK is 
research into improving MDT working, which has been the aim of this thesis, and to date has 
resulted in publication of eight of the Chapters in this thesis along with other related 
manuscripts.  
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A recurring theme in this thesis has been the challenge of measuring the effect of an MDT or 
the effectiveness of an intervention using measures of MDT process or outcome. My first two 
Chapters revealed that previous research has attempted to assess the effect of MDT working 
against a variety of outcomes including patient survival. Such research has struggled to 
demonstrate changes to clinical outcomes in part because the MDT meeting is one part of the 
cancer care pathway, which is a complex process.(31)  Measures of patient outcomes, such as 
survival and complications remain the gold standard of the effectiveness of clinical care, and 
the ultimate aim of my research is to improve the outcomes of patients. A limitation of all 
work to date looking at improving MDT working, including my own, is a failure to 
demonstrate improvements in ‗gold standard‘ outcomes, and instead with a reliance on proxy 
measures, which demonstrate improvements in measures of the process of decision-making 
and MDT working. Demonstrating improvements in such proxy measures across the care 
pathway can provide quality assurance to the care of patients such that the process leading to 
care is the best possible, which is perhaps the best that patients can be offered at present.(113) 
Further research is needed to establish and validate measures of MDT performance against 
patient outcomes before I can be confident that studies that assess interventions using these 
measures translate into real benefits to patients.  
 
12.4.2 Limitations of methods 
12.4.2.1 Sampling 
The sampling method used for the studies in Chapters 4 and 5, and also for the evaluation of 
MDT-QuIC in Chapter 10 involved snowballing (i.e. those who are recruited passing on 
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invitations to participate to other potential participants), which means that the response rate 
cannot be determined. However, the oncologists, nurses and MDT coordinators who 
participated were recruited from a national population and as such represent core MDT 
members from a range of locations throughout the UK. Furthermore, team members who 
participated in the NCAT survey described in Chapters 4 and 5 were only able to give one 
response per statement, which meant that respondents who worked across several teams in 
different tumour types were not able to provide responses reflecting their experience across 
different teams.(79) As a result respondents who were members of multiple teams were 
excluded from my analysis. Only those who worked in one tumour type were included in the 
analysis, in order that study data accurately reflected specific tumour types. Therefore, 
oncologists, radiologists and histopathologists, were underrepresented in the study as they 
commonly work across multiple tumour types. Moreover, the professionals who were 
excluded from the analysis may actually provide interesting insights into the differences 
identified in this study by virtue of working in different and possibly contrasting teams. 
Finally, there is a possibility that as participation of the studies described in Chapters 3,4 and 
10 were opt-in in nature, those who responded are more favorably disposed to the idea of 
MDT working and use of checklists in healthcare, respectively.   
 
12.4.2.2 Observational assessment 
I chose observation as the method of assessment of teamwork and team decision-making in 
MDT meetings and here I will discuss some of the main limitation, most of which I have 
experienced firsthand in my research. Most of the urology MDT meetings I observed were 
busy and case discussions were rapid. In these conditions, it was difficult for me and my 
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fellow observers to capture and rate all aspects of a case discussion, which is a limitation of 
all observational assessment of teamwork.(39) Paradoxically, the interpretation of silence was 
also difficult and is known to affect all observational research.(114) It was difficult as 
observers for us to rate whether a lack of input was constructive or not, and whether silent 
team members were assenting or dissenting to decisions. There was no way of knowing with 
certainty the thoughts of team members other than through their vocal contribution. For 
clarity in the studies described here, a low mark was recorded for silence. However, in reality 
such silence during an MDT meeting is sometimes necessary to permit ordered discussion. In 
addition, the unsystematic presentation of information and contribution to team discussion 
that I observed made data capture difficult. Information on pathology or radiology was often 
presented within the case history, not by the expected or appropriate professional (i.e. the 
Histopathologist or the Radiologist), which at the start was difficult for the non-medical 
observer to tease out. However, learning curves were apparent across the course of the study, 
which implies that observers can eventually learn to separate the information from the 
contribution.   
 
12.4.2.3 Multi-stage intervention study 
The most apparent limitation of the findings of Chapter 11 is the lack of a control group, 
which makes it difficult to attribute causation to the intervention itself, rather than to other 
factors which may have been in effect at the same time. Unfortunately the recruitment of a 
control MDT was beyond the means of this PhD. In order to eliminate the potential effects of 
factors that may have an effect on my outcome measures, my analysis has taken into 
consideration the effects of meeting characteristics. Meeting characteristics were found in 
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Chapter 10 to be associated with changes in Decision Score, Information Score and 
Contribution Score. Previous studies that have looked at the effect of quality improvement 
interventions, which also have not used a control group, have used interrupted time series 
analysis to take account of the effect of any naturally occurring change in the baseline 
performance.(115) However, interrupted time series analysis relies on data collected at 
regular intervals, usually as a result of mandatory retrospective data collection, such as data 
on infection rates or prescribing trends. Unfortunately it was not possible to impose such 
conditions on a working MDT, and data collection was not always possible at regular 
intervals, which prohibited interrupted time series analysis. I have no reason to suspect that 
the team was undergoing any change in performance over time prior to the present study as 
the study team was a long established team with a stable membership and consistent patterns 
of referral. Furthermore, the study presented in Chapter 11 is limited by restrictions to tumour 
type, single institution and sample size, which have all been previously described in more 
depth. 
 
12.5 Implications 
12.5.1 Implications for clinical practice/ MDT meetings 
12.5.1.1 Lack of patient-centred information 
A number of implications that have emerged from the results of this thesis require further 
discussion. Firstly, although I have found that MDT members and patients agree that 
comprehensive information is both desirable and necessary for good decision-making, I have 
found consistently that information relating to the patients disease is more frequently 
220 
 
available and better presented than that which related to the patient as a person. Mandatory 
minimum data sets for information relating to radiological and pathological investigations, 
comorbidities and the patients views and circumstances might ensure that every case 
discussed has the foundations necessary to make a good clinical decision. Thus the 
requirement for minimum data sets may provide quality assurance to the process of decision-
making. Moreover, standardised data requirements might make the decision-making process 
more transparent allowing patients to better understand the reasons for certain decisions.  
 
12.5.1.2 Efficacy of decision-making 
By prospectively assessing and quantifying the decision-making process in Chapter 11, and 
relating it to decision-making efficacy, I have been able to identify factors that are associated 
with improved decision-making. My finding that a decision could be reached in 85% of cases 
is in line with previous findings. A study of 344 patients with lung cancer discussed at an 
MDT meeting in France found that a decision was possible at the first discussion for 47%, 
with an additional 33% made at the second meeting, 15% and the third and 5% thereafter.(62) 
A retrospective analysis of 324 cases discussed at a head and neck MDT in Sweden found 
that 73% of cases could reach a decision at the first discussion. In the latter study the authors 
were able to relate failure of decision-making to a lack of imaging (42%), requirement for 
extra staging information (30%), histological problems (7%), extra information on 
comorbidity needed (6%), and more than one of the above (16%).(52) My own analysis of 
failure of decision-making in Chapter 11 is consistent with that above and underlines the 
importance of comprehensive information at the point of decision-making. Standardised 
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minimum data sets for radiological and pathological information, which are already being 
piloted in the UK, may improve the efficacy of decision-making.(116;117)  
 
12.5.1.3 Structuring MDT meetings and standardisation of discussion 
Just having information present at MDT meetings may not be sufficient to ensure that team 
members make use of such information or contribute to discussion. It may be that 
standardisation of the whole MDT case discussion is needed to ensure that all necessary 
information is presented and relevant team members contribute. One improvement to MDT 
working by participants reported in Chapters 4 and 6 was to work in a more structured way. 
Adopting a standardised and structured method of discussing cases might give MDT 
members who are less inclined to input a mandate with which they can contribute information 
and opinion. Working in a more structured way may also help to make meetings run more 
efficiently by defining what should be prepared before meetings and eliminating what is not 
relevant. An intervention such as MDT-QuIC may be one way of standardising case 
discussion. Standardising the MDT discussion might also provide an audit trail for 
departments who want to evaluate the standard of their own decision-making. In my mind 
MDT-QuIC has two advantages over such decision-aids. Firstly, the MDT-QuIC does not 
attempt to replace the judgment of healthcare professionals (which would be entirely 
undesirable), but only to ensure they have the tools necessary to make high quality decisions. 
Secondly, as cancer care is complex this checklist covers only the steps that are critical for 
good decision-making leaving complex decision-making to healthcare professionals.  
Moreover, although I found only a modest negative association between cases towards the 
end of meetings and the ability to reach a decision, it is of concern as currently there is no 
222 
 
standardised way of structuring MDT meetings or prioritising cases. In the study reported in 
Chapter 11, specialist cases were discussed at the start of the MDT meeting before the local 
cases. It follows that specialist cases are better worked up, and require the input of greater 
numbers of specialists. However, many local cases are complex and also require a high 
standard of information, discussion and decision-making. It may be reasonable to order cases 
discussed at MDT meetings such that more difficult cases get prioritised in order to increase 
the chances of a higher quality discussion.  
 
12.5.1.4 Role of nurses in cancer MDTS 
I have found evidence consistent with that of previous studies that Clinical Nurse Specialists 
play a crucial and unique role in MDTs by coordinating care, bringing the patient‘s views and 
psychosocial aspects of care, and acting as advocates for patients.(44;72) Recent research has 
highlighted the importance of decision-making as a key skill for effective nursing.(118) The 
differences between professional groups that I have found in qualitative and quantitative 
studies may reflect the previously described hierarchy that is apparent in MDT discussion and 
decision-making.(56;92;98) It has been well documented that nurses are often marginalized 
by their medical colleagues and have least input into decision-making.(56;57;98) In addition, 
the information that nurses bring to the clinical decision-making process, such as information 
about the patient‘s lifestyle, their social circumstances, and any emotional of psychological 
effects of illness is frequently overlooked.(56;57;97;98;119) Lack of consideration of these 
issues is linked with non-implementation of MDT decisions (i.e., lower efficacy) – therefore, 
these factors ought to be taken into account in the decision process. Furthermore, the role of 
nursing personnel within MDTs should be reviewed and strengthened in the MDT structure 
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including the development of the skills needed to take prominence in MDT 
meetings.(52;63;120)  
 
12.5.1.5 Introducing red-lines to stop discussion 
One implication of the findings reported in my thesis so far is whether there are 
circumstances in which case discussions should not proceed. Personal knowledge of patients 
is required for high quality clinical decisions that are clinically appropriate and acceptable to 
patients. After all, it would not be appropriate to start an operation without the right 
equipment being available. Similarly, it maybe that discussion of a patient at the MDT 
meeting should not proceed without a minimum dataset for clinical information, information 
about the patient‘s circumstances, or their views, or even without the presence of a team 
member who has met the patient. Indeed, participants in the study described in Chapter 5 
intimated that they would rather discussion of their case was deferred if there was no one 
present who knew them personally. Further research is needed to assess the feasibility of such 
an approach in view of the demands of service provision. 
 
12.5.1.6 Disagreement in decision making 
My finding from Chapter 4 that MDT members recognize that disagreements should be 
recorded, and can be discussed with the patients is reassuring, and requires further 
investigation. As a minimum, the process of recording MDT outcomes, particularly when 
disagreement arises, should be defined, and guidance offered to MDT members. 
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Additionally, such a measure may be introduced as a standard against which teams‘ 
compliance is measured in the peer review, or any coming form of self-assessment process. 
 
12.5.2 Implications for engaging patients 
12.5.2.1 Patients like MDTs 
The idea of being treated by a MDT is popular among the patients involved in the study 
reported in Chapter 6. However, I found that at the time of diagnosis and treatment the 
awareness of patients of the existence and purpose of the MDT was low. Patient satisfaction 
is increasingly important as a marker of performance in healthcare.(121;122) Promoting the 
aspects of care that patients find appealing may improve the experience of patients and 
increase their satisfaction with healthcare services.  
 
12.5.2.2 Need for patient contact prior to MDT meeting 
A second implication is that the cancer care pathway must be arranged to provide sufficient 
time and patient contact for team members to gather comprehensive information that is 
required for decision-making. At present, pressure to manage patients quickly means that 
medical and nursing team members have little time to discuss the patients‘ investigations, 
medical or social background. The need for prompt investigation and diagnosis must be 
balanced against the need for comprehensive information gathering, which may require some 
healthcare providers to change the format of their pre- MDT services.  
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12.5.2.3 Representation of patients in MDT meetings 
The question of how best to bring patient preferences and values into the MDT is a complex 
one.  Chapter 5 suggests that patients value nurses as the team member with whom they can 
relate to and who can act as an interface between the patient and the healthcare system.  The 
importance of the CNS to patients is reinforced by the results of the UK Cancer patients‘ 
survey, which showed that the only feature that predicted patients‘ ratings of cancer teams 
was the number of CNSs in the team.(123) Furthermore, it is widely held by healthcare 
professionals that nurses, by virtue of their skill in gathering and assimilating patient-centred 
information into decisions, should play a central role in clinical-decision making at the MDT 
meeting.(44;57;58;72;98;118;119) My findings from Chapter 4 provides additional evidence 
that healthcare professionals think that the clinical nurse specialist is the preferred team 
member to represent the patient in meetings, but that the Consultant and other team members 
who know the patient well could also share this duty.  However, recent research has 
suggested that the advocacy role of CNS can become compromised by an increasing 
administrative workload.(124) Restructuring of the role of the CNS to reduce administrative 
workload and strengthen the role of CNS as patient advocates, and representatives in MDT 
meetings might increase patient satisfaction as well as the quality of MDT decision-making 
and thus patient care. 
 
12.5.2.4 Need for supportive care  
A patient-centred approach to MDT discussion and decision-making should be extended to 
the whole cancer pathway. Many of the improvements in patient outcomes in recent years 
have been achieved as a result of an emphasis on the treatment of disease. However, living 
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with a diagnosis of cancer places significant physical and emotional burdens on patients and 
their families.(125) Many of these patients will not be cured, and will therefore continue to 
feel the distressing impact of their illness on their physical and psychological health in the 
long term.(126)  As well as treatment, supportive care is needed to help patients and families 
cope with the effects of the disease. Supportive care involves providing physical and 
emotional care, and encouraging and supporting participation in decision-making.(127) NICE 
states that supportive care should be given equal priority alongside diagnosis and 
treatment.(128) A patient-centred decision-making process at the MDT meeting that 
recognises supportive aspects of cancer care should underpin a holistic cancer pathway, and 
reflect the needs of patients. 
 
12.5.3 Implications for training and assessment 
12.5.3.1 Modification of the content of current assessment programme  
Currently, peer review is concerned with standards of organisation of cancer services and 
duties of MDT members, and aside from attendance standards, requires very little of MDT 
meetings or the decision-making process.(3) These features of MDT working are included in 
the current assessment programme because they are measurable.(3) These existing standards 
are necessary for effective MDT working, but not sufficient. This thesis has shown that 
clinical decision-making by the MDT is also influenced by the availability and sharing of 
information, team members‘ behaviour and contribution to the decision-making process. I 
have demonstrated that such features in cancer MDT meetings are also measurable and could 
therefore be improved. These elements should be part of the assessment process in order to 
assure comprehensive standards of care.  
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12.5.3.2 Modification of the method of current assessment programme 
There is currently a growing evidence base on valid, reliable and structured tools to assess 
such non-technical skills for applications across a range of healthcare specialties. (19;24;129) 
Such tools have been shown to improve teamworking and are well received by the teams who 
use them.(130) Robust measures of cancer MDT performance can give an increased 
understanding of how these teams work, allowing identification of factors that improve 
performance as well as those which are potentially detrimental. The evidence that I have 
presented in this thesis has shown that observational and self-assessment of team decision-
making in MDT meetings are feasible, valid and reliable methods of assessing performance. 
Moreover, I have developed a set of tools for MDTs, which with further research and 
development might be used to evaluate performance as part of the National Peer Review 
programme. 
 
12.5.3.3 The use of self-assessment 
Throughout the studies presented in this thesis, there is evidence that cancer care 
professionals have insight into their own team‘s functioning. As I have reported in Chapter 8 
however, participants had a tendency to over-rate aspects of their performance compared to 
an external assessor in relation to patient-centred information (comorbidities, psychosocial 
issues and patients‘ views). Furthermore, the increased variability seen in patient-centred 
categories of self-assessment may suggest that there is disagreement within the team about 
what constitutes good and bad performance in these areas. If this discrepancy is not due to 
inconsistencies in the measurement between self-report and expert assessment (which further 
research could elucidate), then it follows that re-education of MDT members may be required 
228 
 
into the nature and importance of patient-centered information when making clinical 
decisions. If this discrepancy can be rectified, there is an implication that self-report 
assessment tools could be used to complement existing means of assessing MDT     
 
12.5.3.4 Decision efficacy marker for performance 
The data that I have presented in my introductory Chapters, along with that from my 
empirical studies provides further evidence that the ability of an MDT to reach a decision at 
case presentation appears to be useful marker of the effectiveness of the MDT. It is widely 
held that traditional outcome measures, such as data on survival or complications, give a 
good account of the effectiveness and safety of interventions. However, for complex 
processes, such as the cancer care pathway, of which the MDT meeting is one part, it may not 
be possible to relate changes in such outcomes to the effect of the MDT meeting.(113;131) 
Clinical outcomes remain a robust measure of effectiveness in healthcare, and should be 
included when assessing MDT performance, but other short-term process measures (such as 
Decision efficacy, time from first referral to diagnosis, to the first treatment, and costs 
reductions), might also be useful for assessing performance alongside current measures 
included in Peer Review. 
 
12.5.4 Implications for the organisation of cancer services 
12.5.4.1 Organisational factors also necessary 
Data from the studies presented in this thesis reveal that although adequate non-technical 
skills are necessary for optimal MDT functioning, on their own they are not sufficient. 
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Support from the hosting institution, i.e., the local hospital is also required in the form of 
protected time in the participants‘ job-plans to prepare for, attend, and action the workload of 
the meeting. This is a key issue, as it suggests that addressing MDT members‘ team skills 
alone will likely not improve team functioning unless the team is also supported at an 
organisational level. If MDTs want to ensure good attendance, then time for the MDT should 
be incorporated into members‘ job plans. Job plans should include time before the meetings 
to prepare, work that is particularly key for Histopathologists, Radiologists and others to 
prepare cases, adequate time for the meetings and time after the meeting to action the work 
that the MDT has generated. 
 
12.5.4.2 The cost of multidisciplinary care 
With the recent economic downturn, cost effectiveness in healthcare is becoming increasingly 
important alongside clinical effectiveness as a marker of performance. The cost of MDTs has 
not been formally assessed.(132) The costs of getting several consultant grade doctors, 
specialist nurses, administrators and others together for a few hours per week represents a 
considerable amount. Of course, the equipment costs—video conferencing, updating 
radiological archiving systems, microscopy equipment and modified IT systems—will be a 
large up-front. However, the recent NCAT survey found that 88% of respondents agreed or 
strongly agreed with the statement that a good MDT can save time elsewhere in the period 
between meetings, which may provide the basis for cost-effectiveness arguments.(79) 
Furthermore, the initial costs may be offset by optimising the team‘s ability to reach 
management decisions, and maximising the quality of treatment decisions, which might 
reduce the 1·4-15·1% of MDT decisions that are not implemented.(33;52;58;59;62;63) 
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Further research is needed to assess whether efficiency could be further improved by 
streamlining the MDT pathway to prioritise more complex cases with less time spent on cases 
in which the care plan is straightforward. 
 
12.5.4.3 Tumour types may need specific guidance 
Although the areas of difference between tumour types presented in Chapter 4 are few, they 
do suggest that in areas of case selection, preparation for/organisation of meetings, and 
clinical decision-making the recommendations/guidelines for MDT working should be 
sensitive to tumour type (Figure 5). Implementation of MDT working in different tumour 
types may need to be adjusted accordingly to ensure that the mode of MDT working adopted 
is beneficial to patients and healthcare professionals. Similarly, the requirement of different 
tumour types regarding patients with advanced or recurrent disease and the need for re-
presentation at the MDT, or the involvement of palliative care services may need to be agreed 
individually to reflect the differing workload and clinical characteristics of different tumour 
types.(133) 
 
12.5.5 Implications for research 
12.5.5.1 Develop tools for other tumour types 
Whilst I have sought to validate MDT-MODe for use in urology MDT meetings, it remains to 
be seen whether its use can translate to other tumour types, and even non-cancer MDT 
meetings. Such a programme of research would need to examine whether the types of 
information and behaviours assessed by MDT-MODe are necessary and sufficient for other 
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types of MDT meeting, and the tool even feasible for use. Subsequent research could then 
adapt and evaluate interventions that were piloted in Chapter 11, including MDT-QuIC, for 
use in other tumour types. Chapter 4 suggests that the model for effective MDT working is 
common across major tumour types, which suggests that assessment tools and quality 
improvement interventions could also be used across tumour types. In Chapter 11 MDT-
QuIC was used by the MDT to prepare cases and to add structure to information presentation. 
However, the evaluation of MDT-QuIC in Chapter 10 suggested that such an intervention 
could be used in a variety of other ways. It would be interesting to evaluate the utility of 
MDT-QuIC for a variety of uses including case preparation, formal structuring of case 
discussions, informal use as an aide memoire and as a structured record of the case discussion 
and outcome. In addition, such interventions could be assessed on a variety of process and 
outcome measures (see below). 
 
12.5.5.2 Investigate implementation of decisions 
In this thesis I have used the ability of the MDT to reach a decision, along with Information 
and Contribution Scores as markers of decision-making quality, which represent one aspect 
of decision-making quality. The implementation of decisions is related to the patient-
centredness of decision-making, rather than the quality of biomedical information, and is 
another marker of decision-making quality, against which the interventions assessed in 
Chapter 11 could be assessed.(33;52;58;59;62;63) Future research also needs to evaluate the 
validity of other measures of performance related to the patient (satisfaction, survival), the 
team (self rating of satisfaction, participation) and the organisation (time from first referral to 
diagnosis, time from diagnosis to the first treatment, and costs reductions).  
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12.5.5.3 Investigate patient views further 
In Chapter 5 I have taken the initial steps to investigate patients‘ views on MDT working and 
decision making, which has only scratched the surface of an important area for future 
research. The development of patient related outcome and experience measures and 
interventions is needed to measure and improve participation of patient in and satisfaction 
with the MDT decision-making process. Measures of patient satisfaction that have been 
developed for use in other domains of heath care might be validated for use in relation to 
multidisciplinary cancer care. Such objective outcome and experience measures could be 
used to assess the strengths and weaknesses of teams‘ interactions with their patients and to 
inform areas for improvement. Similarly, there are currently no tools for MDTs to assess the 
‗patient-centeredness‘ of their decision-making process and future research should aim to 
inform teams of the desirable aspects of patient-centeredness, and how these can be assessed 
and improved. 
 
12.5.5.4 Assessment of leadership 
Although touched upon in various Chapters, a detailed assessment of leadership in MDTs 
was not possible within the time and resources that were available to me. Leadership has a 
strong effect on the performance of all healthcare teams, including MDTs, and the role of 
MDT chair is recognized as key to the performance of the team as a whole, including 
implementation of any changes to team functioning deemed necessary following team (self-) 
assessment.(46;79;134) Further research should be carried out to assess the effect of 
leadership on MDT performance, which is likely to be significant.(135) Such an evaluation 
should include assessment of the current models of leadership used in MDTs and other 
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healthcare teams, development of metrics to objectively assess leadership quality and its 
effect on clinical decision-making, as well as interventions to improve MDT outcomes 
through enhancing leadership. 
 
12.5.5.5 Time per case and quality 
The relationship between the time per case and the quality of discussion is unclear at present. 
The mean time per case in the study presented in Chapter 7 was 3 minutes 13 seconds, which 
is consistent with a mean time per case of 3 minutes in Chapter 8, but more than that of 2 
minutes and 13 seconds in Chapter 11.(92) Several factors may influence the time per case 
including the complexity of individual cases, how well the case is prepared and presented, 
how concise the discussion is, and equipment- including videoconferencing. A further 
possible consequence of the rate of case discussion is its influence on the ability of an 
observer to make an accurate assessment.  In Chapter 7 I found that the correlation between 
observers appeared to decline when the rate of case discussion was at its highest, a point 
consistent with previous research.(26;92) Further research is also needed to determine the 
effect of strategies to reduce the case load in MDT meetings on the quality of decision-
making, including managing some, perhaps simpler cases by chair‘s action according to 
clearly defined protocol. It remains to be determined whether this would have any effect on 
those cases that did not receive full MDT discussion, or those left in the MDT meeting, as 
well as the perceptions of team members and patients. 
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12.6 Personal reflections 
Prior to starting this PhD I had very little experience of research. With the guidance of my 
supervisors and more experienced colleagues I have gained an understanding of the research 
methods used in behavioural sciences applied to healthcare. I have designed and conducted 
qualitative and quantitative studies, collected data from patients and healthcare professionals 
and used qualitative and quantitative methods of analysis. In addition I have learned to write, 
which is something that I have done unconsciously, but can now appreciate as I write these 
latter Chapters. In addition, I have taken courses in literature searching, study design, 
statistics, and research governance. Now that I have gained the experience detailed in this 
thesis I have found that I have also learned to think critically. I am better able to critique the 
planning, execution and results of my work, which is a skill that I will be able to apply to 
good effect as I return to clinical work.  
 
As a clinical researcher, I have discovered that research skills are necessary but not on their 
own sufficient for undertaking an effective programme of research. During my research I 
have moved from assisting other people in their projects, to running my own small projects 
and running multiple studies in parallel and recruiting and managing more junior researchers 
to help me. Research skills must be coupled with skills in project management. Specific 
experience such as applying for ethical approval, seeking external help with data analysis, 
collaborating with researchers outside my institution have all been challenging, but are 
experiences that I have learned from. I have also learned how to prioritise tasks, taking into 
account importance as well as urgency. Through the research governance course ‗Good 
clinical practice‘ I have been able to ensure that my research is ethical, transparent, and 
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accountable and focussed on the patients‘ well being. These project management skills will 
allow me to work independently in the future, possibly supervising post graduate students and 
managing my own projects. 
 
During my time as researcher I have been part of the Urology registrar on-call rota, which has 
given me experience of managing urological emergencies and in-patients. In addition I have 
helped to develop a service for the diagnosis and treatment of patients with suspected 
urological cancer, including the use of photodynamic diagnosis. Through these activities I 
have learned about the management of patients with urological tumours and the way the 
MDT functions along the care pathway feeding into and actioning plans from the MDT 
meeting. This experience has helped me to keep my research grounded in good clinical 
practice with a focus on improving care for patients. These activities have also meant that I 
have maintained my clinical skills, which will help me as I return to full time clinical work. 
The flexibility of life as an academic has also allowed me to develop my skills in teaching, 
communication and information technology through courses and practical experience at St. 
Mary‘s Hospital. 
 
Most profoundly during my time at Imperial I have become a father, twice. This experience, 
with the guidance and support of my wife, has helped me to learn to prioritise, to manage 
multiple tasks simultaneously and cope with a modicum of sleep deprivation. Most 
importantly, my family has given me a motivation to work hard and succeed in my PhD. 
236 
 
REFERENCES 
 
1. Fleissig AJ, Jenkins V, Catt S, Fallowfield L. Multidisciplinary teams in cancer care: 
are they effective in the UK? Lancet Oncol 2006 Nov;7(11):935-43. 
2. Department of Health. NHS England: Percentage compliance with Peer Review by 
multidisciplinary team against measures within the Manual for Cancer Services 2004. 
Leeds: Department of Health; 2009.  
3. Department of Health. Manual for cancer services 2004.  London: Department of 
Health; 2004.  
4. Expert Advisory Group on Cancer. A policy framework for commissioning cancer 
services: a report to the chief medical officers of England and Wales. The Calman-
Hine Report. London: Department of Health; 1995. 
5. Junior E, Hole D, Gillis C. Management of ovarian cancer: referral to a 
multidisciplinary team matters. Br J Cancer 1994 Aug;70(2):363-70. 
6. Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: 
a study of 3786 patients in the west of Scotland. BMJ 1996 Jan;312(7024):145-8. 
7. NHS Executive. Improving outcomes in colorectal cancer: The manual.  Leeds: 
Department of Health; 1997. 
8. NHS Executive. Improving outcomes in upper gastrointestinal cancer: The manual.   
Leeds: Department of Health; 1996. 
237 
 
9. NHS Executive. Improving outcomes in gynaecological cancer: The manual.   Leeds: 
Department of Health; 1999.  
10. NHS Executive. Improving outcomes in breast cancer: The manual. Leeds: 
Department of Health; 1996.  
11. NHS Executive. Improving outcomes in lung cancer: The manual.  Leeds: 
Department of Health; 1998.  
12. Griffith C, Turner J. United Kingdom National Health Service, Cancer Services 
Collaborative "Improvement Partnership", Redesign of Cancer Services: A National 
Approach. Eur J Surg Oncol 2004 Sep;30 Suppl 1:1-86. 
13. NICE. Published cancer service guidance.  London: National Institute for Clinical 
Excellence; 2006. 
14. Flin R, Patey R. Improving patient safety through training in non-technical skills. 
BMJ 2009;339:b3595. 
15. Undre S, Arora S, Sevdalis N. Surgical performance, human error and patient safety 
in urological surgery. British Journal of Medical and Surgical Urology 2009 
Jan;2(1):2-10. 
16. Calland JF, Guerlain S, Adams RB, Tribble CG, Foley E, Chekan EG. A systems 
approach to surgical safety. Surg Endosc 2002 Jun;16(6):1005-14. 
238 
 
17. Vincent C, Moorthy K, Sarker SK, Chang A, Darzi AW. Systems approaches to 
surgical quality and safety: from concept to measurement. Ann Surg 2004 
Apr;239(4):475-82. 
18. Undre S, Sevdalis N, Vincent C. Observing and assessing surgical teams: The 
Observational Teamwork Assessment for Surgery
©
 (OTAS)
©
. In: Flin R, Mitchell L, 
editors. Safer surgery: analysing behaviour in the operating theatre. 1 ed.  Ashgate; 
2009. 
19. Undre S, Sevdalis N, Healey AN, Darzi A, Vincent CA. Observational teamwork 
assessment for surgery (OTAS): refinement and application in urological surgery. 
World J Surg 2007 Jul;31(7):1373-81. 
20. Lingard L, Espin S, Whyte S, Regehr G, Baker GR, Reznick R, et al. Communication 
failures in the operating room: an observational classification of recurrent types and 
effects. Qual Saf Health Care 2004 Oct;13(5):330-4. 
21. Sevdalis N, Healey AN, Vincent CA. Distracting communications in the operating 
theatre. J Eval Clin Pract 2007 Jun;13(3):390-4. 
22. Hanna G, Shimi S, Cuschieri A. Task performance in endoscopic surgery is 
influenced by location of the image display. Ann Sur 1998;227(4):481-4. 
23. Fletcher G, Flin R, McGeorge P, Glavin R, Maran N, Patey R. Anaesthetists' Non-
Technical Skills (ANTS): evaluation of a behavioural marker system. Br J Anaesth 
2003 May;90(5):580-8. 
239 
 
24. Fletcher G, Flin R, McGeorge P, Glavin R, Maran N, Patey R. Rating non-technical 
skills: developing a behavioural marker system for use in anaesthesia. Cognition, 
Technology and Work 2004;(6):165-71. 
25. Undre S, Koutantji M, Sevdalis N, Gautama S, Selvapatt N, Williams S, et al. 
Multidisciplinary crisis simulations: the way forward for training surgical teams. 
World J Surg 2007 Sep;31(9):1843-53. 
26. Yule S, Flin R, Paterson-Brown S, Maran N. Non-technical skills for surgeons in the 
operating room: a review of the literature. Surgery 2006 Feb;139(2):140-9. 
27. Flin R, Youngson G, Yule S. How do surgeons make intraoperative decisions? Qual 
Saf Health Care 2007 Jun;16(3):235-9. 
28. Sevdalis N, McCulloch P. Teaching evidence-based decision-making. Surg Clin 
North Am 2006 Feb;86(1):59-70, viii. 
29. Jacklin R, Sevdalis N, Darzi A, Vincent CA. Efficacy of cognitive feedback in 
improving operative risk estimation. Am J Surg 2009 Jan;197(1):76-81. 
30. Jacklin R, Sevdalis N, Darzi A, Vincent C. Mapping surgical practice decision 
making: an interview study to evaluate decisions in surgical care. Am J Surg 2008 
May;195(5):689-96. 
31. Fox J, Patkar V, Thomson R. Decision support for health care: the PROforma 
evidence base. Inform Prim Care 2006;14(1):49-54. 
240 
 
32. Acher PL, Young AJ, Etherington-Foy R, McCahy PJ, Deane AM. Improving 
outcomes in urological cancers: the impact of "multidisciplinary team meetings". Int J 
Surg. 2005;3(2):121-3. 
33. Bumm R, Feith M, Lordick F, et al. Impact of multidisciplinary tumor boards on 
diagnosis and treatment of esophageal cancer. Acta Chirurgica Austriaca 207; 
39(3):136-40. 
34. Ganesan P, Kumar L, Hariprasad R, Gupta A, Dawar R, Vijayaraghavan M. 
Improving care in ovarian cancer: the role of a clinico-pathological meeting. Natl Med 
J India. 2008 Sep-Oct;21(5):225-7. 
35. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year 
prospective survey. J Cancer Educ 2008;23(4):235-7. 
36. Chang JH, Vines E, Bertsch H, Fraker DL, Czerniecki BJ, Rosato EF, et al. The 
impact of a multidisciplinary breast cancer center on recommendations for patient 
management: the University of Pennsylvania experience. Cancer 2001 Apr 
1;91(7):1231-7. 
37. Newman E, Guest A, Helvie M et al. Changes in surgical management resulting from 
case review at a breast cancer multldisciplinary tumor board. Cancer 2006; 
107(10):2343- 2351. 
38. Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a 
multidisciplinary team, in a single centre, on treatment and survival in patients with 
inoperable non-small-cell lung cancer. Br J Cancer 2005 Oct 31;93(9):977-8. 
241 
 
39. Healey AN, Undre S, Vincent CA. Developing observational measures of 
performance in surgical teams. Qual Saf Health Care 2004 Oct;13 Suppl 1:i33-i40. 
40. Clarke MG, Wilson JR, Kennedy KP, MacDonagh RP. Clinical judgment analysis of 
the parameters used by consultant urologists in the management of prostate cancer. J 
Urol. 2007 Jul;178(1):98-102.. 
41. Wilson J, Kennedy K, Ewings P, Macdonagh R. Analysis of consultant decision-
making in the management of prostate cancer. Prostate Cancer Prostatic Dis. 
2008;11(3):288-93. 
42. Langenhoff BS, Krabbe PF, Ruers TJ. Computer-based decision making in medicine: 
A model for surgery of colorectal liver metastases. Eur J Surg Oncol. 2007 Dec;33 
Suppl 2:S111-7. 
43. Penel N, Grosjean J, Pichon-Watelle F, Giscard S, Hoppe H, Taieb S et al. Factors 
favouring palliative treatment multidisciplinary decisions for newly diagnosed 
visceral and soft tissue sarcomas. Clin Oncol (R Coll Radiol). 2008 Sep;20(7):523-7. 
44. Junnola T, Eriksson E, Salantera S, Lauri S, Junnola T, Eriksson E, et al. Nurses' 
decision-making in collecting information for the assessment of patients' nursing 
problems. J Clin Nurs 2002 Mar;11(2):186-96. 
45. Borrill C, West M, Shapiro D, Rees A. Team working and effectiveness in health 
care. British Journal of Health Care Management 2000;6(8):364-71. 
242 
 
46. Haward R, Amir Z, Borrill C, Dawson J, Scully J, West M, et al. Breast cancer teams: 
the impact of constitution, new cancer workload, and methods of operation on their 
effectiveness. Br J Cancer 2003 Jul 7;89(1):15-22. 
47. Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ. The multidisciplinary meeting: An 
indispensable aid to communication between different specialities. Eur J Cancer 2006 
Oct;42(15):2459-62. 
48. Delaney G, Jacob S, Iedema R, Winters M, Barton M. Comparison of face-to-face and 
videoconferenced multidisciplinary clinical meetings. Australas Radiol 2004 
Dec;48(4):487-92. 
49. Macaskill EJ, Thrush S, Walker EM, Dixon JM. Surgeons' views on multi-
disciplinary breast meetings. Eur J Cancer 2006 May;42(7):905-8. 
50. National Framework Advisory Group. A National Framework for Service Change in 
the NHS in Scotland: Building a health service fit for the future.  Edinburgh: Scottish 
Executive; 2005. 
51. Kunkler IH, Prescott RJ, Lee RJ, Brebner JA, Cairns JA, Fielding RG et al. 
TELEMAM: a cluster randomised trial to assess the use of telemedicine in multi-
disciplinary breast cancer decision making. Eur J Cancer. 2007 Nov;43(17):2506-14. 
52. Stalfors J, Lundberg C, Westin T. Quality assessment of a multidisciplinary tumour 
meeting for patients with head and neck cancer. Acta Otolaryngol (Stockh) 2007; 
127(1):82-87. 
243 
 
53. Davison AG, Eraut CD, Haque AS, Doffman S, Tanqueray A, Trask CW, et al. 
Telemedicine for multidisciplinary lung cancer meetings. J Telemed Telecare 
2004;10(3):140-3. 
54. Kee F, Owen T, Leathem R. Decision making in a multidisciplinary cancer team: does 
team discussion result in better quality decisions? Med Decis Making 2004 
Nov;24(6):602-13. 
55. Davies AR, Deans DA, Penman I, Plevris JN, Fletcher J, Wall L et al. The 
multidisciplinary team meeting improves staging accuracy and treatment selection for 
gastro-esophageal cancer. Dis Esophagus. 2006;19(6):496-503. 
56. Lanceley A, Savage J, Menon U, Jacobs I. Influences on multidisciplinary team  
decision making. Int J Gynecol Cancer 2008; 18(2):215-22. 
57. Kidger J, Murdoch J, Donovan JL, Blazeby JM. Clinical decision-making in a 
multidisciplinary gynaecological cancer team: a qualitative study. BJOG. 2009 
Mar;116(4):511-7. 
58. Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL. Analysis of 
clinical decision-making in multi-disciplinary cancer teams. Ann Oncol. 2006 
Mar;17(3):457-60. 
59. Wood JJ, Metcalfe C, Paes A, Sylvester P, Durdey P, Thomas MG et al. An 
evaluation of treatment decisions at a colorectal cancer multi-disciplinary team. 
Colorectal Dis. 2008 Oct;10(8):769-72. Epub 2008 Jan 22. 
244 
 
60. Sidhom MA, Poulsen MG. Multidisciplinary care in oncology: medicolegal 
implications of group decisions. Lancet Oncol 2006 Nov;7(11):951-4. 
61. Sidhom MA, Poulsen MG. Group decisions in oncology: Doctors' perceptions of the 
legal responsibilities arising from multidisciplinary meetings. J Med Imaging Radiat 
Oncol. 2008 Jun;52(3):287-92. 
62. Leo F, Venissac N, Poudenx M, Otto J, Mouroux J, Groupe d'Oncologie TA, et al. 
Multidisciplinary management of lung cancer: how to test its efficacy? J Thorac 
Oncol 2007 Jan;2(1):69-72. 
63. Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven V, Nikkhah G, et al. The 
brain tumor board: lessons to be learned from an interdisciplinary conference. 
Onkologie 2005 Jan;28(1):22-6. 
64. Mallinger JB, Shields CG, Griggs JJ, Roscoe JA, Morrow GR, Rosenbluth RJ, et al. 
Stability of decisional role preference over the course of cancer therapy. 
Psychooncology 2006 Apr;15(4):297-305. 
65. Soukop M, Robinson A, Soukop D, Ingham-Clark CL, Kelly MJ. Results of a survey 
of the role of multidisciplinary team coordinators for colorectal cancer in England and 
Wales. Colorectal Dis. 2007 Feb;9(2):146-50. 
66. Catt S, Fallowfield L, Jenkins V, Langridge C, Cox A. The informational roles and 
psychological health of members of 10 oncology multidisciplinary teams in the UK. 
Br J Cancer 2005 Nov;93(10):1092-7. 
245 
 
67. Feldman-Stewart D, Brundage MD, Hayter C, Davidson JR, Groome P, Nickel JC. 
What the prostate cancer patient should know: variations in urologists' opinions. Can 
J Urol 1997 Dec;4(4):438-44. 
68. Penel N, Valentin F, Giscard S, Vanseymortier L, Beuscart R. General practitioners 
assessment of a structured report on medical decision making by a regional 
multidisciplinary cancer committee. Bull Cancer 2007 Oct 1;94(10):E23-26. 
69. Arora S, Ashrafian H, Davis RE, Athanasiou T, Darzi A, Sevdalis N. Emotional 
intelligence in medicine: a systematic review through the context of the ACGME 
competencies. Med Educ. 2010 Aug;44(8):749-64. 
70. Butow P, Harrison JD, Choy ET, Young JM, Spillane A, Evans A. Health 
professional and consumer views on involving breast cancer patients in the 
multidisciplinary discussion of their disease and treatment plan. Cancer 2007 Nov 
1;110(9):1937-44. 
71. Kee F, Owen T, Leathem R. Offering a prognosis in lung cancer: when is a team of 
experts an expert team? J Epidemiol Community Health 2007 Apr;61(4):308-13. 
72. Amir Z, Scully J, Borrill C. The professional role of breast cancer nurses in multi-
disciplinary breast cancer care teams. Eur J Oncol Nurs 2004 Dec;8(4):306-14. 
73. Random.org: True random number service.  Available at: 
http://www.random.org/integers/. Last accessed 14
th
 June 2012.  
74. Kunkler I, Fielding G, Macnab M, Swann S, Brebner J, Prescott R, et al. Group 
dynamics in telemedicine-delivered and standard multidisciplinary team meetings: 
246 
 
Results from the TELEMAM randomised trial. J Telemed Telecare 
2006;12(S3):2006-58. 
75. Fielding RG, Macnab M, Swann S, Kunkler IH, Brebner J, Prescott RJ, et al. 
Attitudes of breast cancer professionals to conventional and telemedicine-delivered 
multidisciplinary breast meetings. J Telemed Telecare 2005;11 Suppl 2:S29-S34. 
76. Kelly MJ, Lloyd TD, Marshall D, Garcea G, Sutton CD, Beach M. A snapshot of 
MDT working and patient mapping in the UK colorectal cancer centres in 2002. 
Colorectal Dis 2003 Nov;5(6):577-81. 
77. Séroussi B, Bouaud J, Gligorov J, Uzan S. Supporting multidisciplinary staff 
meetings for guideline-based breast cancer management: a study with OncoDoc2. 
AMIA Annu Symp Proc. 2007 Oct 11:656-60. 
78. Epstein RJ, Leung TW, Mak J, Cheung PS. Utility of a web-based breast cancer 
predictive algorithm for adjuvant chemotherapeutic decision making in a 
multidisciplinary oncology center. Cancer Invest. 2006 Jun-Jul;24(4):367-73. 
79. NHS National Cancer Action Team. Multidisciplinary team members' views about 
MDT working: Results from a survey commissioned by the National Cancer Action 
Team. London: NHS National Cancer Action Team; 2009.  
80. NHS National Cancer Action Team. The Characteristics of an Effective 
Multidisciplinary team (MDT). London: NHS National Cancer Action Team; 2010.  
247 
 
81. Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care 
management decisions by multidisciplinary cancer teams: a systematic review. Ann 
Surg Oncol 2011 Aug;18(8):2116-25. 
82. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing 
qualitative data. BMJ 2000 Jan 8;320(7227):114-6. 
83. Devitt B, Philip J, McLachlan SA. Team dynamics, decision making, and attitudes 
toward multidisciplinary cancer meetings: health professionals' perspectives. J Oncol 
Pract 2010 Nov;6(6):e17-e20. 
84. Look Hong NJ, Gagliardi AR, Bronskill SE, Paszat LF, Wright FC. Multidisciplinary 
cancer conferences: exploring obstacles and facilitators to their implementation. J 
Oncol Pract 2010 Mar;6(2):61-8. 
85. Holloway I, Wheeler S. Ethical issues in qualitative nursing research. Nurs Ethics 
1995 Sep;2(3):223-32. 
86. Robbins L. Qualitative research: contributions to scientific inquiry and patient care. 
Arthritis Care Res 1998 Aug;11(4):225-7. 
87. Polit DF, Beck CT. The content validity index: are you sure you know what's being 
reported? Critique and recommendations. Res Nurs Health 2006 Oct;29(5):489-97. 
88. Arora S, Sevdalis N, Nestel D, Tierney T, Woloshynowych M, Kneebone R. 
Managing intraoperative stress: what do surgeons want from a crisis training 
program? Am J Surg 2009 Apr;197(4):537-43. 
248 
 
89. Sevdalis N, Undre S, Henry J, Sydney E, Koutantji N, arzi A, et al. Development, 
initial reliability and validity testing of an observational tool for assessing technical 
skills of operating room nurses. Int J Nurs Stud. 2009 Sep;46(9):1187-93. 
90. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol 
Bull 1979 Mar;86(2):420-8. 
91. Abell N, Springer DW, Kamata A. Developing and validating rapid assessment 
instruments. Oxford: Oxford University Press; 2009. 
92. Lamb BW, Wong HW, Vincent C, Green JS, Sevdalis N. Teamwork and team 
performance in multidisciplinary cancer teams: development and evaluation of an 
observational assessment tool. BMJ Qual Saf. 2011 Oct;20(10):849-56. 
93. Jonckheere AR. A test of significance for the relation between m rankings and k 
ranked categories. Brit J Stastist Psych 1954;(7):93-100. 
94. Lamb B, Payne H, Vincent C, Sevdalis N, Green JS. The role of oncologists in 
multidisciplinary cancer teams in the UK: an untapped resource for team leadership? J 
Eval Clin Pract. 2011 Dec;17(6):1200-6. 
95. Lamb B, Green JS, Vincent C, Sevdalis N. Decision making in surgical oncology. 
Surg Oncol. 2011 Sep;20(3):163-8. 
96. Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of 
multidisciplinary care teams: modeling internal and external influences on cancer care 
quality. J Natl Cancer Inst Monogr 2010;2010(40):72-80. 
249 
 
97. Lamb BW, Sevdalis N, Mostafid H, Vincent C, Green JS. Quality Improvement in 
Multidisciplinary Cancer Teams: An Investigation of Teamwork and Clinical 
Decision-Making and Cross-Validation of Assessments. Ann Surg Oncol. 2011 
Dec;18(13):3535-43. 
98. Lamb BW, Sevdalis N, Arora S, Pinto A, Vincent C, Green JS. Teamwork and Team 
Decision-making at Multidisciplinary Cancer Conferences: Barriers, Facilitators, and 
Opportunities for Improvement. World J Surg 2011 Sep;35(9):1970-6. 
99. Hales BM, Pronovost PJ. The checklist--a tool for error management and performance 
improvement. J Crit Care 2006 Sep;21(3):231-5. 
100. Verdaasdonk EG, Stassen LP, Widhiasmara PP, Dankelman J. Requirements for the 
design and implementation of checklists for surgical processes. Surg Endosc 2009 
Apr;23(4):715-26. 
101. Hales B, Terblanche M, Fowler R, Sibbald W. Development of medical checklists 
for improved quality of patient care. Int J Qual Health Care 2008 Feb;20(1):22-30. 
102. Winters BD, Gurses AP, Lehmann H, Sexton JB, Rampersad CJ, Pronovost PJ. 
Clinical review: checklists - translating evidence into practice. Crit Care 
2009;13(6):210. 
103. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove S, et al. An 
intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J 
Med 2006 Dec 28;355(26):2725-32. 
250 
 
104. Pronovost P, Berenholtz S, Dorman T, Lipsett PA, Simmonds T, Haraden C. 
Improving communication in the ICU using daily goals. J Crit Care 2003 
Jun;18(2):71-5. 
105. Lingard L, Regehr G, Orser B, Reznick R, Baker GR, Doran D, et al. Evaluation of 
a preoperative checklist and team briefing among surgeons, nurses, and 
anesthesiologists to reduce failures in communication. Arch Surg 2008 Jan;143(1):12-
7. 
106. Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, et al. A 
surgical safety checklist to reduce morbidity and mortality in a global population. N 
Engl J Med 2009 Jan 29;360(5):491-9. 
107. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et 
al. The Surviving Sepsis Campaign: results of an international guideline-based 
performance improvement program targeting severe sepsis. Crit Care Med 2010 
Feb;38(2):367-74. 
108. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. 
Impact of a prevention strategy targeted at vascular-access care on incidence of 
infections acquired in intensive care. Lancet 2000 May 27;355(9218):1864-8. 
109. Resar R, Pronovost P, Haraden C, Simmonds T, Rainey T, Nolan T. Using a bundle 
approach to improve ventilator care processes and reduce ventilator-associated 
pneumonia. Jt Comm J Qual Patient Saf 2005 May;31(5):243-8. 
251 
 
110. Institute for Healthcare Improvement. What is a bundle?  Available from: 
htttp://www.ihi.org/knowledge/Pages/ImprovementStories/WhatIsaBundle.aspx. Last 
accessed on 14
th
 June 2012. 
111. Lamb BW, Sevdalis N, Vincent C, Green JS. Development and Evaluation of a 
Checklist to Support Decision Making in Cancer Multidisciplinary Team Meetings: 
MDT-QuIC. Ann Surg Oncol 2012 Jun;19(6):1759-65. 
112. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of 
multidisciplinary team working on breast cancer survival: retrospective, comparative, 
interventional cohort study of 13 722 women. BMJ 2012;344:e2718. 
113. Hong NJ, Wright FC, Gagliardi AR, Paszat LF. Examining the potential relationship 
between multidisciplinary cancer care and patient survival: an international literature 
review. J Surg Oncol 2010 Aug 1;102(2):125-34. 
114. Lingard L, Whyte S, Regeher G, Gardezi F. Counting silence: complexities in the 
evaluation of team communication. In: Flin R, Mitchell L, editors. Safer Surgery: 
Analysing Behaviour in the Operating Theatre. Farnham: Ashgate; 2009. p. 283-300. 
115. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression 
analysis of interrupted time series studies in medication use research. J Clin Pharm 
Ther 2002 Aug;27(4):299-309. 
116. Brown G. Radiology Cancer Staging.  National Cancer Intelligence Network. 
Available from: www.ncin.org.uk/view.aspx?rid=853. Last accessed on 14
th
 June 
2012. 
252 
 
117. Harnden P, Berney D, Shelley M. Standards and Datasets for Reporting Cancers: 
Dataset for histopathology reports for prostatic carcinoma (2nd edition). London: The 
Royal College of Pathologists; 2009.  
118. Lamb B, Sevdalis N. How do nurses make decisions? Int J Nurs Stud 2010 Nov 9. 
[Epub ahead of print] 
119. Lamb BW, Allchorne P, Sevdalis N, Vincent C, Green JSA. The role of the Cancer 
Nurse Specialist in the Urology multidisciplinary team meeting. Int J Uro Nurs 
2011;(5):59-64. 
120. The Intercollegiate Cancer Committee. Educational initiatives to improve the 
effectiveness of cancer multidisciplinary teams. London: Academy Of Medical Royal 
Colleges; 2009. 
121. Department of Health. Improving Outcomes: A Strategy for Cancer. London: 
Department of Health; 2011.  
122. Department of Health. The Operating Framework for the NHS in England 2011/12.  
London: Department of Health; 2010.  
123. Department of Health. National Cancer Patient Experience Survey Programme: 
2010 National Survey Report. London: Department of Health; 2010.  
124. Leary A, Crouch H, Lezard A, Rawcliffe C, Boden L, Richardson A. Dimensions of 
clinical nurse specialist work in the UK. Nurs Stand 2008 Dec 17;23(15-17):40-4. 
253 
 
125. Department of Health. The NHS Cancer plan: a plan for investment, a plan for 
reform. London: Department of Health; 2000.  
126. Ahmedzai SH, Walsh D. Palliative medicine and modern cancer care. Semin Oncol 
2000 Feb;27(1):1-6. 
127. Willard C, Luker K. Supportive care in the cancer setting: rhetoric or reality? Palliat 
Med 2005 Jun;19(4):328-33. 
128. National Institute for Clinical Excellence. Guidance on Cancer Services: Improving 
Supportive and Palliative Care for Adults with Cancer. The Manual. London: 
National Institute for Clinical Excellence; 2004.  
129. Arora S, Tierney T, Sevdalis N, Aggarwal R, Nestel D, Woloshynowych M, et al. 
The Imperial Stress Assessment Tool (ISAT): a feasible, reliable and valid approach 
to measuring stress in the operating room. World J Surg 2010 Aug;34(8):1756-63. 
130. Jamtvedt G, Young JM, Kristoffersen DT, Thomson O'Brien MA, Oxman AD. 
Audit and feedback: effects on professional practice and health care outcomes. 
Cochrane Database Syst Rev. 2006 Apr 19;(2):CD000259. 
131. Houssami N, Sainsbury R. Breast cancer: multidisciplinary care and clinical 
outcomes. Eur J Cancer 2006 Oct;42(15):2480-91. 
132. Simcock R, Heaford A. Costs of multidisciplinary teams in cancer are small in 
relation to benefits. BMJ 2012;344:e3700. 
254 
 
133. National Institute for Clinical Excellence. Guidance on Cancer Services: Improving 
Outcomes in Haematological Cancers. The Manual. London: National Institute for 
Clinical Excellence; 2003.  
134. Henrickson PS, Yule S, Flin R, McKinley A. Towards a model of surgeons' 
leadership in the operating room. BMJ Qual Saf 2011 Jul;20(7):570-9. 
135. Kunzle B, Kolbe M, Grote G. Ensuring patient safety through effective leadership 
behaviour: A literature review. Safety Science 2010;48(1):1-17. 
136. Orasanu J, Salas E. Team decision making in complex environments. In Klein GA, 
Orasanu J, Calderwood R, Zsambok CE (Eds) Decision making in action: Models and 
Methods (pp 327-45). Ablex Publishing. 1995. 
137. Tschan F, Semmer NK, Gurtner A, Bizzari L, Spychiger M, Breuer M, Marsch SU. 
Explicit Reasoning, Confirmation Bias, and Illusory Transactive Memory. A 
Simulation Study of Group Medical Decision Making. Small Group Research 2009; 
40(3) 271-300 
138. Larson JR, Christensen C, Franz TM, Abbott AS. Diagnosing groups: The pooling, 
management, and impact of shared and unshared case information in team-based 
medical decision making. Journal of Personality and Social Psychology 1998; 
75(1)93-108. 
139. Schulz-Hardt S, Brodbeck FC, Mojzisch A, Kerschreiter R, Frey D. Group decision 
making in hidden profile situations: Dissent as a facilitator for decision quality. 
Journal of Personality and Social Psychology 1996; 91(6)1080-1093. 
255 
 
140. Christensen C, Abbott AS. Team medical decision making. In Chapman GB, 
Sonnenberg FA (Eds) Decision making in health care (pp. 267-85). Cambridge 
University Press. 2000. 
141. Klein GA. Twenty questions-suggestions for research in naturalistic decision 
making. In Klein GA, Orasanu J, Calderwood R, Zsambok CE (Eds.) Decision 
making in action: Models and methods (389-403). Norwood, NJ: Ablex publishing. 
1995. 
142. Klein GA. Sources of Power – How people make decisions. Cambridge, MA: MIT 
press. 1998. 
143. Jones P, Roelofsma MP. The potential for social, contextual and group biases in 
team decision making: biases, conditions and psychological mechanisms. Ergonomics 
2000;43(8):1129–52. 
144. Kahan JP, Park RE, Leape L, et al.Variations by specialty in physician ratings of the 
appropriateness and necessity of indications for procedures. Med Care. 1996;6:512–
23. 
145. Coulter I, Adams A, Shekelle P. Impact of varying panel membership on ratings of 
appropriateness in consensus panels: a comparison of a multi- and single disciplinary 
panel. Health Serv Res.1995;30:577–91. 
146. Jarboe S. Procedures for enhancing team decision making. In Hirokawa RY, Poole 
MS (eds). Communication and group decision making (2nd edn). Sage Publications. 
1996. 
256 
 
147. Duffy L. Team decision-making biases: An information-processing perspective. In 
Klein GA, Orasanu J, Calderwood R, Zsambok CE (Eds) Decision making in action: 
Models and Methods (pp 346-59). Ablex Publishing. 1995. 
148. Pronovost P, Berenholtz S, Dorman T, Lipsett PA, Simmonds T, Haraden C. 
Improving communication in the ICU using daily goals. Journal of Critical Care 
2003;18:71-5.   
149. Marks MA, DeChurch LA, Mathieu JE, Panzer FJ, Alonso A. Teamwork in 
multiteam systems. J Appl Psychol 2005 Sep;90(5):964-71. 
150. DeChurch LA, Marks MA. Leadership in multiteam systems. J Appl Psychol 2006 
Mar;91(2):311-29. 
151. The Center for Informed Choice at The Dartmouth Institute, USA. 
http://tdi.dartmouth.edu/centers/informed-choice/about/ (Last accessed 15/12/2011) 
152. MAking Good decisions In Collaboration with patients (MAGIC), UK. 
http://www.making-good-decisions.org/ (Last accessed 15/12/2011) 
153. Sevdalis N, Harvey N. Predicting preferences: A neglected aspect of shared 
decision-making. Health Expectations 2006;9:245-51. 
 
 
257 
 
APPENDICES 
 
258 
 
Appendix 1: Evidence from other research into complex decision-making 
 
There is a significant body of work from the fields of psychology and social science that has 
examined decision making by individuals, and more recently by teams in complex 
environments. A useful definition of team decision-making is given by Orasanu and Salas as, 
―the process of reaching a decision undertaken by interdependent individuals to achieve a 
common goal. What distinguishes team decision making from individual decision making is 
the existence of more than one information source and task perspective that must be 
combined to reach a decision. While ostensibly working towards the same goal, participants 
may have differing agendas, motives, perceptions and opinions that must be melded into the 
shared products.‖ The authors go further do distinguish team decision making from that of 
groups as teams tend to have highly differentiated and interdependent members, where as 
groups are consist of homogeneous and interchangeable members. Moreover, for successful 
accomplishment of the tasks performed by teams as opposed to groups (either the decision-
making itself, or that which results from the process of decision making) such multiple, 
interdependent participants are a necessity.[136] 
 
Evidence from the fields of psychology and management studies have shown that the type, 
structure and format of team discussion, the amount of information exchanged, as well as 
leadership style can all affect the quality of team decision-making. Adequate sharing of 
clinical information between medical team members and the presence of dissent have been 
shown to improve decision-making in psychological experiments on teams.[137−140] 
Further, psychological research has also shown that information that is shared is more likely 
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to be discussed and to be part of the decision making process,[140] and that team-members of 
higher professional status tend to have a significantly stronger role and say in the team‘s 
decisions – thus making team leadership and meeting chairing critically important to cancer 
MDTs.[136;139;140] 
 
This research has led to different theoretical models of how teams make complex decisions. 
The concept of shared mental models refers to organized knowledge shared by team 
members. The mental model shared by team members facilitates communication about 
systems, and provides ready terms of reference, for example norms of behaviour and roles of 
team members. The result is that team members can carry out their roles in a timely and 
coordinated fashion without the need for every detail to be negotiated (Figure 18).[141] 
Another theoretical framework is the team mind, based on the concept that teams use the 
same decision strategies as individual decision-makers when making decisions (Figure 19). 
Teams, like individuals use their experience to assess a situation and produce the most 
plausible response based on their interpretation of the situation, before assessing the 
adequacy of their chosen option by using mental simulation of its outcome. Depending on the 
adequacy of the outcome following mental simulation, the option is either implemented or the 
situation reassessed until a more appropriate option if found. Crucially, despite expanded 
cognitive resources, teams did not adopt a more analytic strategy than individuals in similar 
situations.[136;142] 
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Figure 18: A theoretical framework for naturalistic decision making. Adapted from Klein GA. Twenty 
questions-suggestions for research in naturalistic decision making. In Klein GA, Orasanu J, Calderwood 
R, Zsambok CE (Eds.) Decision making in action: Models and methods (389-403). Norwood, NJ: Ablex 
publishing. 1995. 
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A comprehensive review by Jones and Roelofsma describes the biases that can occur in team 
decision making on three levels: that of individual cognitive limitations, that of the social 
context, and at the organizational level.[143] The authors suggest that logistical factors 
(which are decided at an organizational level: the timing of meetings, number of cases; job 
plans of members allowing attendance) and social factors (information pooling and team 
member contribution to decision-making) may affect decision-making in MDT meetings. 
Concerning social factors, specific biases described by Jones and Roelofsma that may affect 
team decision-making include false consensus (a tendency for team members to see their own 
behaviour or judgments as typical), group think (a tendency for teams to produce poorly 
reasoned decisions), group polarization (the response of the group after discussion being 
more extreme than the initial average responses of group members), and escalation of 
commitment (teams having a greater tendency than individuals to continue to support a 
course of action despite evidence that it is flawed).  
 
Jones and Roelofsma concluded that teams are affected by these biases in different ways and 
to varying degrees depending on the specific features of tasks and environments in which 
they function. Research using expert panels shows that team decision-making is influenced 
by clinician specialty and the panel membership, which suggests that research is needed to 
investigate the effects of the format for information exchange and discussion, as well as the 
mechanisms for aggregating opinion, the effect of individual personality, or the occasional 
presence or absence of particular experts.[144;145]  
 
262 
 
 
Figure 19: A schematic representation of the shared mind model of team decision-making. Team 
metacognition represents the team mind. Adapted from Klein GA. Sources of Power – How people make 
decisions. Cambridge, MA: MIT press. 1998. 
 
Interestingly, from a team psychology perspective, dissent is not detrimental to a team – in 
contrast, teams where no-one ever dissents are at risk of ‗false consensus‘ or ‗group-think‘ 
biases, where dissent exists but it is never openly expressed.[136;146] Such attitudes may 
indicate lack of open communication within the team and have been shown to lead to poor 
decision-making.[136;140;147] Psychological research shows that team decision making can 
be improved by some level of standardization that ensures all issues are addressed, team-
members feel psychologically ‗safe‘ within the team, the impact of hierarchy is controlled 
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and a shared view of the task and each others‘ roles is held within the team.[136;140] Clinical 
evidence also shows that such approaches do improve shared understanding within clinical 
teams and their performance.[13] 
 
Consideration must also be given to the way in which the component sub-teams within larger 
teams interact to achieve different goals. Multi team systems (MTSs) have been described as 
two or more teams that interface directly and interdependently in response to environmental 
contingencies toward the accomplishment of collective goals.[149;150] MDTs can be thought 
of as multi team systems that bring surgical, oncological, nursing, radiological, pathological 
teams and others together to work collectively to manage cancer patients. These teams must 
complete intra-team processes to accomplish proximal goals (e.g., secondary review of 
radiological investigations by the radiologists with preparation of a minimum dataset to 
present to the MDT), as well as cross-team processes to complete collective goals (e.g., 
incorporating the different modalities of information into a decision about treatment). 
However, during the MDT meeting, the teams function predominantly to accomplish 
collective goals. Intra-team processes, such as taking a biopsy, or carrying out an operation, 
appear to be conducted before and after the MDT meeting. Such theories might lend support 
to my use of OTAS as the basis for MDT-MODe. OTAS considers processes that occur 
within sub-teams (i.e. nursing, anaesthetic, surgical) as well as collective processes. 
Moreover, OTAS is one of the most widely validated observational tools for teamworking in 
healthcare, and has been validated for use in urological surgery.[18;19] Furthermore, on a 
practical note, my department has many years of experience in the development, validation, 
and use of OTAS, as well as training others to use it. Such expertise is invaluable in 
behavioural research. 
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Interest in shared decision-making between clinicians and patients is increasing. Projects such 
as those at the Center for Informed Choice at the Dartmouth Institute, USA, and ‗MAking 
Good decisions In Collaboration with patients‘ (MAGIC) in the UK have helped to increase 
the understanding of healthcare providers and policy makers on how best to engage patients 
in clinical decision-making.[151;152] Overall, however, patient preferences can be volatile 
[153] and little is known about how patients want their needs and preferences to be 
represented in MDT meetings, which are important issues requiring further exploration. 
 
Certain limitations of the evidence for team decision-making must be acknowledged. In 
particular, much of this work has been performed in experimental that are simplistic and do 
not reflect the complexity of the real life situations, which they are meant to simulate. 
Moreover, whether a team is a real team, with a history of working together, or an ad hoc 
team assembled for an experiment will have an impact on a team‘s behaviour and decision 
making, which could limit the interpretation of research findings. In addition, although 
associations have been found between factors such as decision quality, team behaviours and 
safety practices, it has not been possible to attribute a causal relationship between decisions 
and task performance. Furthermore, such experimental research in healthcare has failed to 
translate into changes to diagnosis and treatment of patients.[136] 
  
This research into team decision-making, however, has yet to be translated into the field of 
cancer MDT working and there is currently no consensus regarding best practice in these 
areas. What does appear to be clear is that many of the factors that are part of MDT working - 
communication, resources, knowledge, team interaction and professional hierarchy- have all 
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been found to affect team decision-making.[136] Therefore, addressing some of these issues 
in the context of decision-making in MDT meetings may provide evidence on which MDTs 
can develop and improve their practice. 
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Appendix 3: Quality scoring of qualitative papers 
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Was ethical approval obtained? 0 0 1 
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Was the researcher trained in qualitative research? 2 0 0 
Was saturation point achieved?  0 0 0 
Were the findings member checked? 2 0 0 
Is there a description of how the themes were identified? 1 2 1 
Were the data analysed by more than one person? 0 1 1 
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Total score (24) 14 13 9 
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Appendix 4: Participant information sheet for patient focus-group 
 
Study Title:  
Patients‟ perspectives on MDT decision making: a focus group study. 
 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read this information leaflet and ask us if there is anything that is not clear, or about any 
further information you want. Participation is entirely voluntary and if you do not wish to 
take part you do not have to do anything further. If you would like to take part please contact 
us directly with the details at the bottom of the leaflet, or via your group representative. 
 
What is the purpose of this study? 
Patients with diagnosed or suspected cancer are cared for by multidisciplinary teams (MDTs), 
which are made up of the doctors (including surgeons, oncologists, radiologists and 
pathologists), specialist nurses and other healthcare professionals (including radiographers, 
social workers and dieticians) who treat patients for cancer. Patients who are being looked 
after by such teams are discussed by the MDT members in a meeting, where test results are 
examined and recommendations for treatment are made. The decisions made in the MDT 
meetings have an important effect on patient care. Healthcare providers realise that it is 
important to understand what patients think about the care they have received, or may receive 
in the future. However, little research has been carried out to assess what patients think of, or 
understand about the role of the MDT in cancer care. The aim of this study is to discuss any 
experiences that patients may have of cancer care, and to assess patients‘ views about MDTs. 
The way I would like to discuss these issues with you is in a focus-group. A focus-group is a 
small group of about five to ten people who are asked questions by a researcher, and who are 
free to answer them how they like, including having a discussion with the researcher and the 
other participants. Focus group discussions allow researchers to discuss a range of issues with 
participants, and to talk in depth about anything that is of particular interest. 
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Why have I been chosen? 
Patients who have been treated for cancer in the past are being recruited to take part in this 
study. You have been asked to take part because you belong to a patient group and your 
group representative has suggested you might like to participate. 
 
Do I have to take part? 
It is up to you to decide whether to take part. If you want to take part you have to reply to the 
email inviting you to participate and state that you would like to participate (by replying to 
this email or calling 0207549727). If you do not want to take part you do not have to do 
anything.  If you do not respond it is assumed that you are not happy to participate.  
 
What will happen if I take part? 
You will be given a copy of the information sheet to keep. If you are happy to take part then 
the researcher will require you to give written consent at the focus group. The researcher will 
lead a discussion that will focus on participants‘ experiences of cancer care, and their 
opinions about multidisciplinary teams. Between seven and ten people will participate in each 
group, all patients. The group will last between one and two hours. You will be free to leave 
at any time. The discussion will be recorded on a digital voice recorder. Before you leave you 
can ask the researcher any questions you may have. Refreshments will be provided. Travel 
expenses incurred as a result of your participation in the study can be reimbursed after the 
study. Please contact the researchers for further details on how to claim. 
 
Procedures, medical tests and tissue collection: 
No procedures, medical tests or tissue collection is required for this study. 
 
What are the disadvantages of taking part? 
Cancer is an emotional subject that can often be upsetting to discuss, particularly for patients 
who have or have had cancer, and their families. By taking part in the discussion you may 
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choose to discuss your own experience, or hear about the experiences of others, which may 
be distressing. If you are distressed as a result of participating in the focus group, or would 
like to discuss this further please contact the researchers (contact details below), or your 
patient group facilitator, who will be able to provide support. 
 
What are the benefits of taking part? 
I hope the study will ultimately help to make cancer MDT‘s more focussed on patients‘ 
needs. Participants may gain information about how cancer is treated. 
 
What will happen to the results? 
After the data from the focus-group has been analysed results from the study will be written 
up as part of the researcher‘s thesis and perhaps in a journal. 
 
Will my taking part in the study be confidential? 
The focus group discussion will be recorded on a digital voice recorder, but none of the data 
will have information that could identify participants (such as names or addresses). 
Obviously the other members of your focus-group will know that you have participated as 
they will be present at the same meeting. However, no one outside the focus-group will know 
that you have participated. Participants will be asked to ensure the discussion remains 
confidential by not sharing it with anyone outside the focus-group, or identifying anyone who 
has participated. The signed consent form with your name on will be kept in a locked 
cupboard in the researcher‘s office separately from the data from meetings. 
 
What if something goes wrong?  
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone‘s negligence, then you may have grounds 
for a legal action.  Regardless of this, if you wish to complain, or have any concerns about 
any aspect of the way you have been treated during the course of this study then you should 
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immediately inform the Investigator Dr Benjamin Lamb, Clinical research Fellow, Imperial 
College London (020 7594 9727 or benjamin.lamb@imperial.ac.uk), or Dr Nick Sevdalis, 
Senior Lecturer in Patient Safety, Imperial College London (020 7594 3431 or 
n.sevdalis@imperial.ac.uk). The normal National Health Service complaint complaints 
mechanisms are also available to you.  If you are still not satisfied with the response, you 
may contact the Imperial College Joint Research Office.   
 
 Who is organising and funding the research? 
 This research is organised by Imperial College London, and is funded by the National 
Institute of Health Research; and Whipps Cross University Hospital NHS Trust R&D 
Department. The researchers are not being paid for including and looking after subjects in the 
study. 
 
Who has reviewed the study? 
South East London (5) Research Ethics Committee has reviewed this study and given it a 
favourable ethical opinion. 
 
Who can I contact if I have any questions or a problem? 
If you have any questions about this study or a problem please contact the research team: 
 
Dr Benjamin Lamb, Clinical research Fellow, Imperial College London 
020 7594 9727 benjamin.lamb@imperial.ac.uk 
 
Dr Nick Sevdalis, Senior Lecturer in Patient Safety, Imperial College London 
020 7594 3431 n.sevdalis@imperial.ac.uk  
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Appendix 5: Topic guide for patient focus-group 
Establish ID of who I‘m speaking to 
Introduce myself 
Introduce project – State aim of the interview, confirm receipt of PIS 
Ask permission to tape interview, assure anonymity, and collect signed consent forms 
Questions to initiate discussion: 
 What is your experience of cancer diagnosis and/or treatment 
 Have you ever heard of a multidisciplinary team (MDT)? Do you know what they 
are? 
 Do you have experiences of being treated by/ interacting with a cancer MDTs  
 What information did you want to be considered by the MDT during your illness? 
 What factors should be considered by MDTs when they make clinical decisions 
about treatment for cancer patients? 
 Would like to attend your own MDT discussion? What might be the potential 
benefits and problems with attending? If you don‘t attend, who would be best 
suited to represent you? 
 How was the outcome of any MDT decision communicated to you? Would you 
change anything? 
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 Appendix 6: Topic Guide for Interview study 
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Appendix 7: Example transcript from interview study 
So just for the transcription, Mr Chadmondone, you’re a consultant urologist? 
 
That’s right. 
 
Is that, where do you work mostly, which Trusts do you work for? 
 
Well, I work half at Newham, half at Barts. 
 
And talking about the local MDT meeting, do you attend 
 
Yes. 
 
The local urology MDT? 
 
Yes. 
 
Where do you attend that? 
 
Mostly at Barts, ... at Barts and I ... I attend from Newham. 
 
And are they separate meetings or are they linked up? 
 
No, it’s a video link. 
 
Video link.  And to attend those meetings do you, is that incorporated into 
your job plan …? 
 
Kind of, kind of, well it’s a lunchtime thing, so it’s, it’s rather, it’s a grey area as to 
whether it’s part of the job plan, because it’s  
 
And when, the cases that are discussed at that local meeting, can you choose 
whichever cases you’d like to go on them or are there protocols as to which 
cases are discussed? 
 
Oh, there’s a protocol in every meeting, so it’s discussed, plus people who have 
suspected cancers, so suspected renal cell cancers or people who’ve had extensive 
general anaesthetic prostate..., when they get discussed at the local MDT. 
 
And where is that MDT held, the local one, is it? 
 
Well it’s on three sites, with a video link between the three. 
 
Are they good facilities on the different sites? 
 
Yes. 
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Have they got purpose built conferencing facilities? 
 
Well, the video conferencing facility at each site is … like in, at Homerton there’s a 
special room, at Barts it’s a library, at Newnham there’s like an academic centre 
room, because it is, it’s fixed and static, so at each site people go to that particular 
venue for that, for that time allocated. 
 
And are there ever any problems with the video conferencing on the …? 
 
Yeah, at times, yeah, at times the links don’t work very well, or at times the looking at 
slides doesn’t work well at times, you can’t see other people’s xrays.  But generally 
speaking it works, the local MDT works pretty well in terms of the video links. 
 
Do you think those disruptions ever affect the decisions that are made about 
patients or the outcome of the meeting? 
 
Rarely, very rare. 
 
So you can manage to work around them? 
 
Sure. 
 
Do you think with video conferencing, does that affect the communication 
within the meeting? 
 
It can do, it can do, in that at times you get extraneous sounds, which you wouldn’t 
notice if you were physically sat, sitting in a room with someone, but over the video 
link it ... picks up various sounds, so.  So often what we do now is if we’re not 
physically talking, we’ll switch, we’ll put the mute function on, so as any scrapings or 
puffings or noises are not transmitted over, on the link. 
 
That sounds good.  Do you think people have to behave differently when it’s a 
video conference? 
 
Not really. 
 
No? 
 
Not really, but except that perhaps it might need more discipline, in terms of not 
more than one person speaking at once.  And at times there’s a delay. 
 
So it’s difficult to know when to step in and speak? 
 
Yes, yes. 
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When it comes to all the information that’s presented at the local MDT 
meetings, is, do you find that the patient’s case history is always presented by 
someone who knows the patient? 
 
It’s rarely, rarely is that the, rarely is that the case.  Well it depends, at the Barts, it’s 
usually one of the SHO level doctors presents the cases, which they’ve gleaned 
from, from the notes or from the information sent to the MDT co-ordinator, but it’s 
rare that they would actually have personal knowledge of the patients.  At Homerton, 
quite often at Homerton, one of the people there has, actually knows the patients 
and at Newham, half the time the person presenting, well probably bit less than that, 
perhaps a quarter of the time the person presenting may know the actual patient, but 
it can, not overall, not generally speaking. 
 
Do you think not having a personal knowledge of the patient affects the quality 
of the presentation or the information that they can give to the meeting? 
 
At times, at times it does, where the situation arises where the patient’s performance 
status may be relevant as to what their routine might suggest or the patient’s social, 
domestic or psychological circumstances may have a bearing on what we would 
recommend.  So that can influence, not knowing the patient, yeah. 
 
Do the junior doctors who present those cases, you mentioned they go 
through the notes or through the information 
 
Respondent indicates agreement 
 
Do they have time before the meeting to do that, or is that done at the 
meeting? 
 
Yes, they only have time before the meeting. 
 
And do you find that enables them to produce a good summary of 
information? 
 
Generally speaking, yes. 
 
And are the notes available at the meetings too, if …? 
 
Usually, not always, but usually. 
 
What about radiological images, are they always presented at the local 
meeting? 
 
Yes. 
 
So, always have access to viewing them 
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Yeah. 
 
As required? 
 
Yes. 
 
And what about pathology slides? 
 
At times we see the slides, at other times the guy just, will just read us the report, so, 
but the slides are available, yeah. 
 
And who decides whether you see the slides or not, is it? 
 
Sorry? 
 
Is it the pathologist who decides? 
 
Yes. 
 
Yeah? 
 
Sure. 
 
What about patient’s comorbidities or if they have social or psychological 
problems, is that brought, often brought to the meeting? 
 
It is where it’s known, yeah, where it’s known it’s, when it’s relevant it’s brought to 
the meeting. 
 
Would it always be, would that information always be requested or is it just if 
it’s presented it’s presented and if not 
 
No, if it’s 
 
No? 
 
If it’s presented, then if it’s presented, if the presenter has the information to hand. 
 
What about any wishes the patients may have expressed regarding their 
treatment, or any preferences? 
 
At times, at times that comes, yeah, at times that comes into play, if the presenting 
doctor knows that or if the consultants or one of the registrars happens to be there, if 
he knows the particular patient preference, so that’s a variable, sort of, and gets fed 
into the process or not. 
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When it comes to chairing or leading the local MDT, what’s the background of 
the Chair of the local meeting you attend? 
 
The Chair, it’s chaired by a consultant neurologist. 
 
And does the Chair rotate at all, or is that a fixed combination? 
 
The Chair I think, the Chair doesn’t rotate, it’s one person, Mr, Mr Nargon, but if he’s 
away or operating, then one of the other, either myself or Miss Petty will, will chair 
the meeting. 
 
And what do you see as the ideal role for the Chair of the MDT? 
 
Just keeping the process moving along. 
 
What qualities do you think are needed to do that well?  Do you think it’s, is it 
personality qualities, or is it clinical experience and skill? 
 
All those things, clinical experience, but I think it’s more, I think it’s more a skill in, it’s 
a generic skill in chairing a meeting and keeping things moving, because you could 
spend half an hour discussing something, but time is very limited that we have 
available, the most important skill is having some discussion but not, but terminating 
it and then moving on. 
 
What are some of the positive aspects your Chair brings to your local 
meeting? 
 
Clinical knowledge. 
 
Yeah? 
 
Yeah. 
 
And if you were Chair, would you, or when you are Chair if Mr Nargon’s away, 
do you do anything differently, would you do things in a different way? 
 
Oh yeah, I tend to, to move the meeting along quicker, so not spend so long 
discussing somewhat arcane things. 
 
When it comes to the discussion about cases, who tends to contribute to that 
discussion, which specialities or which professional groups? 
 
All the groups, the doctors and nurses, the neurologists, the pathologists, really just 
everyone who feels that they want to contribute, contributes. 
 
And are you happy with your own contribution at the local MDT? 
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Yes. 
 
Are there any problems that you’ve encountered at the local meeting with 
people contributing or not contributing, or even dominating the discussion? 
 
Well, it can happen that there are disagreements as to, differences of opinion, as to 
how something should be managed, so that happens from time to time, which is to 
be expected and, but generally, generally it works, yeah, reasonably, pretty well. 
 
And when it comes to having an outcome from the meeting, is there always a 
plan that lets you move forward with treatment, or do patients 
 
Yes. 
 
Have to be re discussed because of problems with …? 
 
Well, at times patients are re discussed because the MDT may say, well we need 
another scan or we need further information or, yeah, so it’s, or they’re having a 
biopsy or something else, or the MDT says they need a biopsy of the lymph gland, 
it’s discussed after that’s been done.  So, so it’s, at times that, at times that happens. 
 
Do you think patients should have all the information ready before they come 
to MDT …? 
 
Sorry, do I think …? 
 
Do you think all their tests, all the radiology, all investigations done before 
coming to MDT, or is that difficult to? 
 
Well, no they do, but the MDT may decide they need something in addition.  So, but 
everything, everything, everything at that standard has been done prior to MDT, but 
MDT may decide we’ll observe this, this lump in the testicle, so, or we discuss this 
three months after they’ve had another scan or 
 
So bringing it back for a subsequent MDT isn’t necessarily a failure of 
 
No. 
 
Making a decision on? 
 
No, no, no, at times a particular member may need to be present to have their own, 
a discussion, and that person’s away, so at times it has to be deferred until the 
following week when that person is there.  But generally speaking, if a case is re 
discussed, it’s for good clinical grounds, or there’s further tests or further suggestions 
of things to further investigate that need to be done.  They can’t just be cancers that 
we’re discussing, we’re discussing suspected cancers as well. 
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When it comes to the, if I move on now to the network MDT, or the specialist 
MDT, do you attend that 
 
Respondent indicates agreement 
 
The network MDT? 
 
Yes, yes … 
 
Where is that held? 
 
Well 
 
Or where do you attend from? 
 
Well, I either attend from Whipps Cross or I attend from Barts, so probably two thirds 
of the time I’d go to Whipps Cross and the third, I’d go to Barts. 
 
Is there any difference in your experience of the meeting, like what you get out 
of it depending on whether you’re at the Cancer Centre Whipps Cross, or at 
one of the other hospitals? 
 
Well, I would dispute whether in fact, well possibly it’s the Cancer Centre, the joint 
centre.  So no, I don’t get anything different out of them all, I don’t get anything 
different depending which site I attend. 
 
And do you get allocated time in your job plan to attend the specialist 
meeting? 
 
No. 
 
Do you have to put off other work in order to attend? 
 
Well, the meeting is, it’s 8am, it starts at 8am, it goes on till nine or 9.30, so it’s 
before the, before the day starts so it’s an additional hour to the day.  I have to put 
that into my job plan, which is going to be discussed in a few day’s time, so I’m going 
to put that, put that time down.   
 
Do you think if these, if the MDT meetings, both the local and the specialist, 
were part of your programmed activities or in your work 
 
Yes. 
 
Do you think that would be a beneficial thing? 
 
Sure. 
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Would it mean other 
 
Sure. 
 
Work had to be covered at other times, or what would happen? 
 
Yes, it would, it would, it would, because if one’s got, you don’t have time, idle time 
doing nothing, we all have, well full job plans and full job descriptions, so which has 
been the case for years and so if they suddenly decide to allocate a whole session to 
an MDT, then something else has to go and, in fact, the plan is to have Tuesday 
mornings as MDT morning, so they’re going to have the specialist MDT followed by 
the local MDT, so that’s likely to take up the whole of Tuesday morning, which will 
have to be job planned. 
 
Is that a good thing in your mind or a bad thing? 
 
I think it’s probably a good thing as far as the service is concerned.  I think for me it’s 
a bad thing, personally it’s a bad thing, but I think for the greater good it’s a good 
thing. 
 
At the specialist MDTs, are there ever problems with the video linking between 
sites then? 
 
Yes, yes, probably, probably half the time, well in fact some problems are permanent 
and other problems are half the time.  So, half the time we cannot link up between 
Whipps Cross and Barts and the Homerton, so quite often each site does its own 
specialist MDT discussion, so that happens about half the time, then all the time we 
cannot see each other’s xrays or slides, or 
 
How does that affect the quality of the discussion about patients? 
 
Well, it’s an adverse effect, because no-one, the other centres can’t have any input, 
because they can’t see them.  So, it does enter the quality of the interaction, plus 
you get bored, because you can’t, one centre’s discussing their image and you can’t 
see it, so. 
 
So none of the  
 
Inaudible 
 
None of the radiology can be seen across sites? 
 
No … 
 
What about histopathology? 
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Well, that can’t be seen either and furthermore, Newham can’t link in to the specialist 
MDT at all, which is why I physically have to go to Whipps Cross, physically have to 
go to Barts and then because I have a session at Newham following that, so I then 
have to go 
 
All the way back. 
 
Back to Newham. 
 
That’s difficult. 
 
Incredibly unsatisfactory. 
 
Do you think the information that’s presented at the specialist MDT, does that 
differ from a local MDT? 
 
No. 
 
So the same factors 
 
Well it only differs, well in fact, it does differ in so far as at the local MDT they provide 
images of prostate cancer and they will then say, well … this patient needs an MRI 
scan before we can decide what treatment and my last case is done six weeks later 
and then what we’ll say is that, that case will now be discussed at the specialist MDT 
in six week’s time following the MRI, so the special MDT would have that, that 
information, which the local MDT wouldn’t have.  But we don’t re discuss it at the 
local MDT, having discussed it again at special MDT. 
 
What do you think the case history, is presented as well as it is, or better even, 
at the specialist MDT? 
I think it’s presented just as well. 
 
Yeah? 
 
Respondent indicates agreement 
 
And are other factors, such as patient choice or psychosocial issues or 
comorbidities, are they taken into account in the same way? 
 
To a certain extent, yes, to a certain extent, it depends on the case, depends on the 
patient, depends on who knows the patient, and also time is limited, we have an 
hour, hour and a half maximum, to discuss an awful lot of cases, so the time is 
limited, it’s, what, how much detail you can go into or find social factors, then patient 
wishes. 
 
Do you think, are, do you follow protocol for referring patients to the specialist 
MDT, is there a set 
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Yeah. 
 
Protocol for refer 
 
Yeah. 
 
Set cases in the discussion? 
 
Yeah. 
 
Do you think, does that make the most of the time, or do you think it could be 
better spent on different cases? 
 
No, I think it’s, I think it’s fine as it is. 
 
When it comes to chairing the specialist MDT, is there 
 
Yeah. 
 
Is there one Chair, or does that Chair rotate? 
 
Tends to be one Chair, tends to be one of the Whipps Cross consultants, Mr Hine, 
because he’s the lead, so he’ll chair the meeting from Whipps Cross, given the link 
between Whipps Cross and Homerton and Barts is up, and if he’s away one of his 
colleagues at Whipps Cross will chair the meeting … 
 
And that’s always, it doesn’t rotate between sites? 
 
No. 
 
It stays at Whipps? 
 
Yeah. 
 
And do you think the ideal role of the Chair of the network meeting is the same 
as the local meeting? 
 
Yes. 
Do you think those generic skills are needed as well as the clinical skills? 
 
Sure, yes I do. 
 
Are there any difficulties that you’ve experienced with the procedure of 
chairing the network meeting? 
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Well, the difficulties have come where there’s differences of opinion as to, as to 
what’s, as to the course of, course of action, of course it’s magnified because there’s 
a lot more people.  So, but that can be, and at times, apart from clinical differences, 
there may be personal … 
 
Sorry, I missed that, I’ve got … 
 
Personal differences, you know, like members may not, may not get on and, 
therefore, that can negatively impact on the discussions. 
 
If and when there are differences, how are they resolved? 
 
There’s no set way, at times it’s, they agree to differ and move on, five or ten 
minutes can be, can be wasted and someone else may say, well let’s just move on 
or 
 
Would you 
 
So, yeah. 
 
Who would decide on the final plan for that case, would it be the Chair of the 
centre in inverted commas, or the local consultant looking after the patient? 
 
Oh, it’s the local consultant.  The MDT can only, can only make recommendations or 
endorsements, but they’re not actually seeing the patient, so with the special M, well 
the special MDT may say, well someone we’ve seen before like that … for example, 
but the patients have got their … through of going, of undergoing surgery, so the 
special MDT is only advising, today, if a consultant’s looking after the patient, he has 
the responsibility to the patient, and the decision, function of the patients, with 
guidance from the special MDT or at least an agreement that the course of action is 
not contraindicated. 
 
And when it comes to that discussion in the meeting, who contributes to the 
discussion at the network meeting? 
 
It tends to be consultants, neurologists, radiologists, pathologists, there’s not, not so 
much nursing input. 
 
Is that, do you think it’s a bad thing? 
 
Don’t think it’s a, I don’t think it’s a good thing, but I don’t think, I don’t think it’s a bad 
thing, yeah. 
 
And is the discussion shared equally between the sites, or do 
 
Yes, yes. 
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So each site attending gets their chance to contribute? 
 
Sure, sure. 
 
Have you encountered any problems other than the ones you mentioned, with 
the discussion at the specialist MDT? 
 
I think, I think nothing that I wouldn’t expect.  I think the thing about the specialist 
MDT, is that probably I reckon probably three quarters is a, is a complete waste of 
time and well, maybe even more than three quarters is largely a waste of time, 
because, and what the key issues of specialist MDT, then we have at a local MDT, 
it’s just more people and we’re only dealing with three or four cancers and the 
treatment options are pretty, are … and so actually you can make decisions perfectly 
well yourself, which, it’s not a huge number of cases that the wider discussion is, is 
of, is of additional value.  There are advantages, or I wouldn’t abolish it, but it’s 
pretty, it’s pretty limited, it’s got, it’s got a, I don’t know, prostate cancer I guess is 
they’re, is a big one and it’s, and it’s, for example, and it’s, it’s organ confined, it’s 
localised in need, well the special MDT will say it’s their associates or for A, B, C or 
D, it’s also send issue E, and then you as the local consultant discuss if A, B, C or D 
with the specialist MDT, which would have done in any case.  So it’s largely a rubber 
stamped exercise that’s, that we’re told we have to do, it’s … 
 
Are there any changes you could make to make it more efficient or, in terms of 
time and resources? 
 
No, what you could do is, is you could say, bring to the specialist MDT those cases 
that are actually clinically problematical, which would cut it down tremendously.  I 
think it’s because of our local circumstance and the fact that we have a joint kind of, 
going back, at our local MDT meetings every, we have all the specialities there 
anyway, we have oncology, we have pathology, we have radiology, we have the 
nurses, we have the doctors.  So for our local, so locally all our special MDT, all it 
adds is more bodies, we don’t obviously have any different expertise of conducting 
all the various therapies, they’re all, they can all be conducted by the people who are 
present at our local MDT in any case.  I think it’s different in other areas where there 
is a very clear divide between what’s, over what can be done locally and what needs 
to be centralised, we’re kind of, we’re kind of in a different situation.  So, for example, 
at Whipps Cross, have the local MDT, the local and special MDT occur all at, all at 
the same time, and they have the special MDT link and then when we’re gone then 
they do the local MDT.  It’s, I don’t think there’s any, it’s rarely, there’s rarely added 
value from having the whole network discuss, discuss the case.  Of course, the other 
point to be made is that we’re supposed to have a network wide special MDT that’s 
joining with Queen’s Hospital, that was tried a few times and defeated by the video 
conferencing on facilities. 
 
So they  
 
So 
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Do they have any input into the network at all? 
 
No, no, they do their thing, or we do our own local and they do their own specialist 
MDT, I guess because they have all the expertise already.  But the plan was to have, 
was to join the whole thing, so we have one specialist MDT and that would occupy 
like a whole morning and the whole two, the technology doesn’t allow us to do that.  
So after three or four abortive efforts, we’re doing our own specialist MDTs. 
 
Separate ways, yeah. 
 
Yeah. 
 
That’s great, that’s run up to half an hour now.   
 
Yeah. 
 
So I’ll press stop on my machine. 
 
END OF INTERVIEW 
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Appendix 8: Sample participant information sheet for observational study 
Study Title:  
The effect of training on MDT decision making: an interventional study. 
 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time to 
read this information leaflet and ask us if there is anything that is not clear, or about any 
further information you want. Participation is entirely voluntary and if you do not wish to 
take part please contact us using the contact details below.  
 
What is the purpose of this study? 
Cancer care in the UK is coordinated by multidisciplinary teams. The decisions made in the 
MDT meetings have an important effect on patient care. Some research has shown that 
decisions within the MDT can be improved. However, the best way to improve the quality of 
the decisions is not known. The aim of this study is to test the effect of a training exercise on 
the quality of decision making by the MDT and get an idea of how it affects this process. 
 
Why have I been chosen? 
Members of the Whipps Cross University NHS Trust Urology MDT are being recruited to 
take part in this study. James Green, The Cancer Lead for Urology has invited us to see 
whether you would like to take part.  
 
Do I have to take part? 
It is up to you to decide whether to take part. If everyone on your team agrees to take part 
then an associate of the researcher will attend your MDT meeting and ask you all to sign a 
consent form. You can decide not to take part at any time. If you want to take part you have 
to reply to the email inviting you to participate and state that you would like to participate (by 
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replying to this email or calling 0207549727). If you do not want to take part you do not have 
to do anything.  If you do not respond it is assumed that you are not happy to participate.  
 
What will happen if I take part? 
You will be given a copy of the information sheet to keep. If all MDT members are happy to 
take part then the researcher‘s associate will require all team members to give written consent 
then the MDT meeting will go ahead as normal. The researcher will observe from a discreet 
position. The observer will be taking notes, but these will not have any patient information, or 
identifiable information about participants. After the meeting the researcher will leave. 
Before he leaves you can ask any questions you may have. After 6 MDT meetings have been 
observed you will be invited to attend a 3 hour workshop on decision-making with your 
MDT. It will involve listening to a lecture, discussing some mock MDT cases and some 
group discussion. The workshop will be facilitated by the researcher and a trained 
psychologist and will take place at Whipps Cross Hospital, probably in the Medical 
Education Centre. A free lunch and refreshments will be provided. In the weeks after the 
workshop the researcher will attend 6 more MDT meetings to make observations. After the 
study has finished the researcher will present the results to the MDT to check that they find 
them true to their experience. 
 
Procedures, medical tests and tissue collection: 
No procedures, medical tests or tissue collection is required for this study. 
 
What are the disadvantages of taking part? 
There are no anticipated disadvantages or risks of taking part in the study. 
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What are the benefits of taking part? 
We hope the study will ultimately help to improve the decision making process in MDT‘s. 
The results may help your MDT to improve some aspects of your own MDT decision 
making. 
 
What will happen to the results? 
After the data from the meeting has been analysed results from the study will be written up as 
part of the researcher‘s thesis and perhaps in a journal. 
 
Will my taking part in the study be confidential? 
None of the data from the meetings will have information that could identify participants. 
Obviously the other members of your team will know that you have participated as they will 
be present at the same meeting. However, no one outside the meeting will know that you 
have participated. The signed consent form with your name on will be kept in a locked 
cupboard in the researcher‘s office separately from the data from meetings. 
 
What if something goes wrong?  
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone‘s negligence, then you may have grounds 
for a legal action.  Regardless of this, if you wish to complain, or have any concerns about 
any aspect of the way you have been treated during the course of this study then you should 
immediately inform the Investigator Dr Benjamin Lamb, Clinical research Fellow, Imperial 
College London (02075949727 or benjamin.lamb@imperial.ac.uk), or Dr Katrina Brown, 
Clinical research Fellow, Imperial College London.02075949727 or 
katrina.brown07@imperial.ac.uk . The normal National Health Service complaint complaints 
mechanisms are also available to you.  If you are still not satisfied with the response, you 
may contact the Imperial College Joint Research Office.   
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 Who is organising and funding the research? 
 This research is organised by The Clinical Safety Research Unit, which  is affiliated with the 
Centre for Patient Safety and Service Quality at Imperial College Healthcare NHS Trust and 
is funded by the National Institute of Health Research; and Whipps Cross University Hospital 
NHS Trust R&D Department. The researchers are not being paid for including and looking 
after subjects in the study. 
 
Who has reviewed the study? 
This study is undergoing ethics review by Riverside Research Ethics Committee and by Whipps Cross 
R&D department. The study will not proceed until approval from both has been received. 
 
Who can I contact if I have any questions or a problem? 
If you have any questions about this study or a problem please contact the research associate: 
 
Dr Katrina Brown, Clinical research Fellow, Imperial College London. 
02075949727 or katrina.brown07@imperial.ac.uk 
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Appendix 9: Self-report survey tool 
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Appendix 10: Checklist Evaluation 
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Appendix 11: Evidence from multi-component intervention: team training 
intervention 
 
Quality Assurance in MDT 
Decision-Making
 MDTs
 Quality in Healthcare
 A ‘systems approach’
 Technical factors
 Non-technical factors
 Practical measures
 Conclusion
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Quality Assurance in MDT Decision-Making
 MDTs
 Decisions made by a team
 Accepted model of cancer care
 Little evidence for improved clinical outcomes
 Complex process
 Anecdotally decisions not always high quality
 
Quality Assurance in MDT Decision-Making
 Quality in Healthcare
 Increasing interest in safety and quality
 Research from other industries
 Applied to healthcare:
 Technical skills
 Patient factors
 Teamwork
 Non-technical skills
 Environment
 ‘SYSTEMS APPROACH’
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